UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 1of 144PROTOCOL  SL0023 AMENDMENT 1
A MUL TI-CENTER, RANDOMIZED, DOUBLE -BLIN D, 
PLACEBO -CONTROLLED, P ARALLEL-GROUP , 
DOSE -RANGING STUDY  FOLLOWED BY AN 
OBSER VATIONA LPERIOD TO EVALUATETHE EFFIC ACY 
AND SA FETY OF D APIROLIZUM AB PEGOL  IN SUBJECTS
WITH MODERA TELYTO SEVERE LYACTIVE SYSTEMIC 
LUPUS ER YTHEMA TOSUS
PHA SE 2B
EudraCT Number: 2015-004457- 40
IND Number: 100807
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60, 1070 
Brussels, Belgium
Protocol/Amendment N umber Date Type of amendment
Final Protocol 12Apr2016 Not applicable
Protocol Amendment 1 14Dec2016 Nons ubstantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 2of 144STUDY CONTA CT INFORM ATION
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 60, 1070 
Brussels, Belgium
Sponsor Study  Phy sician
Name: , MD
Address: UCB BIOSCIENCES GmbH
Alfred -Nobel -Str. 10
40789 Monheim
GERMANY
Phone:
Clinical Project Manager
Name:
Address: UCB Biosciences Inc.
8010 Arco Corporate Drive, Ste 100
Raleigh, NC 27617
USA
Phone:
Clinical Trial Biostatistician
Name:
Address: UCB Biosciences Inc.
8010 Arco Corporate Drive, Ste 100
Raleigh, NC 27617
USA
Phone:
Clinical Monitoring Contract Research Organization
Name: INC Research
Address: 3201 Beechleaf Ct #600
Raleigh, NC 27604
USA
Phone: +1 919 876 9300
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 3of 144SERIOUS A DVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 6563
USA: +1770 970 2494
Canada: +1 877 582 8842
Email Global :safet yreportingCDP7657@ucb.com
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 4of 144TABLE OF CONTENTS
LIST OF ABBREVIATION S..................................................................................................11
1 SUMMARY .....................................................................................................................15
2 INTRODUCTION ...........................................................................................................17
3
STUDY OBJECT IVES ....................................................................................................20
3.1 Primary  objective .............................................................................................................20
3.2 Secondary  objectives .......................................................................................................20
3.3 Other objectives ...............................................................................................................20
4 STUDY VARIABLES .....................................................................................................21
4.1 Efficacy  variables
.............................................................................................................21
4.1.1 Primary  
efficacy  variable .....................................................................................21
4.1.2 Secondary  efficacy  variable .................................................................................21
4.1.3 Other efficacy  variables
.......................................................................................21
4.1.3.1 Clinical assessments of disease activity ....................................................21
4.1.3.2
Variables assessing corticosteroid-sparing effects ....................................22
4.1.3.3
Patient- reported outcome variables ...........................................................23
4.2 Safety
 variables ................................................................................................................23
4.3
Pharmacokinetic variables ...............................................................................................23
4.4 Pharmacod ynamic variables ............................................................................................23
4.4.1 Immunological variables .....................................................................................23
4.5 Immunogenicit
y variables ................................................................................................23
4.6 Biomarkers .......................................................................................................................24
5 STUDY DESIGN .............................................................................................................24
5.1 Study  description .............................................................................................................24
5.1.1 Study  duration per subject ...................................................................................26
5.1.2 Planned number of subjects and sites ..................................................................26
5.1.3 Anticipated regions and countries .......................................................................26
5.1.4 Data Monitoring Committee ................................................................................26
5.2 Schedule of stud y assessments .........................................................................................27
5.3 Schematic diagram ................................ ................................ ................................ ...........33
5.4 Rationale for stud y design and selection of dose .............................................................34
6 SELECTION AND WITHDR AWAL  OF SUBJECTS ...................................................36
6.1 Inclusion criteria ..............................................................................................................36
6.2 Exclusion criteria .............................................................................................................39
6.3 Withdrawal criteria ................................ ................................ ................................ ..........42
6.3.1 Potential drug -induced liver injury  IMP discontinuation criteria........................43
7 STUDY TREATMENTS .................................................................................................44
7.1 Description of IMPs ................................ ................................ ................................ .........44
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 5of 1447.2 Treatments to be administered .........................................................................................44
7.2.1 Treatment preparation and administration ...........................................................45
7.2.1.1 Preparation .................................................................................................45
7.2.1.2 Administration ...........................................................................................45
7.3 Packaging .........................................................................................................................46
7.4 Labeling ...........................................................................................................................46
7.5 Handling and storage requirements
..................................................................................46
7.6 Drug accountability ..........................................................................................................46
7.7 Procedures for monitoring subject compliance ................................................................47
7.8
Concomitant medications/treatments...............................................................................47
7.8.1 Permitted concomitant treatments (medications and therapies) for SLE ............
47
7.8.2 Permitted concomitant treatments (me dications and therapies) other than those 
for SL E.................................................................................................................49
7.8.3 Prohibited concomitant treatments (medications and therapies) .........................
49
7.8.4 Rescue medication for SLE disease flares ...........................................................50
7.8.5 Subject diary ........................................................................................................50
7.9
Blinding............................................................................................................................50
7.9.1 Procedures for maintaining and breaking the treatment blind .............................
50
7.9.1.1 Maintenance of study  treatment blind .......................................................50
7.9.1.2 Breaking the treatment blind in an emergency  situation ...........................
51
7.10 Randomization and numbering of subjects ......................................................................51
8 STUDY PROCEDURES BY 
VISIT ...............................................................................52
8.1 Visit 1 (Week -4 to -1/Day -28 to -1); Screening Visit ....................................................52
8.2 Visit 2 (Day 1); Randomization Visit ..............................................................................54
8.3 Visit 3 (Week 2/Day 14 [±3 days])..................................................................................56
8.4 Visit 4 (Week 4/Day 28 [±3 days]) and Visit 6 (Week 8/Day 56 [±3 days])..................
56
8.5 Visit 5 (Week 6/Day 42 [±3 days])..................................................................................58
8.6 Visit 7 (Week 12/Day 84 [±3 days]), Visit 8 (Week 16/Day 112 [±3 days]), and Visit 9 
(Week 20/Day 140 [±3 days])..........................................................................................58
8.7 Visit 10 (Week 24/Day 168 [±3
days]); Double -Blind Treatment Period End of 
Treatment/Earl y Withdrawal Visit ...................................................................................60
8.8 Visit 11/SFU (Week 28/Day 196 [±3 days]), Visit 13 (Week 36/Day 252 [±3 days]), and 
Visit 15 (Week 44/Day 308 [±3
days])............................................................................62
8.9 Visit 12/SFU (Week 32/Day 224 [±3 days]) and Visit 14 (Week 40/Day 280 [±3
days])63
8.10 Visit 16 (Week 48/Day 336 [± 3day s]); Observation Period Final/Earl y 
Withdrawal Visit ..............................................................................................................65
8.11 Unscheduled Visit ............................................................................................................66
9 ASSE SSMENT OF EFFICACY ......................................................................................67
9.1 Clinical assessments of disease activity ...........................................................................67
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 6of 1449.1.1 BILAG 2004 ........................................................................................................67
9.1.2 SLEDAI -
2K.........................................................................................................68
9.1.3 PGA .....................................................................................................................68
9.1.4 PtGA ....................................................................................................................69
9.1.5 SLICC/ACR Da mage Index ................................................................................69
9.1.6 Tender and Swollen Joint Counts (28 joints) ......................................................70
9.1.7 CLASI..................................................................................................................71
9.1.8 Assessment of flare ..............................................................................................72
9.1.9 Responders based on clinical assessments of disease activity.............................72
9.1.9.1 BICLA .......................................................................................................72
9.1.9.2 SRI-
4, -5, and - 6 ................................ ................................ ........................73
9.1.9.3 SRI-50 .......................................................................................................73
9.2
Patient- reported outcomes ...............................................................................................74
9.2.1 LupusQoL ............................................................................................................74
9.2.2 SLE
-S...................................................................................................................74
9.2.3 SLE
-F...................................................................................................................74
9.2.4 SLE
-M .................................................................................................................75
9.2.5 SLE
-P...................................................................................................................75
9.2.6 SLE
-E ..................................................................................................................75
9.2.7 Subject Experience Interview ..............................................................................75
10 ASSESSMENT OF PK AND PD VARIABLES .............................................................75
10.1 Assessment of PK variables .............................................................................................75
10.2 Assessment of PD variables .............................................................................................76
10.3
Handling and shipment of blood and urine samples for PK and PD assessments ...........76
11 ASSESSMENT OF I MMUNO GENICITY VARIABLES .............................................76
12 ASSESSMENT OF BIOMAR KERS
...............................................................................77
13 ASSESSMENT OF SAFETY ..........................................................................................77
13.1 Adverse events .................................................................................................................77
13.1.1 Definition of adverse event ..................................................................................77
13.1.2
Procedures for reporting and recording adverse events.......................................77
13.1.3
Description of adverse even ts..............................................................................78
13.1.4 Follow up of adverse events ................................................................................78
13.1.5 Rule for repetition of an adverse event ................................................................78
13.1.6 Hypersensitivity  and adverse drug reactions .......................................................78
13.1.7 Thromboembolic events ......................................................................................79
13.1.8 Infections .............................................................................................................79
13.1.8.1 Suspected transmission of an infectious agent via a medicinal p
roduct ...79
13.1.9 Neurological events .............................................................................................80
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 7of 14413.1.10 Pregnancy ............................................................................................................80
13.1.11 Overdose of IMP ..................................................................................................81
13.1.12 Safety  signal detection ................................ ................................ .........................81
13.2 Serious adverse events .....................................................................................................81
13.2.1 Definition of serious adverse event .....................................................................81
13.2.2
Procedures for reporting serious adverse events .................................................82
13.2.3 Follow up of serious adverse events ....................................................................83
13.3
Adverse events of special interest....................................................................................83
13.4 Immediate reporting of adverse events ............................................................................83
13.5 Anticipated serious adverse events ..................................................................................84
13.6
Assessment and management of TB and TB risk factors ................................................84
13.6.1 TB assessments ....................................................................................................85
13.6.2 Chest x -ray...........................................................................................................86
13.6.3 TB signs and s ymptoms questionnaire ................................................................86
13.6.4 TB management ...................................................................................................86
13.7 Evaluation of PDILI .........................................................................................................87
13.7.1 Consultation with Medical Monitor and local hepatologist .................................91
13.7.2 Immediate action: determination of I
MP discontinuation ...................................91
13.7.2.1 IMP restart/rechall
enge (if applicable)......................................................91
13.7.3 Testing: identification/exclusion of alternative etiology .....................................92
13.7.4 Follow -up evaluation ...........................................................................................93
13.8 Physical examination and interim medical history ..........................................................93
13.9 Laboratory  measurements ................................................................................................94
13.10 Vital signs ..............................................................................................................96
13.11
12-lead ECGs ................................ ................................ ................................ .........96
13.12 Asse ssment of suicidal ideation and behavior .......................................................96
14
STUDY MANAGEMENT AND ADMINISTRATION .................................................97
14.1 Adherence to protocol ......................................................................................................97
14.2Monitoring ................................ ................................ ................................ .......................97
14.2.1 Definition of source data .....................................................................................97
14.2.2
Source data verification .......................................................................................98
14.3 Data handling ...................................................................................................................98
14.3.1 Case Report Form completion
.............................................................................98
14.3.2 Database entry  and reconciliation ........................................................................98
14.3.3 Subject Screening and Enrollment L
og/Subject Identification Code list ............98
14.4 Termination of the stud y..................................................................................................99
14.5
Archiving and data retention................................ ................................ ............................99
14.6 Audit and inspection ................................ ................................ ................................ ........99
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 8of 14414.7 Good Clinical Practice ...................................................................................................100
15 STATI STICS .................................................................................................................100
15.1 Definition of anal ysis sets ..............................................................................................100
15.1.1 Enrolled Set .......................................................................................................100
15.1.2
Randomized Set .................................................................................................100
15.1.3 Safety  Set
...........................................................................................................100
15.1.4 Full Anal ysis Set ................................................................................................100
15.1.5 Per Protocol Set .................................................................................................100
15.1.6 Pharmacokinetic Set ..........................................................................................101
15.1.7 Completer Set ....................................................................................................101
15.2 General statistical considerations ...................................................................................101
15.3 Planned efficacy  anal yses..............................................................................................102
15.3.1 Analy sis of the primary  efficacy  variable ..........................................................102
15.3.2 Other efficacy  anal yses......................................................................................103
15.4 Planned safet y and other anal yses..................................................................................104
15.4.1 Safety  
analyses...................................................................................................104
15.4.2 PK analy ses........................................................................................................104
15.4.3 Immunogenicit y anal yses..................................................................................105
15.5
Handling of protocol deviations.....................................................................................105
15.6
Handling of dropouts or missing data............................................................................105
15.7 Planned interim anal ysis and data monitoring
...............................................................106
15.8 Determination of sample size .........................................................................................106
16 ETHI CS AND REGULATOR Y REQUI REMENTS ....................................................107
16.1 Informed consent ...........................................................................................................107
16.2
Subject identification cards............................................................................................107
16.3 Institutional Review Boards and Independent Ethics Committees ................................
108
16.4 Subject privacy ...............................................................................................................108
16.5 Protocol amendments .....................................................................................................109
17 FINANCE, INSURANCE, AND PUBLICATION .......................................................109
18 REFERENCES ................................ ................................ ................................ ..............109
19 APPENDI CES ................................ ................................ ................................ ...............112
19.1 SLICC classification criteria for SLE ................................ ................................ ............112
19.2 Equivalent doses of oral steroids ...................................................................................115
19.3 Suggested management guidelines for infusion reactions .............................................116
19.4 Criteria for diagnosis of anaph ylaxis.............................................................................117
19.5 Protocol -
specific clarification and extension of BILAG 2004 definitions ....................118
19.6 Protocol Amendment 1 ................................ ................................ ................................ ..118
20 DECL ARATION AND SI GNATURE OF INVESTI GATO R ................................ .....143
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 9of 14421 SPONSOR DECLARATION ........................................................................................144
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 10of 144LIST OF TA BLES
Table 5-1: Corticosteroid tapering schedule......................................................................25
Table 5‒2: Schedule of stud y assessments ................................ ................................ .........28
Table 5‒3: Summary  of qualitative evidence leading the selected target DZP C trough
and corresponding dose levels for SL0023 ......................................................35
Table 5‒4: Pharmacokinetic parameters expected at the dose levels proposed in 
SL0023 (median [5th-
95thpercentile]) .............................................................35
Table 6-1: Maximum doses of permitted concomitant antimalarials................................38
Table 6-2: Maximum doses of permitted concomitant immunosuppressants ................... 38
Table 7-1: Prohibited medications and required wash -out periods prior to Screening 
(Visit
1) ............................................................................................................49
Table 9‒1: SLICC/ACR Damage Index organ s ystem scoring ................................ .........70
Table 9‒2: Joint tenderness and swelling grades ................................ ...............................70
Table 9‒3: CLASI activity  and damage scoring ................................ ................................71
Table 13‒1: Anticipated seriou s adverse events for subjects with SL E ..............................84
Table 13‒2: Required investigations and follow up for PDILI ...............................................89
Table 13‒3: PDILI laboratory  measurements ................................ ................................ ......92
Table 13‒4: PDILI information to be collected ................................ ................................ ...93
Table 13-5: Laboratory  measurements ................................................................................95
LIST OF FIGURES
Figure 5-1: Schematic diagram of SL0023.........................................................................33
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 11of 144LIST OF A BBREVIATION S
ACR American College of Rheumatology
ACE angiotensin converting enzy me
ADL activities of daily  living
AE adverse event
ALP alkaline phosphatase
ALT alanine aminotransferase
ANA antinuclear antibody
anti-dsDNA anti-double -stranded deoxy ribonucleic acid
anti-ENA extractable nuclear antigen antibody
anti-RNP anti-ribonucleoprotein antibody
anti-SM anti-Smith antibody
anti-SSA Sjögren’s s yndrome antibody  A 
anti-SSB Sjögren’s s yndrome antibody  B 
aPL antiphospholipid
APS antiphospholipid sy ndrome
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
BICLA BILAG 2004- based Composite L upus Assessment
BILAG 2004 British Isles Lupus Assessment Group Disease Activity  Index 2004
BST BILAG 2004 Systems Tally
C3 complement 3
C4 complement 4
CD40L CD40 ligand
CDMS clinical data management sy stem
CI confidence interval
CLASI Cutaneous L upus Ery thematosus Disease Area and Severity  Index
CPM Clinical Project Manager
CRO contract research organization
CS Completer Set
CSR Clinical Study  Report
C-SSRS Columbia Suicide Severity  Rating Scale
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 12of 144CTSO Clinical Trial Supply  Operations
DMC Data Monitoring Committee
DNA deox yribonucleic acid
DZP dapirolizumab pegol
ECG electrocardiogram
eCRF electronic C ase Report F orm
EDC electronic data capture
eGFR estimated glomerular filtration rate
EHR Electronic Healthcare Record
ES Enrolled Set
EWV Early Withdrawal Visit
Fab´ fragment antigen -binding
FAS Full Anal ysis Set
Fc fragment cry stallizable
FDA Food and Drug Administration
GCP Good Clinical Practice
HIV human immunodeficiency virus
HMG -CoA 3-hydroxy -3-methy l-glutary l-coenzy me A
HRQoL health- related quality  of life
hsCRP high sensitivity  C-reactive protein
IB Investigator’s Brochure
ICH International Council for Harmonisation
IEC Independent Ethics Committee
Ig immunoglobulin
IGRA interferon -γ release assay
im intramuscular (ly)
IMP investigational medicinal product
IP interphalangeal
IRB Institutional Review Board
ITP idiopathic thrombocy topenic purpura
iv intravenous(l y)
IVRS interactive voice response sy stem
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 13of 144IWRS interactive web response sy stem
LupusQoL Lupus Quality  of Life questionnaire
LTB latent tuberculosis
MCI D minimal clinically  important difference
MCP metacarpophalangeal
MCP -Mod Multiple Comparison Procedure –Modelling
MILES Michigan Lupus and Epidemiology  Surveillance Program
mRNA messenger ribonucleic acid
NHP nonhuman primate
NSAID nons teroidal 
anti-inflammatory  drug
NTMB non-tuberculosis my cobacterium
PBO placebo
PD pharmacod ynamics(s)
PDILI potential drug -induced liver injury
PEF peak expiratory  flow
PEG polyethylene gly col
PGA Physician’s Global Assessment of Disease
PIP proximal interphalangeal
PK pharmacokinetic(s)
PK-PPS Pharmacokinetic Per Protocol Set
PPS Per Protocol Set
PRO patient -reported outcome
PS Patient Safety
PtGA Patient’s Global Assessment of Disease
QFT -GIT Quanti-FERON®-TB GOLD in -Tube test
RF rheumatoid factor
RS Randomized Set
SAE serious adverse event
SAP Statistical Analy sis Plan
SFU Safety  Follow -up
SJC swollen joint count
SLE systemic lupus ery thematosus
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 14of 144SLEDAI -2K Systemic Lupus Ery thematosus Disease Activity  Index 2000
SLE-E Systemic Lupus Erythematosus-Emotional States Instrument
SLE-F Systemic Lupus Erythematosus- Fatigue Instrument
SLE-M Systemic Lupus Erythematosus- Mobility  Instrument
SLE-P Systemic Lupus Erythematosus- Pain I nstrument
SLE-S Systemic Lupus Erythematosus- Symptom Inventory  Instrument
SLICC Systemic Lupus International Collaborating Clinics
SOP Standard Operating Procedure
SRI-4, -5, and - 6 Systemic Lupus Ery thematosus Responder Index -4, -5, and -6
SRI-50 Systemic Lupus Ery thematosus Disease Activity  Index -2KResponder 
Index -
50
SS Safety  Set
TB tuberculosis
TJC tender joint count
TT tetanus toxoid
ULN upper limit of normal
VAS visual analog scale
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 15of 1441 SUMM ARY
SL0023 is a 2- part study  consisting of a randomized, double -blind, placebo (PBO) -controlled, 
parallel -group, dose -ranging period (24-week Double -Blind Treatment Period ; Part1)followed 
by a
24-week Observational Period ( Part2)in adult subjects with moderately  to severel y active 
systemic lupus ery thematosus (SL E) who are 
receiving stable standar d-of- care medication s
(ie,corticosteroids, immunosuppress ants, and/or antimalarials) at study
 entry .
The primary  objective of SL 0023 is to assess the dose -response for the efficacy  of intravenous 
(iv) dapirolizumab pegol (DZP; 3 dose groups) at Week 24 of the Double- Blind Treatment 
Period ( Part1).Secondary  objectives are to assess the efficacy of the individual dose regimens of 
iv DZP at 
Week 24 and to assess the safety  and tolerability  of iv DZP . Other objectives are to 
assess the efficacy  of iv DZP at additional time points ; to assess the corticosteroid -sparing effect 
of iv DZP; to assess the pharmacokinetics (PK) of iv DZP and pol yethylene gl ycol (PEG); to 
assess the pharmacodynamics (PD) of iv DZP; to assess the immunogenicity of iv DZP and 
PEG; t o assess the effects of iv DZP on health -related quality  of life (HRQoL ), symptoms, 
fatigue, 
mobility , and pain ;to perform exploratory anal yses of the effects of iv DZP with
transcriptomic and proteomic biomarkers ; to assess durability  of the clinical res ponse after 
withdrawal of iv DZP; and to assess PD after withdrawal of iv DZP (including gene transcription 
signature) .
The primary  efficacy  variable is the British Isle Lupus Assessment Group Disease Activity  Index 
2004 (BILAG 2004)- based Composite L upus Assessment (BI CLA) responder rate across 3 doses 
of DZP and PBO at Week 24. The secondary  efficacy  variable is the BI CLAresponder rate in 
the individual dose groups at Week 24. Several other efficacy  variables assessing disease 
activity , corticosteroid- sparing effects, HRQoL ,symptoms, fatigue, mobility , and pain are also 
included. 
Safety  variables include adverse events (AEs) and serious AEs (SAEs), subject withdrawals due 
to AEs, vital sign parameters, electrocardiograms (ECGs), and safety  laboratory  tests. Several 
variables evaluating PK, PD, biomarkers, 
and immunogenicit y will also be assessed.
The study  consists of a Screening Period of up to 4 weeks , a 24-week Double -Blind Treatment 
Period ( Part1), and a 24-week Observational Period (Part2). At the start of the 24-week
Double
-Blind Treatment Period ( Part1), eligible subjects will be randomized (1:1:1:1) to 1 of 
4treatment arms (DZP 6mg/kg, 24mg/kg, or 45mg/kg, or PBO) and stratified in accordance with 
corticosteroid dose ( ≤10mg/day  or >10mg/day  prednisone equivalent) determined at Screening . 
Study  drug will be administered by  iv inf usion every  4weeks during 
Part1of the study . Subjects 
who withdraw earl yfrom the 24 -
week Double- Blind Treatment Period ( Part 1) will enter an 
8-week Safet y Follow -up (SFU) Period (which ends 12 weeks after the final dose of stud y drug). 
Subjects who complete the 24 -
week Double- Blind Treatment Period ( Part1)willcontinue into a 
24-week Observational Period ( Part2), during which subjects will not receive study  drug but 
will be able to receive standard -of-care treatment, as indicated. The subjects, I nvestigators, and 
study  site staff will remain blinded to the treatment administered during Part 1of the study  until 
the end of the stud y.The maximum dura tion of the entire study  (Parts 1 and 2) per subject will 
be approximately  52weeks.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 16of 144Eligible subjects will have active SLE at Baseline despite stable standard -of-care treatment with 
at least 1 of the following, either alone or in combination: corticosteroids (at dose s of ≤40mg/day  
prednisone or equivalent), and/or antimalarials, and/or immunosuppress ants. In subjects 
receiving concomitant corticosteroids, doses must have bee n stable for at least 2weeks prior to 
Screening, must remain stable until Baseline (Visit 2),and should remain stable until 4 weeks 
after the first study  drug infusion ( until Day 28). Subjects not receiving concomitant 
corticosteroids or who were previously  receiving corticosteroids on an as needed basis must have 
stopped the treatment or been ass igned to a continuous corticosteroid dose at least 2 weeks prior 
to Screening (Visit 1). In subjects receiving concomitant corticosteroid doses between 10mg/day 
and 40mg/day  prednisone or equivalent at Screening, a mandatory  corticosteroid taper must be 
initiated no later than 4weeks after the first study drug infusion (on Day 29). The tapering 
regimen will aim to reduce the dail y prednisone equivalent dose to 7.5mg/day or lower b y 
Week 12 (Day 84) of the study .Treatment with antimalarials and immun osuppressants must 
have been started or stopped at least 12 weeks prior to dosing with study  drug and doses must 
remain stable for at least 4 weeks for antimalarials and at least 8 weeks for immunosuppressants 
prior to the first study  drug infusion (Visit 2). In subjects receiving concomitant antimalarials or 
immunosuppressants
, doses must not exceed the specified maximum permitted doses ( as outlined 
inTable 6-1and Table 6-2). 
The study  is planned to enroll at least 267subjects in order to randomize approximately  
160subjects ( 40 subjects per treatment group). Subjects eligible to enroll in this study  are males 
or females, ≥18 years of age, diagnosed with SL E according to the S ystemic L upus International 
Collaborating Clinics (SLICC) Classification Criteria and having moderately  toseverel y active 
disease , defined as having BILAG Grade A level disease activity  in ≥1 body/organ s ystemor 
BILAG Grade B in ≥2body /organ sy stems if no 
BILAG Grade A level disease is present and
Systemic Lupus Ery thematosus Disease Activity  Index -2000 (SL EDAI -2K) score ≥6 at 
Screening . Subjects must have 1of the following 3 criteria confirmed b y the central l aboratory  at 
Screening: (a)anti-double stranded deoxy ribonucleic acid (anti- dsDNA) antibodies by  Farr 
assay , or (b)low complement (ie,either low complement 3 [C3], low complement 4 [C4],or 
both) , or (c)antinuclear antibody  (ANA) titer of ≥1:80 . In subjects meeting the latter ANA 
criterion “c ,” this must be in combination with at least 1 of the following: (1)historical positivity  
for anti -dsDNA a t least twice in the past, or ( 2) positivity  for extractable nuclear antigen 
antibodies (anti -ENA) (anti -Smith antibody  [anti -SM], Sjögren’s s yndrome antibody A 
[anti-SSA], Sjögren’s s yndrome antibody B [anti -SSB], or anti -ribonucleoprotein antibody 
[anti-RNP]) .
AData Monitoring Committee (DMC) will monitor the safet y of subjects in SL 0023 on an 
ongoing basis , with a particular emphasis on occurrence of thromboembolic events . 
An initial biomarker analysis may be performed on all evaluable biomarker data from Part1of 
the study  when 25% to 35% of the randomized subjec ts have completed Visit 7
(Week 12) of the 
Double
-Blind Treatment Period .Data from subjects who have prematurel y withdrawn from the 
study  prior to Visit 7 will be included . The initial biomarker anal ysis will focus on transcriptomic
biomarker variables (eg, messenger ribonucleic acid [mRNA] ), prespecified in a Biomarker Plan, 
in order to provide guidance for the DZP development program, and will n ot affect the conduct 
of the study .  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 17of 144After the last subject completes Part1of the study, the data for those subjects will be secured 
and an interim Clinical Study  Report (CSR) will be written for the Double- Blind Treatment 
Period ( Part1) of the study ; this interim CSR will not include any  data from the Observational
Period (Part2). A biomarker anal ysis on the full Double -Blind Treatment Period ( Part1) dataset 
will be included in the interim CSR. Subsequently , acomplete final CSR will be written for the 
entire study  following completion of the Observational Period (Part2) of the study .
2 INTRODUCTION
Systemic lupus ery thematosus is a chronic autoimmune disease that can target nearl y all major 
organ s ystems in the body  (Tsokos etal,2007). In Europe, 
the incidence rate of SL E varies from 
1.0 per 100,000 person -years in Denmark to 4.7 per 100,000 person -years in the UK 
(Borchers etal,2010). Studies in the US, Australia, and Canada report a similar incidence, with a 
range of 2 to 5 per 100,000 person -years (Borchers etal,2010). These areas also have 
nonhomogeneous prevalence rates vary ing from 28.3 in Denmark to an estimated 149.5 per 
100,000 adults in the US (Borchers etal,2010). In the Asia Pacific countries, crude incidence 
rates of SLE are repor ted to be 0.9 to 3.1 per 100,000 patient -years and the crude prevalence is 
reporte d to be 4.3 to 45.3 per 100,000 people (Jakes etal,2012). The disease is rarel y diagnosed 
in Africa.
The observed regional variation can be partially  explained by  the racial and ethnic differences in 
SLE occurrence. The prevalence in the US per 100,000 people is estimated to be between 
406 and 694 in blacks, 139 and 244 in Hispanics, 93 and 103 in Asian/Pacific Islanders, and 
164and 203 in whites (Borchers etal,2010) . Two recent studies were designed to minimize 
many  of the limitations in previous US SL E studies (Somers etal,2014; Lim etal, 2014). These 
studies used Centers for Disease Control funded registries including the Michigan Lupus and 
Epidemiology  Surveill ance Program (M ILES) and the Georgia Lupus Registry. In the MILES 
study , the source population was 2.4 million people (in 2 counties in Michigan). The 
age-adjusted incidence of SL E was 5.5 per 100,000 (95% confidence interval [CI ]: 5.0, 6.1) 
person -years, and the prevalence was 72.8 per 100,000 people (95% CI: 70.8, 74.8) 
(Somers etal,2014). These rates are higher than previously  reported but are also calculated from 
more robust data. The study  in Georgia found crude and adjusted incidence rates fo r SLE w ere 
both 5.6 per 100,000 person -years and the prevalence was 74 and 73 (crude and adjusted) per 
100,000 people (Lim etal,2014). The more complete case ascertainment in both of these studies 
resulted in the highest incidence and prevalence statistics reco rded in the US.
Manifestations of SL E are highl y heterogeneous, with the most common organ manifestations 
being musculoskeletal, mucocutaneous, and renal (Nightingale etal,2006; Cervera etal,2003). 
There is a large degree of variability  in disease acti vity and organ s ystem involvement seen 
across patients; thus, the instruments to measure disease activity  should encompass this range of 
organ s ystems. The disease often oscillates between periods of active disease (flare), low disease 
activity , and remiss ion, but can also remain chronically  active .All disease p eriods need 
individual ized treatments; ie,if a patient flares, the patient needs a treatment intervention with 
high dose immunosuppress anttherap y (ie,high dose corticosteroid therapy , potent 
immunosuppressants such as c yclophosphamide ) to induce disease control; if a patient achieve sa 
low disease activity ,the treatment is adapted to lower dose immun omodulatory  therapy  (ie, low 
dose steroids, anti malarials) and/or sy mptomatic treatment to maintain disease control .The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 18of 144highest unmet need remains in patients with frequent flares or persistentl y active disease in spite 
of the use of the currently available treatments .
Corticosteroids are the cornerstone of treatment of SL E, but they  are associate d with an 
extensive number of side effects most frequentl y seen during long -term use but also seen during 
short -term high dose induction therap y. Much of the organ damage in SLE is either directl y or 
indirectly  related to prednisone (Gladman etal,2003). As the dose of prednisone increases in 
SLE patients, the likelihood of organ damage increases and the pattern of organ damage 
observed may  differ depending on how the prednisone is administered (Thamer etal,2009). For 
example, long -term, low dose prednis one may  result in coronary  artery  disease, cataracts, or 
osteoporotic fractures; whereas high dose iv methy lprednisone may  additionally  result in acute 
psychotic events or avascular necrosis of bone.
High dose corticosteroids (eg, short -term 0.5 to 1.0mg/k g/day  oral prednisone [or equivalent] or 
500mg to 1g dail y pulse iv methylprednisolone )are used to manage acute SLE flares such as
newly  presenting grade III or IV lupus nephritis in combination with immunosuppressants as an 
induction therap y to gain disease control . Immunosuppressants are also generall y used in both 
moderate and severe cases when other treatments are ineffective or to limit or prevent long -term 
major organ damage from the disease or corticosteroid use (“steroid -sparing”) 
(Muangchan etal,2015; Al Sawah etal,2015 ).Antimalarials (eg, chloroquine or 
hydroxychloroquine) are generall y recommende d as standard- of-care maintenance treatment in 
SLE, if tolerated. 
Other common drugs are initially  used in the setting of lower -level disease activity , but their use 
continues as the disease progresses; they  include analgesics, nonsteroidal anti-inflammatory  
drugs (NSAIDs), and local steroids, with common supportive medications, including 
vasodilators (calciu m cha nnel blockers, angiotensin- converting enz yme inhibitors) for sy stemic
hypertension or Ray naud’s sy ndrome, local treatments for rashes or sicca sy ndromes, 
transfusions, anticonvulsants, antimigraine medications, narcotic pain medications, 
anticoagulants for recurrent thromboses, and antidepressants ( Muangchan etal,2015).
The CD40 ligand (CD40L) (also known as CD154) is expressed on various ty pes of cells, 
including activated Tcell
s, and can also be found asa soluble protein . Through interactions with 
its receptor, CD40, CD40L  play s an important role in regulating interactions between Tcells and 
other immune cells, notably  Bcells and antigen presenting cells, and thus affects several 
important functional events thought to be involved in autoimmune disea se. There is considerable 
pharmacological evidence in the lite rature (for reviews see Burkl y,2001; 
vanKooten andBanchereau, 2000) showing that blockade of CD40L is efficacious in 
inflammatory  and autoimmune conditions. CD40L blockade could, therefore, b e an innovative 
approach for the treatment of SL E
,specificall y to induce disease control in patients experiencing 
flare or persisted diseas e activity  in spite of standard-of- care medication .
The monoclonal anti -CD40L  antibodies hu5c8 ( also known as BG9588 or ruplizumab 
[Antova®]) and IDEC -131 were developed and previously  evaluated b y Biogen and IDEC, 
respectivel y. Both products were humanized immunoglobulin (Ig) G1 antibodies that blocked 
humoral immune responses in nonhuman primate (NHP) models and showe d evidence of 
potential efficacy  in early  clinical studies in idiopathic thrombocytopenic purpura ( ITP)and SLE 
(Patel etal,2008; Kuwana etal,2004; Boumpas etal,2003; Kalunian etal,2002; 
Davis etal,2001). Administration of hu5c8 was associated wi th an unusually  high incidence of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 19of 144thromboembolic events ( approximately 10% of subjects exposed) and further clinical 
development of hu5c8 was discontinued. In over 150subjects treated with IDEC
-131, there was 
1report in the literature of a thromboembolism ; this subject (who had chronic refractory  ITP, 
and who was diabetic, overw eight, and h ypertensive) had a m yocardial infarction when their
platelet count increased to >100x109/L. Coronary  angiography  revealed longstanding 
atherosclerotic changes in the subject’s coronary  arteries (Patel etal,2008).
The underl ying mechanism for the induction of thromboembolic events by hu5c8 in humans has 
been investigated. It has been known for some time that human platelets carry  both CD40 and 
fragment cry stallizable ( Fc) γIIA(CD32a) receptors, and that they  secrete CD40L  and express 
cell surface CD40L after activation. Hy pothetically , therefore, administration of anti-CD40L 
antibody  may  cause platelet activation via CD32a receptor cross -linking by simultaneously  
binding both to CD40/CD40L  and to the Fc receptor. I ndeed, in a transgenic mouse model, 
administration of anti-CD40L  antibodies caused platelet aggregation and thrombosis in an 
Fc-dependent manner (Robles-Carrillo etal,2010). Th us, it can be h ypothesized that removal of 
the Fc receptor binding site might alleviate this risk of thromboembolism and enable further 
assessment of this therapeutic strategy  in patients with SL E.
Dapirolizumab pegol (previously referred to as CDP7657 )isa purified recombinant, humanized 
fragment antigen -binding ( Fab´) antibody  fragment covalently  bound to PEG that targets CD40L 
and represents a novel approach to the treatment of SL Ein patients experiencing flare or 
persiste ntdisease activity in spite of standard -of-care medication . In particular, DZP lacks the Fc 
portion of whole antibody , and instead has a PEG moiety  to achieve the PK characteristics to
enable adequate exposure (Fab´ PEG). Both hu5c8 and DZP display  cross- reactivit y against 
NHP CD40L  with comparable affinity  and potency  in in vitro studies, and both are active in 
mechanistic studies. Extensive in vivo data from studies in NHPs together with data from in vitro 
functional experiments with human and Rhesus macaque platelets suggest that, f or 
thromboembolism induction with an anti -CD40L  antibody , 2interactions are required: idioty pic 
binding of CD40L and interaction with the CD32a receptor via the Fc portion. I n NHP studies, 
hu5c8 induced significant thromboembolic event -like lesions (thrombi, organized thrombi, and 
intima l hyperplasia) in the lungs of r hesus macaques after repeat dosing. In contrast, 
DZP does 
not result in any  increase in pulmonary  thrombi or vascular intimal hy perplasia above the
background incidence level in r hesus macaqu es. There are no NHP disease models resembling 
SLE. Dapirolizumab pegol display s no cross -reactivity  against murine CD40L ; however, an 
anti-murine CD40L Fab´ PEG antibody  suppresses nephritis and improves renal function 
(proteinuria) in the New Zealand Bla ck/New Zealand White murine lupus model ( see the DZP
Investigator’s Brochure [IB] for further details). The nonclinical efficacy  and safet y data support 
further development of DZP as a potential therap y for patients with SL E.
Two clinical studies have been conducted with DZP. SL0013 was the first -in-human single -dose 
study  of DZP . In Part1of SL 0013, 28 healthy  volunteers received either PBO or DZP at doses 
of 0.004mg/kg to 5mg/kg, and in Part2, 17 subjects with SLE received PBO or DZP at doses of 
5mg/kg to 60mg/kg. Dapirolizumab pegol was well tolerated both in healthy  subjects and in 
subjects with SL E in this study  and no thromboembolic events were reported. The DZP IB
contains additional information pertaining to data obtained in SL 0013.
SL0014 wasa Phase 1 study  evaluating the safet y, tolerability , PK, immunogenicity , and effects 
on disease activity of repeat -dose iv administration of DZP in subjects with active SLE, defined 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 20of 144as having a SL EDAI -2Kscore ≥4. A total of 24 subjects with SL E were randomized (2:1) to 
receive a loading dose of DZP 30mg/kg followed by  DZP 15mg/kg every  2weeks for a total of 
6doses of 
DZP or matching PBO on the same dosing schedule. DZP was well tolerated in this 
study , with a safet y profile similar to subjects administered PBO, with the exception of a slightly  
higher incidence of nonserious infection in the DZP group. There were no AEs of 
thromboembolism and no laboratory  findings suggestive of thromboembolic events. In 
exploratory  anal yses, numericall y greater i mprovements from Baseline were observed in the 
DZP group compared with the PBO group for the BILAG 2004 total score, SL EDAI -2K, 
Patient ’s Global Assessment of Disease, SLEDAI -2K Responder Index -50 (SRI -50) score, and 
BICLA and SLE Responder Index -4 (SRI -4)responders .The BICLA response represents a 
clinical lyrelevant improvement of moderate to severe disease activity , as it represents the 
change from a disease activity  with an indication for sy stemic treatment intervention to a disease 
activity  with no or limited indication to change the preexisting therapy ; the SRI -4 represents a 
relevant decrease in disease activit y.At Week 12, there were more BI CLA and SRI -4 responders 
in the DZP group (45.5% and 41.7%, respectivel y) compared with the PBO grou p (14.3% for 
both BICLA and SRI -4). There was a small but statistically  significant reduction in IgG 
concentrations at Week 12 (p=0.0436) in the DZP group compared with the PBO group. 
Messenger ribonucleic acid analy sis demonstrated changes in the expression of gen es associated 
with Bcelland plasma cell function, as well as reductions in the expression of interferon -
responsive genes (see the DZP IB for further details) .
The current study , SL0023, is a Phase 2b, randomized, double -blind, PBO -controlled, 
parallel -group dose -ranging study  followed b y an observational period that will evaluate the 
efficacy  in inducing disease control and safet y of DZP in subjects with moderatel y to severel y 
active 
SLE. Dapirolizumab pegol or PBO will be added to stable standard-of- caremedication 
and randomization will be stratified b y Screening corticosteroid dose ( ≤10mg/day  or >10mg/day  
prednisone equivalent) . Following completion of the 24 -week Double- Blind Treatment Period 
(Part1) of the stud y, subjects willcontinue into a 24-week Observational Period (Part2), during 
which subjects will not receive stud y drug but will be able to receive standard -
of-care treatment,
as indicated.
3 STUDY OBJECTIVE S
3.1 Primary  objective
The primary  objective of SL0023 is to assess the dose -response fo r the efficacy  of iv DZP 
(
3dose groups )at Week 24 of the Double -Blind Treatment Period ( Part1) in adult subjects with 
moderatel y to severel y active SLEreceiving
stable standard -of-care treatment.
3.2 Secondary  objectives
The secondary  object ives of SL0023 are:
To assess the efficacy  ofthe individual dose regimens of iv DZP at Week 24
To assess the safet y and tolerability of iv DZP
3.3 Other objectives
The other objectives of SL0023 are:
Toassess the efficacy  of the individual dose regimens of iv DZP at addit ional time points
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 21of 144To assess the corticosteroid -sparing effect of iv DZP
To assess the PK of iv DZP and PEG
To assess the PD of iv DZP
To assess the immunogenicity  of iv DZP and PEG
To assess the effects of iv DZP on HRQoL , symptoms, fatigue, mobility , and pain
To perform exploratory  analy ses of the effects of iv DZP with transcriptomic and proteomic 
biomarkers
To assess durability  of the clinical response after withdrawal of study  drug
To assess PD after withdrawal of study  drug (including gene transcriptio n signature)
4 STUDY VA RIABLES
4.1 Efficacy  variables
The Baseline value for efficacy  variables is defined as the last value obtained prior to the first 
infusion of study  drug ( Visit 2), unless otherwise noted.
4.1.1 Primary  efficacy  variable
The primary  efficacy  variable is the BICLA responder rate across 3 doses of DZP and PBO at 
Week 24(see Section 9.1.9.1 for a detailed description of this variable ) .
4.1.2 Secondary  efficacy  variable
The secondary  efficacy  variable is the BICLA responder rate in the individual dose groups at 
Week 24.
4.1.3 Other efficacy  
variables
Other efficacy  variables being evaluated b y visit will include all scheduled visits for that 
particular variable and will exclude the time points at which the primary  and secondary  variables 
are assessed, as specified in Section 4.1.1 and Section 4.1.2.
4.1.3.1 Clinical assessments of disease activity
BICLA responder rates by visit
Time to first maintained BICLA response ( defined as BICLA response at2consecutive stud y 
visits)
Percentage of subjec ts with maintained BICLA response from Week 12 to Week 24
Percentage of subjects with maintained BICLA response from Week 24 to Week 48
Number and percent of subjects with BILAG 2004 improvemen t (all BILAG 2004 Grade A
improved to B, C,or D and 
all BILAG 2004 Grade B improved to C or D) by  visit
Absolute and change from Baseline in total BILAG 2004 score b y visit
BILAG 2004 Systems Tally  (BST)
Absolute and change from Baseline in SRI -50 score by  visit
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 22of 144Absolute and change from Baseline in SLEDAI -2K score b y visit
Change from Baseline in Phy sician’s Global Assessment of Disease (PGA) and Patient’s 
Global Assessment of Disease (PtGA) scores by  visit
SRI-4 responder rates b y visit
SLE Responder Index -5 (SRI -5) responder rates by  visit
SLE Responder Inde
x-6 (SRI -6) responder rates by  visit
Percentage of subjects in each category  in the S ystemic L upus International Collaborating 
Clinics/American College of Rheumatology  (SLICC/ACR) Damage Index score at Week 24
Percent change from Baseline in tender joint c ount (TJC) by  visit
Percent change from Baseline in swollen joint count (SJC) by  visit
Absolute and change from Baseline in Cutaneous Lupus Ery thematosus Disease Area and 
Severity  Index (CL ASI) by  visit
Time to flare (with the occurrence of a flare determi ned by  the Investigator )
Time to flare after Week 24 (with the occurrence of a flare determined by  the Investigator)
Time to flare after Week 24 (with the occurrence of a flare defined as
:a new sustained 
BILAG 2004 Grade A/B [present at ≥2 consecutive visits] after withdrawal of study drug or 
start of new induction therap y [either corticosteroid dose increase to ≥0.5 mg/kg/day  
prednisone equivalent or initiation of cy clophosphamide, rituximab, iv Ig, or plasma 
exchange] after withdrawal of study  drug)
4.1.3.2 Variables assessing corticosteroid -sparing effects
Absolute daily  corticosteroid dose (in prednisone equivalent)
Percentage of subjects with a daily  corticosteroid dose of 7.5mg prednisone equivalent or less 
and BICLA response at Week 24
Percentage of subje cts with a daily  corticosteroid dose of 7.5mg prednisone equivalent or less 
and a maintained BICLA response from Week 12 to Week 24
Percentage of subjects with a daily  corticosteroid dose of 7.5mg prednisone equivalent or les
s 
and SRI -4 response at Week 24
Time -weighted area under the curve in corticosteroid dose for the period covering Baseline
to Week 24
Percentage of subjects with a daily
 corticosteroid dose of 7.5 mgor less prednisone 
equivalents by visit
Percent ageof subjects with no concomitant corticosteroid treatment by visit
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 23of 1444.1.3.3 Patient -reported outcome variables
Change from Baseline in Lupus Quality  of Life (LupusQoL) questionnaire score sby visit
The following exploratory patient- reported outcome (PRO) variables being developed b y 
UCB will be assessed at sites in English- and Spanish- speaking countries (approximately  
45% to50% of the projected study  population):
Change from Baseline in the SL E-Symptom Inventory  Instrument (SL E-S) scores by  visit
Change from Baseline in the SLE-Fatigue Instrument (SLE-F) score sby visit
Change from Baseline in the SLE-Mobility Instrument (SL E-M) score sby visit
Change from Baseline in the SLE-Pain Instrument (SL E-P)score sby visit
Change from Baseline in the SL E-Emotional States Instrument (SL E-E) scores b y visit
4.2 Safet y variables
Incidence of AEs, SAEs, and AEs of interest including and not limited to infections, 
infusion- related reactions, thromboembolic events , neurological events , and malignancies
Subject withdrawals due to AEs
Changes from Baseline in vital sign parameters by visit
ECGs (normal/abnormal) by  visit
Changes from Baseline in s afety laboratory  tests (hemat ology [including l ymphocyte 
sub
sets], blood chemistry , urinaly sis)by visit
4.3 Pharmacokinetic variables
Plasma concentrations of DZP and PEG
Urine concentrations of PEG
4.4 Pharmacody namic variables
Whole blood mRNA signature profiling to characterize potential changes in gene expression 
relevant to the i nflammatory  and immune response to DZP in SLE
4.4.1 Immunological variables
Lupus Autoantibod y Profile: anti -dsDNA antibodies, ANAs, anti -ENA (anti -SM, anti -SSA, 
anti-SSB, and a nti-RNP ), rheumatoid factor (RF), and antiphospholipid (aPL) antibodies
Ig (total Ig, IgG, IgM, IgA, and IgE)
High sensitivity  C-reactive protein (hsCRP)
C3andC4 levels
4.5 Immunogenicity  variables
Anti- DZP and anti -PEG antibodies
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 24of 1444.6 Biomarkers
In addition to the PD variables ( Section 4.4), the following samples will also be taken:
Serum 
will be taken and stored for protein and lipid anal ysis to characterize potential changes 
relevant to inflammatory  and immune responses and c ardiovascular risk in SL E.
Whole blood will be taken and stored to isolate deoxy ribonucleic acid (DNA) which may  be 
used to examine genetic and epigenetic changes. If samples are not used immediately , they  
will be stored at -80°C for later anal ysis until t he completion of the DZP development 
program. They  will be stored at BioStorage Technologies GmbH (Germany ) and they  will 
only be used in the context of understanding the molecular taxonomy  of SLE and/or response 
to treatment with DZP.
5 STUDY DESIGN
5.1 Stud y d
escription
SL0023 is a 2- part study  consisting of a randomized, double -blind, PBO -controlled, 
parallel -group, dose -ranging period (24-week Double -Blind Treatment Period; Part 1) followed 
by a 24
-week Observational Period ( Part2)in adult subjects with mod erately  to severel y active 
SLE who are receiving stable st andard -
of-care medications (ie, corticosteroids, 
immunosuppress ants, and/or antimalarials) at study  entry .
The study  consists of a Screening Period of up to 4 weeks , a 24-week Double -Blind Treatment 
Period ( Part1), and a 24 -week Observational Period ( Part2) (see Figure 5-1). At the start of the 
24-week Double -Blind Treatment Period ( Part1), eligible subjects will be r andomized (1:1:1:1) 
to 1 of 
4treatm ent arms ( DZP 6mg/kg, 24mg/kg, or 45mg/kg, orPBO) and stratified in 
accordance with Screening corticosteroid dose ( ≤10mg/day  or >10mg/day  prednisone 
equivalent) . Study  drug will be administered by  iv infusion every  4weeks during Part1of the 
study . Subjects who withdraw earl y from the 24 - week Double- Blind Treatment Period ( Part1) 
will enter an 8
-week SFU Period (which ends 12 weeks after the final dose of study  drug).
Subjects who complete the 24 -
week Double- Blind Treatment Period ( Part1) will continue into a 
24-week Observational Period ( Part2), during which subjects will not receive study  drug but 
will be able to receive standard -of-care treatment, as indicat ed. The subjects, I nvestigators, and 
study  site staff will remain blinded to the treatment administered during Part 1of the study  until 
the end of the stud y.
Eligible subjects will have active SLE at Baseline despite stable standard -of-care treatment with
at least 1 of the following, either alone or in combination: corticosteroid s (at doses of ≤40mg /day 
prednisone or equivalent ),and/or antimalarials, and/or immunosuppress ants. In subjects 
receiving concomitant corticosteroids , doses must have been stable for at least 2 weeks prior to 
Screening
, must remain stable until Baseline (Visit 2), and should remain stable until 4 weeks 
after the first study  drug infusion ( until Day 28).Subjects not receiving concomitant 
corticosteroids or who were previously  receiving corticosteroids on an as needed basis must have 
stopped the treatment or been assigned to a continuous corticosteroid dose at least 2weeks prior 
to Screening (Visit 1). Treatment with antimalarials and immunosuppressants must have be en 
started or stopped at least 12 weeks prior to dosing with study  drug and doses must remain stable 
for at least 4 weeks for antimalarials and at least 8 weeks for immunosuppressants prior to the 
first study  drug infusion (Visit 2). In subjects receiving concomitant antimalarials or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 25of 144immunosuppressants, doses must not exceed the specified maximum permitted doses (as outlined 
in Table 6-1and Table 6-2). 
In subjects receiving concomitant corticosteroid doses between 10 mg/day and 40mg/day  
prednisone or equivalent at Screening
, amandatory  corticosteroid taper must be initiated no later 
than 4 weeks after the first study  drug infusion ( onDay 29). The taper ing regimen , as
recommended in Table 5-1,will aim to reduce the daily  prednisone equivalent dose to 7.5 mg/day 
or lower b y Week 12 (Day 84) of the study .If such a rapid tapering is not consider ed by the 
Investigator to be appropriate for the individual subject ,a slower tapering regimen can be used.
Subjects achieving adose of 7.5mg/day
 or lower may  remain on this dose or continue to taper at 
the discretion of the Investigator. Subjects who cannot fulfill the taper based on the 
Investigator’s judgment should remain in th e study and receive corticosteroids at an appropriate 
dose as determined b y the Investigator. Subjects will be considered nonresponders for the 
primary  endpoint if the corticosteroid dose exceeds the prednisone equivalent dose at Baseline. 
Subjects will be issued a daily  diary  in which to record corticosteroid doses taken on a dail y 
basis at home in between visits. Use of oral or parenteral steroids for non -SLE related conditions 
should be discussed in advance with the Sponsor on an individual basis.
Table 5-1: Corticosteroid tapering schedule
Day Corticosteroid dosea(mg/day; prednisone equivalent)
Starting Dose 40a35a30a25a20a15a10a7.5b5b2.5b0
Day 1 to Day 7 40 35 30 25 20 15 10 7.5 5 2.5 0
Day 8 to Day 14 40 35 30 25 20 15 10 7.5 5 2.5 0
Day 15 to Day 21 40 35 30 25 20 15 10 7.5 5 2.5 0
Day 22 to Day 28 40 35 30 25 20 15 10 7.5 5 2.5 0
Day 29 to Day 35 30 30 20 20 15 10 7.5 NAbNAbNAbNAb
Day 36 to Day 42 30 20 20 15 15 10 NAbNAbNAbNAbNAb
Day 43 to Day 49 20 20 15 15 10 7.5 NAbNAbNAbNAbNAb
Day 50 to Day 56 20 15 15 10 7.5 NAbNAbNAbNAbNAbNAb
Day 57 to Day 63 15 15 10 7.5 NAbNAbNAbNAbNAbNAbNAb
Day 64 to Day 70 15 10 7.5 NAbNAbNAbNAbNAbNAbNAbNAb
Day 71 to Day 77 10 7.5 NAbNAbNAbNAbNAbNAbNAbNAbNAb
Day 78 to Day 84 7.5 NAbNAbNAbNAbNAbNAbNAbNAbNAbNAb
aCorticosteroid tapering is only required in those subjects receiving continuous corticosteroids at doses ≥10mg/day 
at the time of enrollment into the study.
bSubjects starting at or achieving adose of 7.5mg/day or lower may remain on this dose or taper a t the discretion of 
the Investigator.
Eligible subjects who are receiving a corticosteroid dose at Screening that is in between the 
specified starting doses of the corticosteroid tapering schedule (Table 5-1; eg, 12.5mg/day  or 
17.5mg/day ) should transition to the lowest nearest pres pecified starting dose over the first 
2weeks of Screening and will enter the study  on this dose ; the dose will be c onsidered stable in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 26of 144this case. This dose should then remain stable until 4 weeks after the first study  drug infusion 
(until Day 28).
An initial biomarker analysis may  be performed on all evaluable biomarker data from Part1of 
the study  when 25% to35% of the randomized subjects have completed Visit 7 (Week 12) of the 
Double
-Blind Treatment Period. Data from subjects who have prematurel y withdrawn from the 
study  prior to Visit 7 will be included. The initial biomarker anal ysis will focus on transcriptomic 
biomarker variables (eg, mRNA), prespecified in a Biomarker Plan, in order to provide guidance 
for the DZP development program, and will not af fect the conduct of the study .
After the last subject completes Part1of the study, the data for those subjects will be secured 
and an interim CSR will be written for the Double- Blind Treatment Period ( Part1) of the stud y. 
Acomplete final CSR will be written for the entire study  following completion of the 
Observational Period (Part2)of the stud y .See Section 15.7 for further details regarding these 
analyses.
5.1.1 Study duration per subject
The maximum duration of the entire stud y (Parts 1 and 2) per subject will be approximately  
52weeks, including a Screening Period of up to 4 weeks, a 24-week D ouble -Blind Treatment 
Period ( Part1),and a 24 -week Observational Period ( Part2).
The end of the stud y is defined as the date of the last visit of the last subject in the study .
5.1.2 Planned number of subjects and sites
The study  is planned to enroll at least 267subjects in order to randomize approximately  
160subjects ( 40 subjects per treatment group). The study  will be conducted at approximately  
70sites. 
5.1.3 Anticipated regions and countries
This study  is anticipated to be conducted in Western Europe, Eastern Europe, Latin America, and 
North America, with possible extension to other regions and countries, as needed. Capping rules 
for regions and sites will be described in detail in the interactive voice response sy stem 
(IVRS)/interactive web response s ystem (I WRS) specifications.
5.1.4 Data Monitoring Committee
A DMC will be formed to monitor the ongoing safety of the stud y. The DMC will consist of at 
least 3 individuals. These are clinicians knowledgeable about the disease or the treatment and 
1member may  bea statistician. All members will have experience and expertise in clinical trials. 
The DMC members may  not participate in the study  as principal or coinvestigators, or as study  
subject care ph ysicians. The duration of membership for the DMC will be inclusive of planned 
analyses for SL0023. The DMC will periodically  review study  data and eval uate the treatments 
for excess adverse effects and other potential safety  issues. The DMC may also be asked to 
provide a review of final study  results, as deemed appropriate. The detailed role, scope, 
composition, responsibilities, and operation of the DMC , as well as the identity  of the DMC
members, will be defined in a separate DMC Charter. 
Safety  and tolerability  data will be made available to the DMC at each meeting as described in 
the DMC Statistical Analy sis Plan (SAP) . The data will be provided in a semi unblinded fashion 
(data will be visualized by real treatment groups, but the treatment/dose assigned to each group 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 27of 144will remain blinded) and the full unblinding can be requested by  the DMC members ,if 
appropriate. Pharmacokinetic data may  be provided to the DMC at their request. These safet y, 
tolerability , and PK data will be presented by  individuals not otherwise involved in the conduct 
of the study . The deliberations and decisions of the DMC willbe formall y minuted/documented.
Ad hoc DMC meetings ca n be held for other reasons if deemed appropriate by  the 
Sponsor or the 
DMC members.
In addition to ongoing review of safety  data and safet y signal detection within UCB (see 
Section 13.1.12), the occurrence of AEs of interest including thromboembolic events, in 
particular, will be monitored b y the DMC to provide an assessment of the risk of occurrence of 
these events in the stud y. Statistical modeling will be used to provide estimates for quantification 
of the level of risk in the study  based on the risk in the SL E population and in the intended 
patient population in the study  (see Inclusion and Exclusion Criteria in Section 6
). This analy sis 
will inform any  decisions regarding changes in study  conduct and/or study  termination.
The DMC procedures will ensure that the data remain blind edto the study team and investigators 
at all times throughout the conduct of the stud y until the data for Part1of the study  have been 
unblinded.
5.2 Schedule of study  assessments
A schedule of stud y assessme nts is provided inTable 5‒2.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 28of 144Table 5‒2: Schedule of study  assessments
Period Screening Double -Blind Treatment Period (Part 1) Observational Period (Part 2)
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10/
EWVV11/ 
SFU bV12/ 
SFU bV13 V14 V15 V16/
EWV
Week aW-4 to -1 1aW2 W4 W6 W8 W12 W16 W20 W24 W28bW32bW36 W40 W44 W48
Day a(±3 days for Visits 3 to 16) D-28 to -1D1aD14 D28 D42 D56 D84 D112 D140 D168 D196bD224bD252 D280 D308 D336
Written informed consent X
Dem ographic information X
Lifestyle X
History: general medical/procedures X
TB Signs & Symptoms questionnaire X XcXcX
Chest x -ray dX
Verification of eligibility X Xc,e
C-SSRS X X XfX
Physical exam/interim medical history X XcXcXcXcXcXcX X X X
12-lead ECG X XcX X
Randomization Xc
Recording of concomitant medications X XcX XcX XcXcXcXcX X X X X X X
Reco rding of medical procedures XcX XcX XcXcXcXcX X X X X X X
Adverse events X X X X X X X X X X X X X X X X
With draw al criteria check XcX XcX XcXcXcXcX XgXgX X X
Overnight fast (prior to visit) hXhXhXhXhXh
Contact IVRS/IWRS X X X X X X X X X X
Study drug administration X X X X X X
Dispense daily diary X X X X X X X X X X X XgX X X
Collect/revie w daily diary/corticosteroid 
taperXcX XcX XcXcXcXcX X X X X X X
Dispense urine collection container iX X X X X XgX X
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 29of 144Table 5‒2: Schedule of study  assessments
Period Screening Double -Blind Treatment Period (Part 1) Observational Period (Part 2)
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10/
EWVV11/ 
SFU bV12/ 
SFU bV13 V14 V15 V16/
EWV
Week aW-4 to -1 1aW2 W4 W6 W8 W12 W16 W20 W24 W28bW32bW36 W40 W44 W48
Day a(±3 days for Visits 3 to 16) D-28 to -1D1aD14 D28 D42 D56 D84 D112 D140 D168 D196bD224bD252 D280 D308 D336
Vital signs j:
Unspecified time during visit X X X X X X X X X X
Predose; every 15min post start of 
infusion; every 30min until 2h post end 
of infusionX X X X X X
Collection of blood samples for:
TB test kX
HIV and hepatitis screening X
Serum pregnancy testing (β -hCG) 
(subjects of childbearing potential)X
Hem atology lX XcX XcXcXcXcXcX X X X X
Clinical chemistry lX XcX XcXcXcXcXcX X X X X
Additional laboratory assessments:
Anti-dsDNA antibodies X XcXcXcXcXcXcX X X X
ANAs , anti -ENAs (anti -SM, 
anti-SSA, anti -SSB, anti -RNP), and 
RFX X X
aPL antibodies (anticardiolipin 
antibodies, lupus anticoagulant, and 
anti-β2 glycoprotein -1)X X X
Anti-DZP, anti -PEG antibodies XcXcXcXcXcXcX X X X
Coag ulation and hemostasis tests mX XcX X X
Total Ig, IgG, IgM, IgA, and IgE XcX XcXcXcXcXcX X X
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 30of 144Table 5‒2: Schedule of study  assessments
Period Screening Double -Blind Treatment Period (Part 1) Observational Period (Part 2)
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10/
EWVV11/ 
SFU bV12/ 
SFU bV13 V14 V15 V16/
EWV
Week aW-4 to -1 1aW2 W4 W6 W8 W12 W16 W20 W24 W28bW32bW36 W40 W44 W48
Day a(±3 days for Visits 3 to 16) D-28 to -1D1aD14 D28 D42 D56 D84 D112 D140 D168 D196bD224bD252 D280 D308 D336
Serum complement (C3, C4) X XcX XcXcXcXcXcX X X X
hsCRP X XcX XcXcXcXcXcX X X X X
Whol e blood mRNA XcX XcXcXcX X X
Proteomic signature profile X X XcXcXcXcX X X
Cardiovascular proteins, lipids, lipid 
particles hXc,hXhXc,hXhXh
DNA (PGx analysis) XcX X
Plasma PK sampling n:
Unspecified time during visit X X X X X X X X
Predose; end of infusion; 30min, 1h, 
2h post end of infusionX X X
Predose; end of infusion X X X
Collection of urine for:
Urine pregnancy testing (β -hCG) 
(subjects of childbearing potential)XcX XcX XcXcXcXcX X X X X X X
Urinalysis, chemistry, microscopylX XcX XcXcXcXcXcX X X X X
Urine PK sampling (to be collected at 
home)iX X X X X X X X
Clinical assessments of disease activity:
BILAG 2004 X XcXcXcXcXcXcX X X X
SLEDAI -2K X XcXcXcXcXcXcX X X X
SRI-50 XcXcXcXcXcX X X X
PGA XcXcXcXcXcXcX X X X
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 31of 144Table 5‒2: Schedule of study  assessments
Period Screening Double -Blind Treatment Period (Part 1) Observational Period (Part 2)
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10/
EWVV11/ 
SFU bV12/ 
SFU bV13 V14 V15 V16/
EWV
Week aW-4 to -1 1aW2 W4 W6 W8 W12 W16 W20 W24 W28bW32bW36 W40 W44 W48
Day a(±3 days for Visits 3 to 16) D-28 to -1D1aD14 D28 D42 D56 D84 D112 D140 D168 D196bD224bD252 D280 D308 D336
PtGA XcXcX X
SLIC C/ACR Damage Index X X X
TJC, SJC X XcXcXcXcXcXcX X X X
CLASI X XcXcXcXcXcXcX X X X
Investigator Assessment of Flare X XcX XcXcXcXcX X X X X X X
Patient-reported outcomes:
LupusQoL XcXcXcXcXcXcX X X X
SLE-SoXc,oXc,oXc,oXc,oXc,oXc,oXoXoXoXo
SLE-FoXc,oXc,oXc,oXc,oXcXc,oXoXoXoXo
SLE-MoXc,oXc,oXc,oXc,oXcXc,oXoXoXoXo
SLE-PoXc,oXc,oXc,oXc,oXcXc,oXoXoXoXo
SLE-EoXc,oXc,oXc,oXc,oXcXc,oXoXoXoXo
Subject Experience Interview oXc,oXo
ANA=antinuclear antibody; anti -dsDNA=anti -double -stranded deoxyribonucleic acid; anti -ENA=extractable nuclear antigen antibody; anti -RNP=anti -ribonucleoprotein antibody; 
anti-SSA=Sjögren’s syndrome antibody A; anti-SSB=Sjögren’s syndrome antibody B; anti-SM=Smith antibody; aPL=antiphospholipid; β - hCG=β -human chorionic 
gonadotropin; BILAG 2004=British Isles Lupus Assessment Group Disease Activity Index 2004; C3=complement 3; C4=complement 4; CLASI=Cutaneous Lupus 
Erythematosus Disease Area and Severity In dex; C -SSRS=Columbia Suicide Severity Rating Scale; D=Day; DZP=dapirolizumab pegol; ECG=electrocardiogram; EWV=Early 
Withdrawal Visit; HIV=human immunodeficiency virus; hsCRP=high sensitivity C -reactive protein; Ig=immunoglobulin; IGRA=interferon-γ release assay; 
IVRS/IWRS=interactive voice/web response system; LupusQoL=Lupus Quality of Life questionnaire; mRNA=messenger ribonucleic aci d; PEG=polyethylene glycol; 
PGA=Physician’s Global Assessment of Disease; PGx=pharmacogenomics; PK=pharmacokinetic; PtGA=Patient’s Global Assessment of Disease; QFT- GIT=Quanti -
FERON®-
TB GOLD in -Tube test; RF=rheumatoid factor; SFU=Safety Follow-up; SJC=swollen joint count; SLEDAI-2K=Systemic Lupus Erythematosus Disease Activity Index 2000; 
SLE-E=Systemic Lupus Erythematosus -Emotional States Instrument; SLE -F=Systemic Lupus Erythematosus -Fatigue Instrument; SLE -M=Systemic Lupus Erythematosus-
Mobility Instrument; SLE -P=Systemic Lupus Erythematosus -Pain Instrument; SLE -S=Systemic Lupus Erythematosus -Symptom Inventory Instrument; S LICC/ACR=Systemic 
Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SRI -50=Systemic Lupus Erythematosus Disease Activity Index-2K Responder 
Index -50; TB=tuberculosis; TJC=tender joint count; V=Visit; W=Week
Note: Unsc heduled visits are described in Section 8.11.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 32of 144Table 5‒2: Schedule of study  assessments
Period Screening Double -Blind Treatment Period (Part 1) Observational Period (Part 2)
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10/
EWVV11/ 
SFU bV12/ 
SFU bV13 V14 V15 V16/
EWV
Week aW-4 to -1 1aW2 W4 W6 W8 W12 W16 W20 W24 W28bW32bW36 W40 W44 W48
Day a(±3 days for Visits 3 to 16) D-28 to -1D1aD14 D28 D42 D56 D84 D112 D140 D168 D196bD224bD252 D280 D308 D336
aDay 1 is the first day of Week 1; for all other weeks, the day shown is the final day of the week indicated.
bSubjects who withdraw prior to Week 32 (Visit 12) will complete an EWV (Visit 10 assessments if withdrawn prior to Visit 10; Visit 16 assessments if withdrawn after 
Visit 10) as well as Visits 11 and 12 for SFU assessments at 8 and 12 weeks after their final dose of study drug (as applicable). Subjects who withdraw after Week 32 
(Visit 12) do not require additional SFU visits and will complete the Visit 16/EWV assessments only.
cTo be performed before study drug dosing is started.
dA chest x -ray should be performed if one is not available within 3 months prior to Visit 1 (Screening).
eSubject must have a SLEDAI -2K score without any laboratory values of ≥4 at Visit 2 in order to be eligible to be randomized .
fPerformed only in subjects who have wi thdrawn from the study prior to Week 32 (Visit 12) and are undergoing SFU assessments.
gPerformed only in subjects who are continuing into Part 2.
hSubjects should undergo an overnight fast (at least 8 hours) prior to coming to the site for Visits 2, 5, 7, 1 0, and 16 for the collection of fasting blood samples for 
cardiovascular proteins, lipids, and lipid particles. Subjects may then eat breakfast after serum samples have been obtained for these assessments and before study drug 
administration (if applicable).
iFor urine PK assessments, a urine collection container will be dispensed to the subject at the designated visits for urine co llection at home prior to their next visit. Prior to 
Visits 9 and 10 only, the subject will collect overnight urine samples, which includes the first void after the subject goes to sleep the night before the visit through the first 
morning void the morning of the visit. The subject should note the times for the first and last urine collection. For all oth er noted visits (Visits 2, 11, 12, 13, 14, and 16), the 
subject will only collect their first morning void.
jHeight will only be measured at Screening. With the exception of weight, which should be measured predose, all other vital si gns (pulse rate, blood pressure, and body 
tempe rature) should be measured at the times indicated. Weight should only be measured at Screening and on dosing visits. Vitals s igns should be measured within ±5min of 
the scheduled time point for the every 15min assessments and within ±10min of the scheduled time point for the every 30min assessments. There are no time window 
requirements for vital signs assessments when measured pre -dose or at unspecified times during the visit.
kTuberculosis testing should be done using IGRA. The QFT- GIT is the preferred IGR A test (see Section 13.6 ). It is recommended that the QFT -GIT be the first test performed 
at Screening to reduce the number of screening procedures conducted for any QFT -GIT-positive subjects that may need to be withdrawn from the study.
lHematology, clinical chemistry, and urinalysis parameters to be assessed are defined in Section 13.9.
mAs defined in the Laboratory Manual.
nBlood samples for PK measurements should be drawn within ±10min of the scheduled time point for each post -infusion time point or within 10min after the infusions ends 
for end of infusion time points (ie, not prior to the end of the infusion; further details are provided in the Laboratory Manual). Th ere are no time window requirements for 
blood samples for PK measurements when measured pre -dose or at unspecified times during the visit.
oThe exploratory SLE -
S, SLE -F, SLE -M, SLE -P, and SLE -E Instruments and Subject Interview will be assessed at sites in English - and Spanish-speaking countries only.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 33of 1445.3 Schematic diagram
A schematic diagram of the study  design is provided in Figure 5-1.
Figure 5-1: Schematic diagram of SL0023
CS=corticosteroids; DZP=dapirolizumab pegol; PBO=placebo; q4w=every 4 w eeks; SOC=standard -of-care
aStratified in accordance w ith Screening corticosteroid dose ( ≤10mg/day or >10mg/day prednisone orequivalent) .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 34of 1445.4 Rationale for study  design and selection of dose
Moderate lyto severe ly active SLE is a disease area w ith high unmet need, as,in many  patients ,
disease remains uncontrolled and poorly  managed with current standard-of- care
immunosuppress antsand corticosteroids at tolerable doses . Dapirolizumab pegol has been 
evaluated in 2small Phase 1studies :1 single dose study at doses up to 5mg/kgin healthy  
subjects (SL0013, Part 1) and up to 60mg/kg in subjects with SL E (SL0013, Part2), and 1repeat 
dose study  utilizing a loadin g dose of 30mg/kg followed by  5doses of 15mg/kg ever y 2weeks in 
subjects with SLE(SL0014). No treatment -limiting safet y findings were observed in either 
study ,and the results of SL 0014 showed a trend for clinical efficacy  in subjects with SL E. 
SL0023 is a dose- ranging stud y in subjects with moderatel y to severel y active SLE (including 
neurological and renal involvement), where a spectrum of DZP doses will be administered over a 
Double- Blind Treatment Period of 24weeks (Part1) in subjects who have active disease despite 
stable 
standard -of-care treatment. Subjects completing the Double -Blind Treatment Period 
(Part1) will enter a 24-week Observational Period (Part2).
SL0023 is intended to evaluate 
3 dose levels of DZP, 6mg/kg, 24mg/kg, and 45mg/kg,
administered every  4weeks for 24 weeks. These doses have been selected to explore a 
dose-response curve for DZP in SLE. The clinical data generated thus far for DZP have not 
allowed an exposure -response relationship to be defined in order to aid in the selection of doses 
to be tested in SL 0023. Therefore, several target C trough values were defined based on qualitative 
evidence from nonclinical and clinical data and dose levels were selected to maintain the DZP 
plasma concentration above the target C trough values in more than 90% of subjects for the 
majority  of the dosing interva l.
TheDZP dosing regimen in SL 0014 ( 30 mg/kg loading followed by  15mg/kg every  2weeks) 
was chosen in order to maintain DZP plasma concentration sabove 100
μg/mL,and in fact ,the 
majority  of subjects in SL0014 had Ctrough ≥100μ g/mL. The 100μg/mL target wa s determined 
based on clinical data observed in clinical studies for hu5c8, a full length anti- CD40L  
monoclonal antibody . Study  C99 -1021 was an open -label, multiple dose study  to evaluate the 
efficacy , safet y, and PK of hu5c8 in subjects with proliferative lupus glomerulonephritis. 
Pharmacological activity  was observed for hu5c8 in term s of meaningful changes in 
anti-dsDNA. Hu5c8 at 20mg/kg was pla nned to be administered every  2 weeks for 3 doses, and 
then every  28days for 4 doses. Data from subjects who r eceived at least 3 doses were evaluated. 
Following hu5c8 administration, th ere was a significant treatment -related decline in anti -dsDNA 
antibody  titers, with mean reductions of 25.1% on Day 29 and 23.9% and 18.9%, respectively , 
1 month and 2 months after the last treatment (Boumpas etal,2003). A limited PK/PD 
relationship (log -linear model) was determined, and it highlighted that to ac hieve the 25% 
reduction in anti -dsDNA antibody  titers, an hu5c8 plasma concentration >100μg/mL  was 
required. Therefore, 1 00μg/mL  was set as the target C trough to be maintained in SL 0014 and this 
study  demonstrated greater improvement in clinical measures of disease activity  in the DZP 
group compared with the PBO group. For SL0023 ,the dosing frequency  is being reduced to 
every  4 weeks as a more patient -oriented regimen and no loading dose is proposed. A dose level 
of 45 mg/kg administered every  4 weeks is predicted to maintain the C trough >100 μg/mL for the 
majority  of the dosing interval.
In order to explore the dose respon se curve, 2 DZP dose levels below 45mg /kg have bee n 
selected (24mg/kg and 6mg/kg) . The 24mg/kg dose has been selected in consideration of results 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 35of 144from the hu5c8 anti -dsDNA antibody PK/PDmodel demonstrating that minimum changes in 
anti-dsDNA antibod y titers could be achieved with an hu5c8 plasma concentration of 40μ g/mL. 
The dose of 24 mg/kg every  4weeks wasselected to maintain a C trough >40μg/mL for the majority  
of the dosing interval.
The lowest DZP dos e level in SL 0023 (6mg/kg) has been selected based on nonclinical 
pharmacology data. Nonclinical data from a NHP tetanus toxoid (TT) model showed that a
minimal reduction of anti-TT IgG/IgM titers was observed at a dose of DZP 5mg/kg with a 
plasma concentration range of 15 to 31μg/mL. Based on these data, a target DZP C trough of 
10μg/mL  for minimum pharmacological effect in nonclinical models has been defined and 
c
orresponds to a dose level of 6mg/kg every  4weeks in SL 0023. 
A summary  ofthe target C trough values and corresponding proposed doses in SL 0023 is provided 
in Table 5‒3.
Table 5
‒3: Summary  of qualitative evidence leading the selected target DZP 
Ctrough and corresponding dose levels for SL0023
Evidence Target DZP C trough
(μg/mL)SL0023 D ose Level 
(mg/kg every 4 weeks )
DZP plasma concentration for minimum
pharmacological effect in preclinical models10 6
Hu5c8 plasma concentration to produce minimum 
observed change from baseline in anti -dsDNA
antibodies40 24
Ctrough in SL0014 that showed evidence of clinical 
efficacy
Hu5c8 plasma concentration to produce 25% 
reduction from baseline in anti -dsDNA antibodies100 45
anti-dsDNA=anti -double -stranded deoxyribonucleic acid; C trough=trough concentration; DZP=dapirolizumab pegol
The expected C max, AUC τ (over the last dosing interval of 28 days),and C trough at the proposed 
dose levels in SL 0023 are presented in Table 5‒4.
Table 5
‒4: Pharmacokinetic parameters expected at the dose levels proposed in 
SL0023 (median [5th-95thpercentile])
DZP d ose level 
(mg/kg) every 4 weeksCmax(μg/mL) AUCτ ( μg.day /mL) Ctrough (μg/mL)
6 145 (93, 241) 1357 (974, 1384) 20 (10, 36)
24 582 (373, 966) 5429 (3895, 7937) 33 (17, 59)
45 1091 (698, 1811) 10179 (7305, 14882) 149 (75, 267)
AUC τ=area under the curve over the dosing interval; Cmax=maximum concentration; C trough=trough concentration; 
DZP=dapirolizumab pegol
At the highest DZP dose level proposed of 45mg/kg every  4weeks, the expected DZP C max is 
1091μg/mL  (698-1811μg/mL ) and the expected AUCτ over the 28 -day dosing interval is 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 36of 14410179μg .day/mL(7305 -14882 μg.day/mL) (median [5th-95thpercentiles]). When comparing the 
mean AUC τwith the mean toxicokinetic data at the no-observed-adverse- effect level ( NOAEL )
of 50mg/kg obtained in the 26-week toxicology  study  in Cynomolgus monkey s, there is an 
exposure margin of 4 -foldfor AUC and 2 -fold for C max.
6 SELECTION A ND WITHDR AWAL  OF SUBJECTS
Subjects who initially  fail to meet eligibility  criteria or for whom eligibility assessments could 
not be completed as planned may  be rescreened once on a case -by-case basis after discussion 
with the Medical M onitor (see Section 8.1).
6.1 Inclusion criteria
To be eligible to participate in this study , all of the following criteria must be met:
General
1a. An Institutional Review Board (I RB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated b y the subject prior to the initiation of any  study -
specific assessment at Screening ( Visit 1). 
2.Subject is considered reliable and capable of adhering to the protocol ( eg,able to understand 
and complete diaries), visit schedule, and medication intake according to the judgment of the 
Investigator .
3. Subject (male or female) is ≥18years of age at Screening ( Visit 1).
4.Subject has a bod ywei ght of ≥50kg and ≤ 160kg .
5.Adequate reading and writing abilities (in native language) such that the subject can 
comprehend and answer the questions on the subject completed assessments.
Disease -specific
6. The subject has SLE diagnosed by  a phy sician, confirmed by the SLI CC Classification 
Criteria for SL E (see Appendix 19.1; Petri etal,2012 ) . 
7.The subject has at least 1of the following :
Anti- dsDNA antibodies by  Farr assay  confirmed by  the central laboratory  at Screening 
(Visit 1)
OR
Low complement (ie,either low C3, or low C4, or both) confirmed by the central 
laboratory  at Screening ( Visit 1)
OR
ANA titer of ≥1:80 con firmed by  the central laboratory  at Screening ( Visit 1) in 
combination with at least 1 of the following :
◦Historical positivity  for anti- dsDNA (as defined for the SLICC criteria, at least twice
in the past )
or
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 37of 144◦Positivity  for anti-ENA ( anti-SM, anti -SSA, ant i-SSB, or anti -RNP )confirmed by  the 
central laboratory  at Screening ( Visit 1)
8.The s ubject has moderate to severe SLE disease activity  as demonstrated b y BILAG 2004
Grade A level disease activity  in at least 1 body /organ s ystem at Screening ( Visit 1) or 
BILAG 2004 G rade Blevel disease activity  in at least 2 body /organ s ystems if no 
BILAG 2004 Grade Alevel disease is present.
9.The subject has moderate to severe SLE disease act ivity as demonstrated by a SLEDAI -2K
total score of ≥6 at Screening ( Visit 1) and a SLEDAI -2K score without any  laboratory  
values of ≥4at Baseline (Visit 2).
10.The subject is receiving stable standard -of-care medication ,defined as at least 1 of the
following, either alone or in combination: corticosteroids, and/or antimalarials, and/or 
immunosuppressants
.
If the subject is receiving concomitant corticosteroids on a continuous regimen, the dose 
must be ≤40mg/day  prednisone or equivalent dependent on the Investigator’s assessment 
of disease activity  (refer to the list of prednisone equivalents in Appendix 19.2). Doses of 
corticosteroids must have been stable for at least 2
weeks prior to Screening ( Visit 1), 
must remain stable until Baseline (Visit 2), and should remain stable until 4 weeks after 
the first study  drug infusion (until Day 28). Subjects not receiving concomitant 
corticosteroids or who were previously  receiving corticosteroids on an as needed basis 
must have stopped the treatment or been assigned to a continuous corticosteroid dose at 
least 2 weeks prior to Screening ( Visit 1).
◦Subjects who are receiving a corticosteroid dose at Screening ( Visit 1) that is in 
between the specified starting dose s of the corticosteroid tapering schedule 
(Table 5-1; eg, 12.5mg/day  or 17.5mg/day  prednisone or equivalent) should transition 
to the lowest nearest pre specified starting dose over the first 2
weeks of Screening 
and will enter the study on this dose ; the dose will be considered stable in this case. 
This dose should then remain stable until 4 weeks after the first study  drug i nfusion 
(until Day 28). 
◦If iv steroids have been administered for treatment of acute disease flare, this must 
have occurred at least 6 weeks prior to the first study  drug infusion ( Visit 2). 
Treatment with a ntimalarials must have been started or stopped at least 12 weeks prior to 
dosing with study  drug. If the subject is receiving concomitant antimalarials at Screening, 
doses must remain stable for at least 4weeks prior to the first study  drug infusion 
(Visit 2). The maximum doses for allowed antimalarials are specified in Table 6-1.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 38of 144Table 6-1: Maximum doses of permitted concomitant an timalarials
Antimalarial ( generic name) Maxi mum d ose allowed
Hydroxychloroquine 400mg /day
Chloroquine 500mg/day
Quinacrine 200mg/day
Quinine Any dose allowed
Treatment with i mmunosuppressants must have been started or stopped at least 12 weeks 
prior to dosing with study  drug . If the subject is receiving concomitant 
immunosuppressants at Screening, doses must remain stable for at least 8 weeks prior to 
the first study  drug infusion ( Visit 2).The maximum doses for allowed 
immunosuppressants are specifi ed in 
Table 6-2.
Table 6
-2: Maximum doses of permitted concomitant immunosuppressants
Immunosuppressant (generic name) Maximum dose allowed
Azathioprine 300mg/day oral
Mycophenolate mofetil 3000mg/day oral
Leflunomide 40mg/day oral
Methotrexate 25mg/week any route
11.Subjects receiving memantine, bromocriptine (parlodel), danazol, dapsone,
dehy droepiandrosterone, or retinoids must be o n a stable dose for at least 4 weeks prior to the 
first study  drug infusion ( Visit 2)and the doses should remain stable throughout the 
Treatment Period .
12.Female subjects of child bearing potential must have a negative serum pregnancy  test at the
Screening Visit, which is confirmed to be negative by  urine testing prior to the first dose of 
study  drug at Week 1 (Visit 2) and prior to further dosing at each stud y visit thereafter . 
13a.Female subjects of childbearing potential must agree to use a highly  effective method of 
birth control duri ng the study  and for a period of 12 weeks after their final dose of study  drug
(ie,through completion of the 
SFU Period) . Highly  effective fo rms of birth control are 
methods which achieve a failure rate of less than 1% per year when used consistently  and 
correctly . Highl y effective methods of birth control include , but are not limited to :
Combined (estrogen- and progesterone -containing) hormona l contraception (oral, 
implant, or injectable) associated with inhibition of ovulation (whic h must be stable for at 
least 1 full month prior to Screening [ Visit 1], and should remain stable during the stud y)
Progesterone -only hormonal contraceptives (oral, implant, or injectable) associated with 
inhibition of ovulation (whic h must be stable for at least 1 full month prior to Screening 
[Visit 1], and should remain stable during the study)
Progesterone -releasing intrauterine s ystems or the TCu380A intrauterin e device
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 39of 144Vasectomized partner (provided sole partner and partner has medical proof of surgical 
success)
True heterosexual sexual abstinence is an acceptable form of contraception when this is 
in line with the preferred and usual lifesty le of the p erson. Pe riodic abstinence 
(eg,calendar, ovulation, sy mptothermal, postovulation methods), declaration of 
abstinence for the duration of the study, and withdrawal are not acceptable methods of 
contraception.
Women not agreeing to use birth control must be of nonch ildbearing potential, defined as 
being:
Postmenopausal (for at least 2 years before the Screening Visit), verified b y serum 
follicle -stimulating hormone level >40mIU/mL at the Screening Visit, or
Permanently  sterilized (eg, bilateral tubal occlusion, hy sterectom y, bilateral 
salpingectomy ), or
Congenitall y sterile
14. Contraception methods for male subjects and their female partners:
Male subjects with a partner of childbearing potential must be willing to use a condom 
when sexually  active d uring the study  and for 12 weeks after the final administrati on of 
study  drug (ie,through completion of the SFU Period ; approximately  5half-lives).
In addition, the female partner of childbearing potential of a male subject must be willing 
to use a highl y effective method of contraception (per I nclusion Criterion #13 ) during the 
study  period and for 12weeks after the final administration of study  drug.
6.2 Exclusion criteria
Subjects are not permitted to enroll in the study  if any  of the following criteria is met:
Gener al
1.Subject has previously  been randomized in this study  or has previousl y participated in a DZP 
clinical study .
2.Subject has an y medical or psychiatric condition that, in the opinion of the Investigator , 
could jeopardize or would compromise the subject’s ab ility to participate in this study .
3. Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the 
study or within 3 months following their final dose of study  drug.
4.Subject has a h istory  of malignan cy, except the following treated cancers: cervical carcinoma 
in situ, basal cell carcinoma, or dermatological squamous cell carcinoma.
5a. Subject has a mixed connective tissue disease, scleroderma, and/or overlap sy ndromes of 
SLE.
Subjects with SL E and secondary  Sjögren’s sy ndrome are pe rmitted provided they  meet 
the eligibility  criteria.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 40of 144Clarification: Subjects with rheumatoid arthritis in their medical history  are not 
considered as having an overlap s yndrome and are thereb y eligible, except when erosive 
arthritis is the only symptom at Screening.
Disease specific
6.Subjects with severe neuropsy chiatric SLE or other neurological symptoms that in the 
opinion of the I nvestigator, would prevent the subject from completing protocol required 
procedures and assessments.
7. Subject has active lupus that, in the opinion of the Investigator , requires an increase in 
standard -of-care therapy  outside of that permitted in Table 6-1and Table 6-2.
8.
Subject has new or worsening Class III or IV l upus nephritis.
9.Subject has c hronic kidney  failure stage 3b, manifested by  
estimated glomerular filtration 
rate ( eGFR )<45mL/min/1.73m2, or serum creatinine >2.5mg/dL, or proteinuria >2g/day , or 
protein:creatinine ratio >2
26mg/mmol .
10.Subjects requiring plasma exchange or immunoabsorption in the 4 months prior to Visit 2 or 
during the stud y.
Infection -related risks
11.Subject has evidence of human immunodeficiency  virus ( HIV)infection, 
agammaglobulinemias, T -cell deficiencies, or human T -cell ly mphotropic virus -1 infection at 
any time prior to or during the study .
12. Subject has clinically  significant active or latent infection, for example, but not limited to ,
chronic viral hepatitis B or C.
13.Subject has a history  of a serio us infection within the last 60 days prior to the first study  drug 
infusion ( Visit 2) that required iv/intramuscular (im) antibiotics or required 
hospitalization/prolonged hospitalization. Subjects must have completed any prior 
anti-infective therap y for serious infections prior to the first study  drug infusion.
14. Subject had an opportunistic infection (for example, but not limited to, pneumocy stis, 
cytomegalovirus, herpes simplex vir us, or herpes zoster) within 12 weeks prior to the first 
study  drug infusion ( Visit 2), or is currently  receiving suppressive therap y for an 
opportunistic infection.
15.Subject has a clinicall y relevant recurrent (more than 3 times a y ear) infection.
16. Subjects with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or 
latent TB (LTB) infection are excluded.
a.Known TB infection whether present or pa st is defined as:
Active TB infection or clinical signs and s ymptoms sugge stive of TB (pulmonary  or 
extra pulmonary ).
History  of active TB infection involving any  organ sy stem or findings in other organ 
systems consistent with TB infection.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 41of 144Any evidence by  radiography  or other imaging modalities consistent with previously  
active TB infection that is not reported in the subject's medical history .
b.High risk of acquiring TB infection is defined as:
Known exposure to another person with active TB infection withi n the 3 months prior 
to Screening (Visit 1)
.
Time spent in a healthcare delivery  setting or institution where individuals infected 
with TB are housed and where the risk of transmission of infection is high.
c.LTB infection (refer to Section 13.6 for further details and instructions).
17. Subjects who have received live/live attenuated vaccines within 6 weeks prior to the first 
study  drug infusion ( Visit 2) or who plan to receive these vaccines during the study  or 
12weeks after the final dose of study  drug will be excluded. Use of nonlive vaccines is 
allowed during the stud y; however, based on current evidence, it cannot be excluded that the 
effectiveness of these vaccines may  be compromised by  the study  drug.
Other safety risks
18.Subjects with a history of thromboembolic events within 12months of Screening ( Visit 1), 
including but not limited to the following: deep venous thrombosis, pulmonary  embolism , 
cortical sinus thrombosis, my ocardial infarction, stroke, transient ischemic attack ,or arterial 
insufficiency  causing digi tal gangrene or tissue necrosis.
Note: Subjects with antiphospholipid syndrome (APS) can be enrolled if they  are on 
stable anticoag ulation therapy  at an effective dose (ie, International Normalized Ratio
[INR] target 2 to 3 depending on clinical situation) and did not have a thromboembolic 
event and/or obs tetric morbidity * within the 12 months prior to Screening ( Visit 1).
*Obstetric morbidity is defined as 1 or more unexplained deaths of a morphologically normal fetus at or 
beyond the 10thweek of gestation with the latest incidence within 12 months prior to Screening ( Visit 1) 
OR 1or more preterm births of a morphologically normal n eonate before the 34thweek of: (i) eclampsia or 
severe pre
-eclampsia or (ii) recognized features of placental insufficiency with the latest incidence within 
12months prior Screening ( Visit 1).
19.Subjects with a history  of catastrophic APS or saddle pul monary  embolism.
20.Subject has b lood laboratory  values as follows : s ignificant hematologic abnormalities of 
hemoglobin <7.0g/dL, or lymphocy tes< 500/mm3, or absolute neutrophil count <500/mm3,or 
platelets <25,000/mm3at Screening ( Visit 1)
.Subjects with a higher platelet count should 
also be excluded if they  have a clinical risk of bleeding for reasons other than SL E.  
Note: Subjects with an isolated laboratory  parameter outside of the normal range at the 
Screening Visit may have a repeat t est. If the repeat laboratory  parameter is within normal 
range, the subject may  be randomized at the Baseline Visit, provided they  meet all other 
eligibility  criteria.
21.Subject has a vascular graft, valvular heart disease ,or atrial fibrillation .
22.Subject has a known h ypersensitivity  to an y components of the investigational medicinal 
product (IMP), including PEG.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 42of 14423.Subject has a history  of an anaphy lactic reaction to parenteral administration of contrast 
agents, human or murine proteins, or monoclon al antibodies.
24.Subject has suicidal ideation in the past 6 months as indicated b y a positive response (“Yes”) 
to either Question 4 or Question 5 of the “Screening/Baseline” version of the Columbia 
Suicide Severity Rating Scale ( C-SSRS )at Screening.
25.Subject has ≥3xthe upper limit of normal ( ULN )alanine aminotransferase ( ALT) , aspartate 
aminotransferase (AST), or alkaline phosphatase ( ALP), or >ULN bilirubin ( ≥1.5xUL N 
bilirubin if known Gilbert’s sy ndrome). If subject only  has >1.5xUL N bilirubin, fractionate 
bilirubin to identify  possible undi agnosed Gilbert’s sy ndrome (ie, direct bilirubin <35%) , 
except in the case where the abnormal test values are ascribed to SLE hepatitis or hemoly tic 
anemia , in the opinion of the Investigator. In case of a su spected SL E hepatitis, eligibility  
must be discussed with the Medical Monitor.
For subjects with a baseline result >ULN, a baseline diagnosis and/or the cause of an y 
clinically  meaningful elevation must be understood and recorded in the e CRF.
If subject ha s >ULN that does not meet the exclusion limit for AL T, AST, or AL P at 
Screening, repeat, if possible, prior to dosing to ensure there is no further ongoing clinicall y 
relevant increase. In case of a clinicall y relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor. 
An ALT and/or AST result up to 25% above the exclusion limit may  be repeated once for
confirmation. This includes re screening.
Prior and concomitant medications
26.Subject has used the prohibited medications list ed in Table 7-1, regardless of route (with the 
exception of ey e drops) , within the time frame (Wash-O ut Period) listed in the table prior to 
Screening ( Visit 1). Subject has used investigational agents not included in Table 7-1,
including other investigational or recently  approved biologi cs or device products, within 
3months or 5 times the half -life prior to Screening ( Visit 1), whichever is longer.
Concomitant participation in studies where no pr oduct or device is administered/ used may  be 
allowed if discussed and approved b y the Medical Monitor /UCB . If there are an y ques tions 
regarding acceptable wash -out periods not mentioned, the I nvestigator should contact the 
Medical Monitor .
Hormone replacement therap y is allowed provided i t is not initiated within the 4 weeks 
prior to Screening ( Visit 1) or during the stud y . The hormone replacement therapy may 
be decr eased and/or discontinued at an y time during the stud y.
27.Subject should stay  on stable doses of 
the following other concomitant medications for the 
treatment of SLE during the study  unless changes in these treatments are clinically  indicated:
analgesics , NSAIDs, 3 - hydroxy -3-methy l - glutary l-coenzy me A (HMG -CoA) reductase 
inhibitors ( statins), angiotensin converting enzy me (ACE) inhibitors, and other 
anti-hypertensive drugs.
6.3 Withdrawal criteria
Subjects are free to withdraw from the study  at any  time, with out prejudice to their continued 
care.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 43of 144Subjects must be withdrawn from the stud yif any  of the following occurs at an y time during the 
study :
Subject withdraws his/her consent.
The Sponsor or a regulatory  agency  requests withdrawal of the subject.
Subjects must be discontinued from study drug (but not from the study )if any  of the following 
occurs during Part 1of the study  (ie,through Visit 10 [Week 24] of the Double -Blind Treatment 
Period):
There is confirmation of a nongoing pregnancy  during the study , as evidenced by a positive 
pregnancy  test.
Subject experiences a thromboembolic event.
Subject has a TB test that is confirmed positive or any  further evidence suggestive of 
potential TB infection (eg, exposure) and further examinations result in a diagnosis of active 
TB or LTB. Refer to Section 13.6 (Assessment and management of TB and TB risk factors) 
for further details and instructions.
Subject receives a live /live attenuated vaccine.
Subject requires an induction therapy  with cy clophosphamide for management of acute flare 
of lupus nephritis or other severe manifestation of SL E, in the opinion of the Investigator.
Subjects may be withdraw nfrom the stud y, at the I nvestigator’s discretion, if any  of the
following occur s:
Subject develops a clinically  meaningful illness that would interfere with his/her continued 
participation , and/or render safety  and efficacy  data to be unreliable in the o pinion of the 
Investigator .
Subject is noncompliant with the study  procedures or medications , in the opinion of the 
Investigator , in a manner that impact s the subject’s safet y.
Investigators should contact the Medical Monitor, whenever possible, to discuss the 
withdrawal of a subject in advance.
Investigators should attempt to obtain information on subjects in the case of withdrawal . For 
subjects consid ered as lost to follow up, the I nvestigator sh ould make an effort (at least 1 phone 
call and 1 written message to the subject), and document his/her effort (date and summary  of the 
phone call and cop y of the written message in the source documents), to complete the final 
evaluation . All results of these evaluations and observations, together with a narrativ e description 
of the reason(s) for removing the subject, must be recorded in the source documents . The 
electronic 
Case Report F orm ( eCRF) must document the primary  reason for withdrawal or 
discontinuation.
6.3.1 Potential drug -induced liver injury IMP discontinuation criteria
Subjects with potential drug -induced liver injury  (PDILI )must be assessed to determine if IMP 
must be 
discontinued. I n addition, all concomitant medications and herbal supplements that are 
not medically  necessary  should also be discontinued. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 44of 144The following PDILI criteria require immediate and permanent discontinuation of IMP:
Subjects with any  of the following:
ALTor aspartate aminotransferase ( AST )≥8xULN
ALTor AST ≥3xUL N and co- existing total bilirubin ≥2xUL N
The following PDILI criterion requires immediate discontinuation of I MP: 
Subjects with AL Tand/or AST ≥3xULN who exhibit temporally  associated symptoms of
hepatitis (excluding SLE-related hepatitis) or hypersensitivity . Hepatitis symptoms include
fatigue, nausea, vomiting, right upper quadrant pain or tenderness . Hypersensitivity  
symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
If a non -drug related cause for the s ymptoms can be confirmed, these subjects may resume IMP 
administration after discussion with the responsible UCB ph ysician, but only  when the 
requirements for rechallenge with I MP as provided in Section 13.7.2.1 are followed.
The following PDILI criteria allows for subjects to continue on IMP at the discretion of the 
Investigator :
ALTor AST ≥3xUL N (and ≥2x baseline) and <8xULN, total bilirubin < 2xULN , and no 
eosinophilia (ie, ≤5%), with no fever, rash or s ymptoms of hepatitis (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness)
Evaluation of PDILI must be initiated as described in Section 13.7. I f subjects are unable to 
comply  
with the applicable monitoring schedule, IMP must be discontinued immediately (see 
Section 8.10) . 
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study  
until investigation and monitoring are complete. All results of t hese evaluations and 
observations, together with a narrative description of the reason(s) for IMP discontinuation and 
subject withdrawal (if applicable), must be recorded in the source documents. The eCRF must 
document the primary  reason for IMP discontinu
ation.
7 STUDY TREA TMENTS
7.1 Description of IMPs
The DZP IMP will be supplied by  UCB Clinical Trial Supply  Operations (CTSO) or designee , as 
follows :
DZP 20mL vial l yophilized drug product. Each DZP vial will be labeled.
The PBO IMP will not be supplied by  UCB CTSO. The sites will use commercial 0.9% sodium 
chloride aqueous solution (phy siological saline, preservative free) of pharmacopoeia 
(USPharmacope ia/European Pharmacopoeia) quality .
7.2 Treatments to be administered
During the 24 -week Double -Blind Treatment Period ( Part1), eligible subjects will be randomly  
allocated in a 1:1:1:1 ratio to receive 
an iv infusion of DZP (6mg/kg, 24mg/kg, or 45mg /kg) or 
PBO every  4weeks, for a total of 
6doses (on Day 1 and at Weeks 4, 8, 12, 16, and 20) . The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 45of 144subject’s bod y weight at Baseline (Visit 2) will be used to calculate the individual dose 
throughout the stud y.
Following completion of the 24-week Double- Blind Treatment Period ( Part1), subjects will 
enter a 24 -week Observational Period, during which subjects will not receive study  drug 
but will 
be able to receive standard-of-care treatment, as indicated. The subjects, Investigators, and study  
site staff will remain blinded to the treatment administered during Part1of the study  until the 
end of the stud y.
Refer to 
Table 5‒2for details regarding the visits at which IMP should be administered.
7.2.1 Treatment preparation and administration
7.2.1.1 Preparation
Only  DZP l yophilized drug product will be supplied by  UCB CTSO. The ly ophilized drug 
product provided in a 20mL  vial will be reconstituted by  adding 10mL water for injection and 
then diluted with saline to prepare for administration. Complete preparation instructions will be 
outlined in the Pharmacy Manual.
For PBO, commercial 0.9% sodium chloride aqueous solution will be used. Thus, in order to 
maintain blinding, an unblinded pharmacist or other suitably  qualified site personnel will prepare 
each dose of IMP and provide it to 
the blinded site personnel for administration.
All the preparation steps, including the reconstitution of DZP and preparation for infusion, PBO 
material requirements, and dispensing material requirements will be described in full detail in the 
Pharmacy  Man ual.
7.2.1.2 Administration
The IMP will be administered as an iv infusion through a cannula placed in an easil y accessible 
vein of the arm (eg, cephalic vein or median cubital vein); an iv infusion pump will be used for 
IMP administration.
For all subjects, t he infusion volume will be 150mL and the infusion time will be approximately  
120min. These timings are provided to allow a slow rise in plasma concentration and for the 
possibility  of interrupting the infusion in case of an acute AE. Further instructions on 
administration will be pr ovided in the Pharmacy  Manual.
The infusion rate may  be reduced at any  time at the discretion of the Investigator. If an infusion 
is interrupted, it can be restarted if the Investigator considers it appropriate to do so. I n such 
instances, the total infusion time may exceed 120min in order to administer the entire planned 
dose. The chronology  of these events should be recorded accuratel y in the source data and eCRF.
After the infusion is completed, the subject will remain in the clini c for observation and 
assessments for at least 2 hours , or longer at the discretion of the Investigator.
Data from clinical studies SL 0013 and SL0014 arelimited ,and because DZP is an iv
administered protein, an increased risk for infusion-related reactions, including anaph ylaxis,
cannot be excluded at this time. A mandatory  premedication for proph ylaxis of infusion -related
reactions is not planned in this study ; however, premedication (with acetaminophen or
antihistamines) is permitted at the discretion of the I nvestigator considering the individual risk 
profile of the subject (for example ,but not limited to ,medical history , comorbidities, and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 46of 144concomitant medication) and current knowledge on the risk of DZP to induce anaph ylactic 
reactions .Corticostero ids should be avoided as an anti allergic premedication given the protocol 
requirements for stable corticosteroid use and planned tapering ( refer to Section 5.1and 
Section 7.8.1).
7.3 Packaging
Dapirolizumab 
pegol lyophilized drug product is supplied in 20mL  vials. Each vial and each box 
will be labe led and will be for individual use.
The site carton will be suitably  packaged in such a way  as to protect the product from 
deterioration during transport and storage. Further information regarding storage and transport 
conditions will be provided in the Ph armacy  Manual.
The diluent and materials such as s yringes and needles, perfusor s yringes, and administration 
sets required for reconstitution, dilution ,and final administration will be provided in the original 
packaging to the sites b y the contract research organization (CRO )or will be sourced b y the sites 
based on the material specifications noted in the Pharmacy  Manual and provided by  UCB. 
7.4 Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing 
Practice and will include any  locall y required statements. I f necessary , labels will be translated 
into the local language and adapted to the size of the I MP package .
7.5 Handling and storage requirements
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored b y the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned in the I MP Handling Manual .
Appropriate storage condition must be ensured by controlled refrigerator temperature either 
using an automated temperature monitoring and recording s ystemor by using a 
minimum/max imum thermometer an d completing daily  a temperature log in accordance with 
local requirements. Temperature data for IMP should be recorded on each working day  with the 
actual and minimum/maximum temperatures reached during this period.
In case an out -of-range temperature is noted, it must be immediately  reported as per instructions 
contained in the IMP Handling Manual .
The phy siological saline [0/9% sodium chloride] used for administration should be handled per 
specific site requirements and stored according to label require ments.  
7.6 Drug accountability
A Drug Accountability  form will be used to record I MP dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study . Details of 
any IMP lost , damaged (due to breakage or wastage), not used, partially  used, disposed of at the 
study  site, or retu
rned to the S ponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study  only to
the designated unblinded monitor (or designee) forreview. In addition, the site will document all 
materials used for each subject dosing, including water for injection used for reconstitution, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 47of 144saline for PBO, and infusion and other materials. T he site will keep a log with the names of those 
individuals with access to I MP, including the names of those who are involved in preparation of 
doses for IMP administration.
The Investigator (or designee) is responsible for retaining all used, unused, and partiall y used 
containers of IMP until returned or destro yed.
The Investigator must assign duties for drug accountability  at the study  site to an appropriate 
unblinded pharmacist (or designee ) .
The Investigator must ensure that the IMP is used only  in accordance with the protocol.
Periodically , and/or after completion of the clinical phase of the study , all used (including empty
containers )/partially  used , unused, damaged, and/or expired IMP must be reconciled and either 
destroy ed at the site according to local law s, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study  cannot be used for an y other 
purpose than that described in this protocol.
7.7 Procedu res for monitoring subject compliance
The IMP will be administered b y designated study site staff. The unblinded monitor will review 
the pharmacy  records at each site, including the Drug Dispensing Record Form. The unblinded 
monitor will compare the dispen sing record and vials to the individual subject’s identifiers and 
visit schedule to assure that the subject received the correct treatment and dose, and that the 
dosing schedule is correct. The unblinded monitor’s report will include details of an y missed 
doses, errors in dose, treatment errors or schedule errors, and reasons for these. All supplies and 
pharmacy  documentation must be made available throughout the study  for the 
unblinded monitor 
to review. 
Subjects are expected to receive all doses of IMP as detailed in the schedule of assessments. An y 
subject who deviates from the dosing schedule or misses any  scheduled treatment should be 
reported to the Medical Monitor in a blinded fashion for determinati on of possible schedule 
adjustments and continued eligibility . These instances will be handled on a case -by-case basis.
7.8 Conc omitant medications/treatment s
7.8.1 Permitted concomitant treatments (medications and therapies) for 
SLE
The following concomitant medications are permitted for the treatment of SLE and SL E 
associated signs and s ymptoms under certain conditions:
Corticosteroids ( ≤40mg/day  prednisone or equivalent ; see Inclusion Criterion #10 )
Antimalarials (eg, hydroxy chloroquine, chloroquine, and quinacrin e) (see Inclusion 
Criterion #10 and maximum dose restrictions in Table 6-1)
Other immunosuppress
antor immunomodulatory agents including (see Inclusion 
Criterion #10 and maximum dose restrictions in Table 6-2)
Methotrexate
Azathioprine
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 48of 144Mycophenolate (including m ycophenolate mofetil, my cophenolate mofet il hydrochloride, 
and my cophenolate sodium)
Leflunomide
Analgesics, NSAIDs , HMG -CoA reductase inhibitors (statins), ACE inhibitors, and other 
anti-hypertensive drugs
In subjects receiving concomitant corticosteroids , doses must have been stable for at least 
2 weeks prior to Screening, must remain stable until Baseline (Visit 2), and should remain stable 
until 4 weeks after the first study  drug infusion ( until Day 28). Subjects not receiving 
concomitant corticosteroids or who were previously receiving corticosteroids on an as needed 
basis must have stopped the treatment or been assigned to a continuous corticosteroid dose at 
least 
2 weeks prior to Screening (Visit 1). 
In subjects receiving concomitant corticoster oid doses between 10mg/day  and 4 0mg/day  
prednisone or equivalent, a mandatory  corticosteroid taper must be initiated no later than 
4weeks after the first study drug infusion (on Day 29)The tapering regimen ,as recommended in 
Section 5.1 and Table 5-1,will aim to reduce the daily  prednisone equivalent dose to 7.5mg/day  
or lower b y Week 12 (Day 84) of the study . If such a rapid tapering is not considered b y the 
Investigator to be appropriate for the individual subject, a slower tapering regimen can be u sed. 
Subjects achieving a dose of 7.5mg/day  or lower may  remain on this dose or continue to taper at 
the discretion of the Investigator. Subjects who cannot fulfill the taper based on the 
Investigator’s judgment or whose corticosteroid dose has to be incre ased, if indicated, should 
remain in the study  
and receive corticosteroids at an appropriate dose as determined by  the 
Investigator (see Section 7.8.4). Subjects will be considered nonresponders for the primary  
endpoint if the corticosteroid dose exceeds the prednisone equivalent dose at Baseline. Subjects 
will be issued a daily  diary  in which to record corticosteroid doses taken on a daily  basis at h
ome 
in between visits ( Section 7.8.5 ). Use of oral or parenteral steroids for non -SLE related 
conditions should be discussed in advance with the Sponsor on an individual basis. 
Treatment with antimalarials or immunosuppressants must have been started or stopped at least 
12weeks prior to dosing with study  drug. In subjects receiving concomitant antimalarials used 
for the treatment of SLE, doses must have been stable for at least 4 weeks prior to the first study  
drug infusion ( Visit 2). In subjects receiving concomitant immunosuppressants for the treatment 
of SL E, doses must have been stable for at least 8 weeks prior to the first study  drug infusion
(Visit 2). Increases in doses of antimalarials and immunosuppress antor immunomodulatory  
agents above Baseline are not permitted until Visit 10 (Week 24) of the study , unless absolutel y 
clinically  indicated ( dose reductions are allowed, if medicall y indicat ed [eg, due to toxicity ], per 
the Investigator’s discretion; refer to Section 7.8.4 for further details) .
Subject sshould stay  on stable doses of the following other concomitant medications for the 
treatment of SLE during Part1(Double -Blind Treatment Period) of the study , unless changes in 
these treatments are clinically  indicated: analgesics, NSAIDs, HMG -CoA reductase inhibitors 
(statins), ACE inhibitors, and other anti- hypertensive drugs .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 49of 1447.8.2 Permitted concomitant treatments (medications and therapies) other 
than those for SLE
Concomitant medications for comorbidities are permitted as long as the ycomply  with the 
restrictions imposed in the inclusion criteria ( Section 6.1), exclusion criteria ( Section 6.2), and 
are not explicitly  prohibited ( Section 7.8.3). Both ACE inhibitors and angiotensin receptor 
blockers are permitted.
Subjects will record their concomitant corticosteroid doses in the subject diary  (Section
7.8.5).
7.8.3 Prohibited concomitant treatments (medications and therapies)
Table 7-1provides a list of concomitant medications prohibited during the study  until Visit 12 
(Week 32)or until 10 weeks after permanent study  drug discontinuation. Also included in this 
table are the wash -out period s(and, if applicable, additional requirements) as apply  to inclusion 
(Section 6.1) and exclusion ( Section 6.2) criteria. 
Table 7
-1: Prohibited medications and required wash- out periods prior to 
Screening ( Visit 1)
Generic 
(trade) namesWash -out period 
prior to ScreeningGeneric 
(trade) namesWash -out period 
prior to Screening
Biologics (Mabs and Fusion Proteins) Immunosuppressants
Abatacept (CTLA4 -Ig) 
(Orencia®)6 months Cyclophosphamide 
(Cytoxan®)6 months
Belimumab (Benlysta™) 6 months Cyclosporine 
(Sandimmune®, Neoral®, 
Gengraf®)(except 
cyclosporine eye drops)4 weeks
Blisibimod 8 weeks Pimecrolimus (Elidel®) 4 weeks
Eculizumab (Soliris®) 3 months Sirolimus (Rapamune®) 4 weeks
ETI – 201 (Elusys 
Heteropolymer Product)3 months Tacrolimus (FK506) 
(Prograf®)4 weeks 
(oraland topical)
Rituximab (Rituxan®), 
Ofatumumab (Arzerra®), 
Obinutuzimab (Gazyva®), 
Ocrelizumab, 
Veltuzumab12 months Others
Intravenous 
immunoglobulin4 weeks
IPP-201101 (Lupuzor™) 3 months
Natalizumab (Tysabri®) 12 weeks Anifrolumab (MEDI 546)
Sifalimumab (MEDI 545)3 months
Vedolizumab (Entyvio®) 24 weeks
Tabalumab 12 weeks Minocycline 4 weeks
TACI- Ig (atacicept) 3 months Thalidomide or 
lenalidomide (Thalomid®, 
Revlimid®)2 months
Tocilizumab (Actemra®, 
MRA)3 months
Note: Topical formulations (eg, eye drops) are permitted without wash -out, unless otherwise indicated .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 50of 1447.8.4 Rescue medication for SLE disease flares
Rescue treatment of SLE disease flares with corticosteroids ( oralor iv) or with changes to dosing 
of the immunosuppressant medications listed in Section 7.8.1 are allowed at the discreti on of the 
Investigator, if clinicall y indicated . Investigators should carefully  evaluate their treatment 
decision, as an increase above the baseline dose between Visit 2 (Baseline ) and Visit 10 
(Week 24) will define a subject as a nonresponder with respect to the primary endpoint.
Subjects who receive rescue therap y should continue in the study  (at the Investigator’s 
discretion) , unless they  require one of the prohibited medications listed in Table 7-1prior to
Visit 12 (Week 32)
.
7.8.5 Subject diary
Subjects will be issued daily  diaries at each visit to record concomitant corticosteroid doses taken 
on a daily  basis at home in between visits. S ubjects will be instructed to bring the diary  to the 
clinic at each visit. Site personnel will collect and review the diary  at each visit to ensure that 
subjects are adhering to their prescribed corticosteroid tapering regimen (where applicable), and 
will issue a new diar y for the subject to use until their next visit.
7.9 Blinding
7.9.1 Procedures for maintaining and breaking the treatment blind
7.9.1.1 Maintenance of study treatment blind
All subject treatment details will be allocated and maintained by  the IVRS/IWRS .
The following individuals will receive the randomization code at the start of the study :
Sponsor and designated CRO bioanaly tical staff analy zing PK samples.
Sponsor clinical trial supply  staff
IVRS/I WRS provider
Study  site pharmacists or other suitably  qualified site p ersonnel who are responsible for 
preparation of IMP treatments and an y necessary assistants will have access to treatment 
allocations for individual subjects via the IVRS /IWRS . The unblinded pharmacy  monitors from 
the CRO , the Clinical Supply  Manager, and the unblinded CPM (or designee) will also have 
access to the treatment allocations and to the drug accountability  records, if applicable.
The following individuals may  have access to the randomization code as indicated:
Sponsor Patient Safety  (PS) staff a s needed for reporting SAEs to r egulatory  authorities.
On request, members of the DMC who participate in unblinded (closed) sessions will be 
given information about the IMP allocation for those subjects for whom data are provided at 
these sessions. 
Sponsor and/or CRO staff supporting preparation of the initial biomarker analy sis.
Sponsor and/or CRO staff supporting preparation of the data outputs for the DMC review.
A Quantitative Clinical Pharmacologist/Modeling & Simulation Scientist may have access to 
the randomization code if PK data are requested for review b y the DMC .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 51of 144The following individuals may  receive access to the randomization code and the first initial 
biomarker anal ysis:
Quantitative Clinical Pharmacologist/Modeling & Simulation Scientist
If necessary , the results of the initial biomarker analy sis during the Double- Blind Treatment 
Period ( Part1) may  be shared with key  UCB and Biogen personnel in order to facilitate 
additional Clinical Planning or Portfolio Management decisions. Only  unblinded summary  
results will be provided, and individual subjec
t data will be kept blinded. Those individuals who 
are not involved in the study  conduct ,but seeing unblinded summary  data ,will be documented in 
the Trial Master File . The DMC will also have access t o any initial biomarker anal ysisdata,if 
needed .
With the exception of emergency unblinding on a case -by-case basis as described in 
Section 7.9.1.2, the following individuals will remain blinded to the treatment assignment in 
Part1until the end of the study :
Investigators
Study  site staff
Subjects
CRO staff
,with the exception of the unblinded pharmacy  monitors and any CRO staff 
supporting preparation of the analyses
Personnel working on the study  at the BILAG 2004 central independent efficacy  reader
Under normal circumstances, the blinded treatment must not be revealed. It will be possible to 
break the blind ,if medically  indicated ( Section 7.9.1.2 ). This should be discussed in advance 
with the Medical Monitor or the Sponsor’s Study  Physician whenever possible .
7.9.1.2 Breaking the treatment blind in an emergency  situation
If a situation arises in which it is medically  indicated to determine the treatment (ie,knowledge 
of the nature and/or dose of the applied s tudy drug determines decisions on further diagnos tic 
procedures or treatment)
, it will be possible to determine to which treatment arm and dose the 
subject has been allocated during the Double -Blind Treatment Period by contacting the 
IVRS/I WRS. All sites w ill be provided with details of how to contact the s ystem for code 
breaking at the start of the study . The Medical Monitor or the Sponsor’s Study  Physician should 
be consulted prior to unblinding, whenever possible.
The CPM will be informed immediately  viathe IVRS/I WRS when a code is broken, but will 
remain blinded to specific treatment information. Any  unblinding of the IMP performed by  the 
Investigator must be recorded in the source documents and on the Study  Termination eCRF 
page.
7.10 Randomization and numbering of subjects
An IVRS/I WRS will be used for assigning eligible subjects to a treatment regimen based on 
predetermined randomization schedules generated by  the CRO . The IVRS/I WRS is responsible 
for issuing 
treatment kit numbers, as appropriate, acco rding to the visit schedule.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 52of 144To enroll a subject ( Visit 1), the Investigator or designee will contact the IVRS/I WRS and 
provide brief details about the subject to be enrolled. Each subject will receive a unique 5 -digit 
subject number assigned at Screening that serves as the subject identifier throughout the study . 
The subject number will be required in all communication between the Investigator or designee 
and the IVRS/I WRS regarding a particular subject. Enrolled subjects who withdraw from the 
study  prior to randomization will retain their subject number without receiv ing a randomization 
number (ie, subject numbers will not be reassigned).
To randomize a subject ( Visit 2), the I nvestigator or designee will contact the IVRS/I WRS and 
provide brief details abo ut the subject to be randomized. The I VRS/I WRS will automatically  
inform the Investigator or designee of the subject’s unique 5- digit randomization number. The 
IVRS /IWRS will allocate treatment kit numbers to the subject based on the subject number 
during the course of the study . Randomization numbers and treatment kit numbers will be 
tracked via the IVRS and also will be required to be entered into the eCRF.
The study  is planned to enroll at least 267subjects in order to randomize approximately  
160subjec ts (40 subjects per treatment group). During the 24 -week Double- Blind Treatment 
Period ( Part1), subjects will be r andomized in a 1:1:1:1 ratio to receive DZP (6mg/kg, 24mg/kg, 
or 45mg/kg) or PBO. The randomization will be stratified b y Screening corticost eroid dose 
(≤10mg/day  or >10mg/day  prednisone equivalent).
During the 
Observational Period ( Part2), subjects will not receive study  drug but will be able to 
receive standard -of-care treatment, as indicated. The subjects, Investigators, and study  site staff 
will remain blinded to the treatment administered during Part1of the study until the end of the 
study .
8 STUDY PROCEDURES BY VISIT
Table 5‒2provides a general overview of study  assessments to be conducted at each visit. A 
detailed listing of procedures to be undertaken at each visit is presented in the sections that 
follow.
Visit windows of ±3 days on eit her side of the scheduled date are permitted for Visits 3 to16
only; however, the Investigator should try  to keep the subjects on the original dosing schedule. 
The window of ±3 days is relative to Baseline and applicable for all subsequent visits. Changes
to the dosing schedule outside of the 3- day window must be discussed with the Medical Monitor 
and may  result in subject withdrawal. 
8.1 Visit 1
(Week -4 to -1/Day -28 to -1); Screening Visit
The Screeni ng Period lasts a maximum of 28 days (Day -28 to -1). Prior to any  study  activities, 
subjects will be asked to read and sign an Informed Consent form that has been approved b y an 
IEC/IRB and the Sponsor, and which complies with regulatory  requirements. Subjects will be 
given adequate time to consider an y information concerning the stud y given to them by  the 
Investigator or designee. As part of the informed consent procedure, subjects will be given the 
opportunity  to ask the Investigator any questions regarding potential risks and benefits of 
participation in the study . 
It is recommended that the Quanti FERON®-TB GOLD in -Tube test ( QFT -GIT)be the first test 
performed at Screening to reduce the number of screening p rocedures conducted for an y 
QFT -GIT positive subjects that may  need to be withdrawn from the study . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 53of 144Subjects who initially  fail to meet eligibility  criteria or for whom eligibility assessments could 
not be completed as planned may  be rescreened once after discussion with the Medical Monitor. 
In addition, s ubjects with an isolated laboratory  parameter outside of the normal range (or 
negative in the case of auto -antibody  assessments) at the Screening Visit may have a repeat test. 
If the repeat laboratory  parameter meets the entry  criteria , the subject may  be randomized at the 
Baseline Visit, provide d they  meet all other eligibility  criteria.
Assessments at Visit 1 (Screening )include:
Obtain written informed consent(s)
Demographic data (includes date of birth, gender, and race/ethnicit y)
Lifesty le(includes a lcohol, tobacco ,and drug use )
Medical and procedure history  and concomitant disease, including SLE disease history
Prior and concomitant medications
TB assessments:
TB test ( QFT -GIT
)
TB Signs and Sy mptoms questionnaire
Chest x -ray (if one is not available wi thin 3 months prior to Screening)
Verif ication of eligibility (inclusion/exclusion criteria)
C-SSRS
Physical examination
HIV and hepatitis screening
Vital signs: systolic and diastolic blood pressure, pulse rate, temperature , body  weight ,and 
height
12-lead ECG
Serum pregnancy  test for women of childbearing potential
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
ANAs , anti-ENAs (anti-SM, anti -SSA, anti -SSB, anti -RNP) , and RF
anti-dsDNA antibodies
aPL antibodies
coagulation and hemostasis tests
serum complement (C3, C4)
hsCRP
proteomic signature profile
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 54of 144BILAG 2004
SLEDAI -2Kassessing the past 10 day s
SLICC/ACR Damage Index
TJC/SJC 
CLASI
AEs
Dispense subject dail y diary
Dispense urine collection container (for first morning urine collection at home on the 
morning of the irnext visit)
Contact the IVRS /IWRS to indicate the subject has been enrolled
8.2 Visit 2 (Day 1); Randomization Visit
Visit 2 can occur at an y time after the laboratory  results from the Screening Visit are available, 
but no later than 28 days after the Screening Visit. Prior to Visit 2, the site must have received 
confirmation from the central independent efficacy  reader for BILAG 2004 data that the subject 
has met BILAG 2004 eligibility  for randomization. The site must confirm wh ether or not the 
subject is eligible to be randomized p rior to contacting the IVRS/I WRS .
Subjects should undergo an overnight fast (at least 8 hours) prior to coming to the site for Visit 2. 
Subjects may  then eat breakfast after serum samples have been obt ained for the assessment of 
cardiovascular proteins, lipids, and lipid particles, and before stud y drug administration.
The PRO questionnaires should then be completed in a quiet place b y the subjects themselves at 
the start of the stud y visit and prior to the remaining visit assessments.
All assessments should be performed prior to study  drug dosing, unless otherwise indicated.
Assessments at Visit 2 (Randomization) include:
LupusQoL
PROs at sites in English- and Spanish- speaking countries only :
SLE-S
SLE-F
SLE-M
SLE-P
SLE-E
Verification of continued eligibility  (inclusion/exclusion criteria ; including verification that 
the SL EDAI -2K score without any  laboratory  values is ≥4 prior to Randomization; see 
below )
TB Signs and Sy mptoms questionnaire
Concomit ant medications
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 55of 144Medical procedures
Collect/review subject daily  diary
Collect PK urine sample obtained at home ( first morning urine collection on the morning of 
the visit )
Physical examination /interim medical history
Urine pregnancy  test for women of childbearing potential
Withdrawal criteria check
Vital signs:
systolic and diastolic blood pressure, pulse rate, and temperature: predose; every  15mins 
post start of infusion; every  30mins until 2h post end of infusion
body  weight :predose
Note: Blood sam ples must not be drawn through the infusion cannula .
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
anti-dsDNA antibodies
anti-DZP and anti -PEG antibodies
total Ig, IgG, IgM, IgA, and IgE
serum complement (C3, C4)
hsCRP
whole blood mRNA
cardiovascular proteins, lipids, and lipid particles ( blood samples should be collected 
under fasting conditions [at least 8 hours] )
DNA
PK plasma sampling (predose; end of infusion; and 30min, 1h, and 2h post end of infusion )
BILAG 2004
SLEDAI -2Kassessing the past 10 day s(including the SL EDAI -2K score without laboratory  
values assessment [defined as an y SLEDA I-2K defined features excluding all laboratory  
parameters in the past 10days prior to Baseline] of ≥4 prior to Randomiz ation)
PGA
PtGA
TJC/SJC
CLASI
Contact the IVRS/I WRS for randomization or to note screen failure
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 56of 144Study  drug preparation (predose) , administration, and accountability (postdose)
AEs (preand postdose)
Dispense subject dail y diary (postdose)
8.3 Visit 3 (Week 2/Day 14 [±3days])
Assessments at Visit 3 (Week 2) include:
Concomitant medications
Medical procedures
Collect/review subject daily  diary
Urine pregnancy  test for women of childbearing potential
Withdrawal criteria check
Vital signs (s ystolic and diastolic blood pressure, pulse rate, and temperature)
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
total Ig, IgG, IgM, IgA, and IgE
serum complement (C3, C4)
hsCRP
whole blood mRNA
proteomic signature profile
PK plasma sample
Investigator assessment of flare
AEs
Dispense subject dail y diary
Contact the IVRS/I WRS
8.4 Visit 4 (Week 4/Day 28 [±3days]) and Visit 6 (Week 8/Day 56 
[±3days])
The PRO questionnaires should be completed at the start of the study  visit in a quiet place and b y 
the subjects themselves.
All assessments should be performed prior to study  drug dosing, unless otherwise indicated.
Assessments at Vis it4 (Week 4) and Visit 6 (Week 8) include:
LupusQoL
PROs at sites in English- and Spanish- speaking countries only :
SLE-S
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 57of 144SLE-F
SLE-M
SLE-P
SLE-E
Subject Experience Interview ( Visit 4 only )
Concomitant medications
Medical procedures
Collect/review subject daily  diary
Physical examination/interim medical history
Urine pregnancy  test for women of childbear ing potential
Withdrawal criteria check
Vital signs:
systolic and diastolic blood pressure, pulse rate, and temperature: predose; every  15mins 
post start of infusion; every  30mins until 2h post end of infusion
body  weight :predose
12-lead ECG ( Visit 4 only )
Note: Blood samples must not be drawn through the infusion cannula .
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
anti-dsDNA antibodies
anti-DZP and anti -PEG antibodies
total Ig, IgG, IgM, IgA, and IgE
serum complement (C3, C4)
hsCRP
whole blood mRNA ( Visit 4 only )
proteomic signature profile
PK plasma sampling :
Visit 4:predose; end of infusion; and 30min, 1h, and 2h post end of infusion
Visit 6: predose; end of infusion
BILAG 2004
SLEDAI -2K assessing t he past 30 days
SRI-50
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 58of 144PGA
TJC/SJC
CLASI
Investigator assessment of flare
Contact IVRS/I WRS
Study  drug preparation (predose), administration, and accountability  (postdose)
AEs (pre and postdose)
Dispense subject dail y diary  (postdose)
8.5 Visit 5 (Week 6/Day 42 [±3days])
Subjects should undergo an overnight fast (at least 8 hours) prior to coming to the clinic for 
Visit 5. Subjects may  then eat breakfast after serum samples have been obtained for the 
assessment of cardiovascular proteins, lipids, and lipid pa rticles, and prior to any  other 
assessments.
Assessments at Visit 5 (Week 6) include:
Concomitant medications
Medical procedures
Collect/review subject daily  diary
Urine pregnancy  test for women of childbearing potential
Withdrawal criteria check
Vital signs (s ystolic and diastolic blood pressure, pulse rate, and temperature)
Additional laboratories: 
cardiovascular proteins, lipids, and lipid particles ( blood samples should be collected 
under fasting conditions [at least 8 hours])
PK plasma sample
Inves tigator assessment of flare
AEs
Dispense subject dail y diary
Contact the IVRS/I WRS
8.6 Visit 7 (Week 1
2/Day 84 [±3days]), Visit 8 (Week 16/Day 112 
[±3days]), and Visit 9 (Week 20/Day 140 [ ±3days])
Subjects should underg o an overnight fast (at least 8 hours) prior to coming to the site for Visit 7
only. Subjects may  then eat breakfast after serum samples have been obtained for the assessment 
of cardiovascular proteins, lipids, and lipid particles, and before stud y drug administration.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 59of 144The PRO questionnaires should then be completed in a quiet place b y the subjects themselves at 
the start of the stud y visit and prior to the remaining visit assessments.
All assessments should be performed prior to study  drug dosing, unless otherwise indicated.
Assessments at Visit 7 (Week 12), Visit 8 (Week 16), and Visit 9 (Week 20) include:
LupusQoL
PROs at sites in English- and Spanish- speaking countries only :
SLE-S
SLE-F
SLE-M
SLE-P
SLE-E
TB Signs and Sy mptoms questionnaire ( Visit 7 only )
Concomitant medications
Medical procedures
Collect/review subject daily  diary
Collect PK urine sample obtained at home ( Visit 9 only ; overnight void collection at home 
the night before the visit through the first morning void the morning of the visit)
Physical examination/
interim medical history
Urine pregnancy  test for women of childbearing potential
Withdrawal criteria check
Vital signs:
systolic and diastolic blood pressure, pulse rate, and temperature: predose; every  15mins 
post start of infusion; every 30mins until 2h post end of infusion
body  weight : predose
Note: Blood samples must not be drawn through the infusion cannula.
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
anti-dsDNA antibodies
anti-DZP and anti -PEG antibodies
coagu lation and hemostasis tests (Visit 7 only )
total Ig, IgG, IgM, IgA, and IgE
serum complement (C3, C4)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 60of 144hsCRP
whole blood mRNA ( Visits 7 and 8 only )
proteomic signature profile ( Visits 7 and 8 only )
cardiovascular proteins, lipids, and lipid particles ( Visit 7 only ; blood samples should be 
collected under fasting conditions [at least 8 hours])
PK plasma sampling:
Visits 7 and 8: predose; end of infusion
Visit 9: predose; end of infusion; and 30min, 1h, and 2h post end of infusion
BILAG 2004
SLEDAI -2K assessing the past 30 day s
SRI-
50
PGA
PtGA (Visit 7 only )
TJC/SJC
CLASI
Investigator assessment of flare
Contact IVRS/I WRS
Study  drug preparation (predose), administration, and accountability  (postdose)
AEs (pre and postdose)
Dispense subject dail y diary  (pos tdose)
Dispense uri ne collection container ( postdose; Visits 8 and 9 only ; for overnight void 
collection at home the night before their next visit through the first morning void the morning 
of the visit)
8.7 Visit 10(Week 24/Day 168 [ ±3days]); Double -Blind Treatment 
Period End of Treatment/Early  Withdrawal Visit
Subjects who withdraw prior to Week 32 (Visit 12) will complete an Early  Withdrawal 
Visit (EWV; Visit 10 assessments if withdrawn prior to Visit
10; Visit 16 assessments if 
withdrawn after Visit 10) as well as Visits 11 and 12 for SFU assessments at 8 and 12 weeks 
after their final dose of study  drug (as applicable). S ubjects who withdraw after Week 32 
(Visit 12) do not require additional SFU visits and will complete the Visit 16/EWV assessments 
only.
Subjects should underg o an overnight fast (at least 8 hours) prior to coming to the site for 
Visit 10. Subjects may  then eat breakfast after serum samples have been obtained for the 
assessment of cardiovascular proteins, lipids, and lipid particles ,and prior to any  other 
assessments .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 61of 144The PRO questionnaires should then be completed in a quiet place b y the subjects themselves at 
the start of the stud y visit and prior to the remaining visit assessments.
Assessments at Visit 10 (Week 24) include:
LupusQoL
PROs at sites in English- and Spanish- speaking countries only :
SLE-S
SLE-F
SLE-M
SLE-P
SLE-E
Subject Experience Interview
TB Signs and Sy mptoms questionnaire 
Concomitant medications 
Medical procedures 
Collect/review subject daily  diary  
Collect PK urine sample obtained at home ( overnight void collection at home the night 
before the visit through the first morning void the morning of the visit )
C-SSRS
Physical examination/interim medical history
Urine pregnancy  test for women of childbearing potential
Withdrawal criteria check
Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature )
12-lead ECG
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
ANAs , anti -ENAs (anti-SM, anti -SSA, anti -SSB, anti-
RNP), and RF
anti-dsDNA antibodies
anti-DZP and anti -PEG antibodies
aPL antibodies
coagulation and hemostasis tests
total Ig, IgG, IgM, IgA, and IgE
serum complement (C3, C4)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 62of 144hsCRP
whole blood mRNA
proteomic signature profile
cardiovascular proteins, lipids, and lipid particles ( blood samples should be collected 
under fasting conditions [at least 8 hours])
DNA
PK plasma sampling
BILAG 2004
SLEDAI -2Kassessing the past 30 day s
SRI-50
PGA
PtGA
SLICC/ACR Damage Index
TJC/SJC
CLASI
Investigator assessme nt of flare
Contact IVRS/I WRS
AEs
Dispense subject dail y diary
Dispense urine collection container (for first morning urine collection at home on the 
morning of their next visit)
8.8 Visit 11/SFU ( Week 28/Day 196 [±3days]), Visit 13 
(Week 36/Day 252 [ ±3days]), and Visit 15 (Week 44/Day 308 
[±3days])
Subjects who withdraw prior to Week 32 (Visit 12) will complete an EWV (Visit 10 assessments 
if withdrawn prior to Visit 10; 
Visit 16 assessments if withdrawn after Visit 10) as well as 
Visits 11 and 12 for SFU assessments at 8 and 12 weeks after their final dose of study  drug (as 
applicable). Subjects who withdraw after Week 32 (Visit 12) do not require additional SFU visits 
and will complete the Visit 16/EWV assessments only .
Assessments at Visit 11 (Week 28), Visit 13 (Week 36), and Visit 15 (Week 44) include:
Concomitant medications
Medical procedures 
Coll
ect/review subject daily  diary  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 63of 144Collect PK urine sample obtained at home ( first morning urine collection at home on the 
morning of visit; Visit s 11 and 13 only )
Urine pregnancy  test for women of childbearing potential 
Withdrawal criteria check (only  performed in subjects who are continuing in the study )
Vital signs (systolic and diastolic blood pressure, pulse rate, and temperature )
Safety  labora tories ( Visit 11only): hematology , clinical chemistry , and urinaly sis
Additional laboratories: 
anti-DZP and 
anti-PEG antibodies (Visit 11 only )
hsCRP (Visit 11 only )
PK plasma sampling (Visit s
11 and 13 only )
Investigator assessment of flare
AEs
Dispense subject dail y diary
Dispense urine collection container ( for first morning urine collection at home on the 
morning of their next visit)
8.9 Visit 12/SFU
(Week 32/Day 224 [ ±3days])and Visit 14 
(Week 40/Day 280 [ ±3days])
Subjects who withdraw prior to Week 32 (Visit 12) will complete an EWV (Visit 10 assessments 
if withdrawn prior to Visit 10; 
Visit 16 assessments if withdrawn after Visit 10) as well as 
Visits 11 and 12 for SFU assessments at 8 and 12 weeks after their final dose of study  drug (as 
applicable). Subjects who withdraw after Week 32 (Visit 12) do not require additional SFU visits 
and will complete the Visit 16/EWV assessments only .
The PRO questionnaires should be completed at the start of the study  visit in a qu iet place and b y 
the subjects themselves.
Assessments at Visit 12 (Week 32) and Visit 14(Week 40) include:
LupusQoL
PROs at sites in English
-and Spanish- speaking countries only :
SLE-S
SLE-F
SLE-M
SLE-P
SLE-E
Concomitant medications 
Medical procedures 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 64of 144Collect/review subject daily  diary  
Collect PK urine sample obtained at home ( first morning urine collection at home on the 
morning of visit )
C-SSRS (Visit 12;only performed in subjects who have withdrawn from the study  and are 
undergoing SFU assessments)
Physical examination/interim medical history
Urine pregnancy  test for women of childbearing potential 
Withdrawal criteria check (only  performed in subjects who are continuing in the study )
Vital signs (s ystolic and diastolic blood pressure, pulse rate, a nd temperature)
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
anti-dsDNA antibodies
anti-DZP and anti -PEG antibodies (Visit 12 only )
coagulation and hemostasis tests ( Visit 12 only )
total Ig, IgG, IgM, IgA, a nd IgE (Visit 12 only )
serum complement (C3, C4) 
hsCRP
whole blood mRNA ( Visit 12 only )
proteomic signature profile ( Visit 12 only )
PK plasma sampling 
BILAG 2004
SLEDAI -2K assessing the past 30 days 
SRI-50
PGA
TJC/SJC
CLASI
Investigator assessment of flare
AEs
Dispense subject dail y diary  (onl y performed in subjects who are continuing in the stud y)
Dispense urine collection container (for first morning urine collection at home on the 
morning of their next visit; only  performed at Visit 12 in subjects w ho are continuing in the 
study ; not done at Visit 14)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 65of 1448.10 Visit 16 (Week 48/Day 336 [ ±3days]); Observation Period
Final /Early  Withdrawal Visit
Subjects who withdraw prior to Week 32 (Visit 12) will complete an EWV (Visit 10 assessments 
if withdrawn prior to Visit10; 
Visit 16 assessments if withdrawn after Visit 10) as well as 
Visits 11 and 12 for SFU assessments at 8 and 12 weeks after their final dose of study  drug (as 
applicable). Subjects who withdraw after Week 32 (Visit 12) do not require additional SFU visits 
and will complete the Visit 16/EWV assessments only .
Subjects should underg o an overnight fast (at least 8 hours) prior to coming to the site for 
Visit 16. Subjects may  then eat breakfast after serum samples have been obtained for the 
assessment of cardiovascular proteins, lipids, and lipid particles
,and prior to any  other 
assessments.
The PRO questionnaires should then be completed in a quiet place b y the subjects themselves at 
the start of the stud y visit and prior to the remaining visit assessme nts.
Assessments at Visit 16 (Week 48) include:
LupusQoL
PROs at sites in English- and Spanish- speaking countries only :
SLE-S
SLE-F
SLE-M
SLE-P
SLE-E
Concomitant medications
Medical procedures
Collect/review subject daily  diary
Collect PK urine sample obtained at home ( first morning urine collection at home on 
morning of visit)
C-SSRS
Physical examination/interim medical history
Urine pregnancy  test for women of childbearing potential
Vital signs (s ystolic and diastolic blood pressure, pulse rate, and temperature)
12-lead ECG
Safety  laboratories: hematology , clinical chemistry, and urinal ysis
Additional laboratories: 
ANAs , anti -ENAs (anti-SM, anti -SSA, anti -SSB, anti -
RNP), and RF
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 66of 144anti-dsDNA antibodies
anti-DZP and anti -PEG antibodies
aPL antibodies
coagulation and hemostasis tests
total Ig, IgG, IgM, IgA, and IgE
serum complement (C3, C4)
hsCRP
whole blood mRNA
proteomic signature profile
cardiovascular proteins, lipids, and lipid particles ( blood samples should be collected 
under fasting conditions [at least 8 hours])
DNA
PK plasma sampl e
BILAG 2004
SLEDAI -2Kassessing the past 30 days
SRI-50
PGA
PtGA
SLICC/ACR Damage Index
TJC/SJC
CLASI
Investigator assessment of flare
AEs
8.11 Unscheduled Visit
If at an y point during the study  the Investigator determines that a subject requires additional 
safet y evaluations, the subject canreturn to the site and the Investigator may  perform additional 
assessments, as clinicall y indicated, such as, but not limite d to, the following assessments:
Concomitant medications
Medical procedures
Vital signs (s ystolic and diastolic blood pressure, pulse rate, and temperature)
12-lead ECG
Standard safet y laboratories: hematology, serum chemistry , and urinal ysis
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 67of 144hsCRP
Urine p regnancy  test for women of childbearing potential
AEs
Contact the IVRS/I WRS
9 ASSESSMENT OF EFFICA CY
9.1 Clinical assessments of disease activity
9.1.1 BILA G2004
The BILAG 2004 will be used as a clinical assessment of SL E disease activity  
(Tsokos etal,2007). 
The I nvestigators will assess 97 BILAG 2004 components and record the assessments in the 
eCRF. Only  clinical features attributable to SLE are to be recorded and based on the su bject’s 
condition in the last 4 weeks compared with the previous 4weeks. For vital si gns and laboratory  
parameters, I nvestigators must indicate whether or not values are outside the normal range and, if 
outside the normal range, whether or not they  are due to SL E. 
Nine body /organ -based sy stems will be assessed separately :
Constitutional (fatigue, fever, anorexia, weight loss, etc)
Mucocutaneous (rash, alopecia, mucosal ulcers, etc)
Neurops ychiatric (headache, seizure, ps ychosis, etc) 
Musculoskeletal (arthritis, my algia, etc) 
Cardiorespiratory  (coronary  vasculitis, cardiac failure, effusion, etc) 
Gastrointestinal (lupus enteritis, hepatitis, peritonitis, etc)
Ophthalmic (keratitis, scleritis, optic neuritis, etc)
Renal (proteinuria, urine microscop y for red blood cells , casts, etc)
Hematology  (cytopenias, coagulopathy , etc)
The Investigator must maintain/provide independent supporting source document (chart, 
worksheet, clinic notes, and labs) capable of withstanding audit: 
For each entry  indicating activity  (and first time pri or entry  is no longer present)
Indicating wh y feature new, improving, same, or worse 
Sufficient descriptive detail to support future changes (improved, wors ening);
eg,number/location of arthritic joints, size/location of rashes, etc
Information indicatin g that all other features were not active at the time point of the visit
The Sponsor will provide centralized grading (A, B, C, D, and E) based on BILAG 2004 eCRF 
pages completed b y the Investigator. Prior to Visit 2, the site must have received confirmation 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 68of 144from the central independent efficacy  reader for BILAG 2004 data that the subject has met 
BILAG 2004 eligibility  for randomization. 
The BILAG 2004 grading is anchored in the ph ysician’s intention to treat. Disease activity  is 
graded separately  for 9 bo dy systems to 5 different grades (A to E) as follows:
A (“Active”) =Severely active disease (sufficient to require systemic immunosuppress antor 
anticoagulant therapy ;eg, >20mg/day prednisone, immunosuppress ants, or 
cytotoxics)
B (“Beware”) =Moderately active disease (requires low dose or local immunosuppressant 
therapy or symptomatic therapy ;eg, prednisone ≤20mg/day prednisone, or 
antimalarials)
C (“Contentment”) =Mild stable disease (no indication for changes in treatment)
D (“Discount”) =Inactive now but previously active
E (“Excluded”) =Never affected
Refer to Appendix 19.5 for protocol -specific clari fication and extension of BILAG 2004
definitions.
A shift from BILAG 2004 Grade Aor B to a lower grade indicates a clinically  relevant change in 
disease activity  as the BILAG 2004 grades mirror the decision points for treatment interventions.
In addition, the BST is a new m ethod of representing the BILAG 2004 scores longitudinally , 
which combines the flexibility  and simplicity  of numerical scoring with the clinical intuitiveness 
and meaningfulness of the BILAG 2004
categorical score. It was devised using a data- driven 
methodology  and is based on counts of the number of s ystems with active/worsening disease and 
improving disease between 2assessments. Further details will be provided in the SAP.
Only  Investigators that complete BILAG 2004 training will be allowed to perform the 
BILAG 2004 assessments. Preferably , the same I nvestigator should evaluate the subject at each 
BILAG 2004 assessment from Screening to stud y completion.
9.1.2 SLEDA I-2K
TheSLEDAI -2K (30days) measures dise ase activity . Disease activit y in the 30 days prior to and 
at the time point of the assessment shall be considered. It isa global index and includes 
24clinical and laboratory  variables that are weig hted by  the t ype of manifestation, but not by  
severit y. The SLEDA I
-2K includes scoring for antibodies ( anti-dsDNA positive or negative ) and 
low complement, as well as some renal and hematologic parameters. The total score falls 
between 0 and 105, with higher scores representing increased disease activity . The SLEDAI -2K 
has been shown to be a valid and reliable disease activity  measure in multiple subject groups 
(Gladman etal,2002).
To confirm subject eligibility at Baseline ( Visit 2), the SL EDAI -2K score without any laboratory  
values is calculated based on all the clinical variables only , without factoring in the laboratory  
variables . AtScreening (Visit 1), the SL EDAI -2K will include laboratory  parameters. For both 
Visits 1 and 2, the SL EDAI -2K will asse ss disease activity  in the past 10 days onl y.
9.1.3 PGA
The Investigator will rate the overall status of the subject in response to the following statement:
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 69of 144“Please mark a vertical line on the scale below to assess the overall status of the subject’s
Systemic Lu pus Ery thematosus signs and s ymptoms and the functional capacity  of the
subject. Zero is ‘very  good, asy mptomatic and no limitation of normal activities’ ; 100 
indicates ‘ severe disease ’and is at the very  end of the scale. This refers to the most severe 
possible dis ease, and does not reflect the most severe ever seen in a particular patient, but the 
most severe disease ever seen in all SL E patients. ”
When s
coring the PGA ,the assessor should always look back at the score from the previous 
visit. This assess ment by  the I nvestigator must be made blinded to the PtGA performed at the 
same visit.
9.1.4 PtGA
Subjects will rate their global assessment of their SL E disease activit y for the day of the visit in 
response to the statement “Considering all the ways y our SLE affects y ou, please mark a ver tical
line on the scale below for how you are feeling today” using a 100mm visual analog scale ( VAS )
where 0 is “very  good, no sy mptoms” and 100 is “very  poor, very  severe sy mptoms.”
9.1.5 SLICC/A CR Damage Index
The SLICC/ACR Damage Index (version 1996) for SL E measures irreversible, accumulated 
organ damage from either the disease process or disease treatment, which has been present for at 
least 6 months, in 12 organ sy stems. It is an important predictor of long -term mortality  and i s an 
independent outcome measure separate from the BILAG 2004 and SLEDAI -2K. Onl y 
nonreversible change that has occurred since the onset of SL E is to be included, rather than 
change related to active inflammation. Consequently , a damage/feature once documented cannot 
disappear. Otherwise, the original grading must be reassessed.
Definition of damage:
Nonreversible change
Occurring since onset of lupus 
Not related to active inflammation
Present for at least 6 month s
Ascertained b y clinical assessment/x -rays
The Investigator (or qualified designee) will perform the SLICC/ACR Damage Index assessment 
for the 12 different organ sy stems (Table 9‒1), and check “Yes” if the criterion is present (and 
tick the appropriate box if there is more than 1 choice); or check “No ,” or “Unknown,” as 
appropriate.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 70of 144Table 9‒1: SLICC/A CR Damage Index organ sy stem scoring
Organ system Range of possible scores
Ocular 0–2
Neuropsychiatric 0–6
Renal 0–3
Pulmonary 0–5
Cardiovascular 0–6
Peripheral vascular 0–5
Gastrointestinal 0–5
Musculoskeletal 0–6
Skin 0–3
Diabetes 0–1
Premature gonadal failure 0–1
Malignancy 0–2
ACR=American College of Rheumatology; SLICC=Systemic Lupus International Collaborating Clinics
9.1.6 Tender and Swollen Joint Count s (28 joints)
The joint assessment will be carried out on 28 joints, including the shoulders, elbows, wrists 
(radiocarpal, carpal, and carpometacarpal bones were considered as a single unit), 
metacarpophalangeal (MCP) joints (MCP 1, 2, 3, 4, and 5), thumb interphalangeal (IP) joint, 
proximal inter phalangeal (PI P) joints (PI P 2, 3, 4, and 5), and the knees.
Artificial and ank ylosed joints will be excluded from tenderness and swelling assessments.
Subjects taking maintenance NSAIDs/analgesics, medical marijuana, or narcotics should not take 
a dose of these medications within 12 hours prior to the TJC/SJC assessment visits in order to 
allow a true assessment of the joint tenderness and swelling to be conducted.
Tenderness and swelling will be graded on a 2 -point scale as described in Table 9‒2.
Table 9
‒2: Joint t enderness and swelling grades
Grade Swelling Response Tenderness Response (28)
0 Not swollen Not tender
1 Detectable synovial thickening with or 
without loss of bony contours, or bulging 
synovial proliferation with or without 
cystic characteristicsPositive response to questioning (tender), 
spontaneous response elicited (tender and 
winced ), or withdrawal by subject on 
examination (tender, winced, and withdrew)
Every  effort should be made to ensure each subject isevaluated b y the same Investigator 
(assessor) during all study visits.
The total TJC and SJC are the sum of all individual respective tenderness and swelling grades. If 
there are missing observations in the TJC or SJC , then the remaining observations are assessed 
and weighted b y dividing by the number of nonmissing values and multiply ing b y 28. If a joint is 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 71of 144not evaluable at B aseline, then that joint is set to missing throughout the study . If more than 50% 
of the tenderness or swelling grades are missing, then no imputation is done and the total TJC or 
SJC are set to missing. The total scores are used to assess the percentage c hange from Baseline.
9.1.7 CLASI
The CL ASI consists of 2 scores; the first summarizes the activity  of the disease and the second is 
a measure of the damage done by  the disease (Table 9‒3) (Albrecht etal,2005) . Activity  is 
scored on the basis of erythema, scale/h ypertroph y of skin and 
mucous membrane s, acute hair 
loss, and nonscarring alopecia. Damage is scored in terms of dy spigmentation and scarring, 
including scarring alopecia. Subjects are asked whether d yspigmentation due to cutaneous lupus 
erythematosus lesions usually  remains visible for more th an 12 months, which is taken to be 
permanent. If so, the d yspigmentation score is doubled. The scores are calculated b y simple 
addition based on the extent of the s ymptoms. The extent of involvement for each of the skin 
symptoms is documented according to specific anatomic areas that are scored according to the 
worst affected lesion within that area for each s ymptom. Associated symptoms, including itch, 
pain, and fatigue are recorded separatel y on a 1 to 10 VAS by the subjects.
Table 9‒3: CLASI activity and damage scoring
Activity Damage
Erythema 0=absent
1=pink; faint erythema
2=red
3=dark red; purple/ violaceous/
crusted/ hemorrhagicDyspigmentation 0=absent
1=dyspigmentation
Scale/
Hypertrophy0=absent
1=scale
2=verrucous/hypertrophicScarring/Atrophy/ 
Panniculitis0=absent
1=scarring
2=severely atrophic scarring 
or panniculitis
Mucous 
Membrane 
Involvement0=absent
1=lesion or ulcerationDuration of 
Dyspigmentation 
(after active lesions 
have resolved)0=dyspigmentation usually 
lasts <12 months
1=dyspigmentation usually 
lasts ≥12months
AlopeciaaAlopeciaa
Recent Hair 
Loss (within 
the last 
30days)0=no
1=yesScarring of the 
Scalp (judged 
clinically)0=absent
3=in 1 quadrant
4=2 quadrants
5=3 quadrants
6=affects the whole skullAlopecia 
(clinically not 
obviously 
scarred)0=absent
1=diffuse; noninflammatory
2=focal or patchy in 1 quadrant
3=focal or patchy in >1 quadrant
CLASI=Cutaneous Lupus Erythematosus Disease Area and Severity Index
aIf scarring and nonscarring aspects seem to coexist in 1 lesion, both should be scored.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 72of 1449.1.8 Assessment of flare
The reduction in lupus flares and increase in time to lupus flare is considered an appropriate 
measure to evaluate the efficacy  of potential new lupus treatments. However, there is a lack of a 
universally  accepted definition of a lupus flare. A recent international initiative involving 
multiple SL E experts led to a proposal for a consensus definition of disease flare in lupus 
(Ruperto etal,2011):
A flare is a measurable in crease in disease activity in 1 or more organ systems involving new 
or worse clinical signs and symptoms and/or laboratory measurements. It must be 
considered clinically significant by the assessor and usually there would be at least 
consideration of a change or an increase in treatment.
Flare will be assessed b y the Investigator and by  the Sponsor, as follows.
Investigator Assessment of Flare:
To determine if th e definition of flare is fulfilled in the opinion of the I nvestigator , the following 
question wi ll be answered by  the Investigator at each visit after Visit 2:
“Do you consider that the SL E disease activity  of the patient in 1or more organ s ystems 
(involving new or worse clinical signs and s ymptoms and/or laboratory  measurements) 
increased clinicall
y significantly since the last visit and that you consider ed a change or 
increase the treatment for SL E of your patient? ”
Sponsor Assessment of Flare:
The definition of flare according to the Sponsor is: a new sust ained BILAG 2004 Grade A/B 
(present at ≥2 consecutive visits) after withdrawal of study  drug or start of new induction therap y 
(either corticosteroid dose increase to ≥0.5 mg/kg/day  prednisone equivalent or initiation of 
cyclophosphamide, rituximab, iv Ig, or plasma exchange] after withdrawal of study  drug.
9.1.9 Responders based on clinical assessments of disease activity
9.1.9.1 BICLA
The primary  efficacy  variable, the BI CLA responder rate across 3 doses of DZP and PBO at 
Week 24, is a categorical response variable (y es/no) incorporating the following criteria for 
achie vement of responder status (ie, all criteria must be met to achieve responder status):
1.BILAG 2004
improvement, defined as BILAG 2004 Grade A s at study  entry  improved to 
B/C/D, and BILAG 2004 Grade Bs at study  entry  improved to C/D, and no 
BILAG 2004 2004 worsening in other BILAG 2004 organ s ystems such that there are no
new BILAG 2004 Grade As or greater than 1 new BILAG 2004 Grade B(s); and
2.No worsening in the SLEDAI -2K total score compared to study  entry  (defined as no increase 
in SLEDAI- 2K total score); and 
3.No worsening in the Physician’s Global Assessment of Disease Activity compared to study  
entry (“no worsenin g” is defined as <10% worsening, equivalent to a 10mm increase on a 
100mm VAS) ; and
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 73of 1444. No changes in concomitant medications according to the following criteria (all criteria must 
be met):
No increase of (or addition of a new) immunosuppressant nor antimalarial doses over 
Baseline ( Visit 2) levels, nor initiation of any  medication listed in Table 7-1
No increase in oral corticosteroid dose over Ba seline ( Visit 2) levels for an SL E
-related
indication
No iv, im, nor intra -articular injections of cortico steroids which are SL E related
In addition, subjects who discontinue study  drug prematurel y are primarily  categorized as 
nonresponders.
The BICLA resp onder rate is based primaril y on the BILAG 2004 disease activity  measurement 
instrument. The BILAG 2004 was selected as the primary  tool for measurement of disease 
activity  on the basis of its comprehensiveness, ability  to capture incremental changes in disease 
activity , and the clinical relevance of its grading s ystem. The BILAG 2004 grading is anchored 
in the phy sician’s intention to treat. A shift from BILAG 2004 Grade A or B to a lower grade 
indicates a clinicall y relevant change in disease activity  as the BILAG 2004 2004 grades mirror 
the decision points for treatment interventions. Consequently  it represents the induction of 
disease control.
It is important to note tha t for the BILAG 2004 improvement, all As and B s at entry  need to 
improve. If an A improves to a B but a single B remains from entry ,then the subject has not 
improved in their BILA G 2004.
9.1.9.2 SRI-4, -
5, and -6
The SRI -4, SRI -5, and SRI -6 define responders as (ie, all criteria must be met):
Reduction in SL EDAI -2K score of ≥4, ≥5, and ≥6 points, respectivel y
No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
No more than 1 shift from BILAG 2004 Grade C, D, 
or E to B, or from B to A, post-Baseline
Increase in Phy sician’s Global Assessment of Disease from Baseline of <10% (<10mm)
Assessments of SRI -4, -5, and -6 will include an assessment of nonresponders based on 
concomitant medication rules.
9.1.9.3 SRI-50
The SRI -50 is comprised of the same 24 descriptors covering 9 organ s ystems as the 
SLEDAI -2K and describes the improvement in disease activity of at least 50% compared with 
the previous assessment; the SRI -50 reflects disease activity  over the 30 daysprior to the 
assessment (Touma etal,2011). The total sc ore of SL EDAI -2K falls between 0 and 105, with 
higher scores representing increased disease activity . 
The SRI -50 score corresponds to the sum of each of the 24 descriptor scores on the SRI -50 data 
retrieval form. The method of scoring is simple, cumulative, and intuitive and similar to the 
SLEDAI -2K. One of 3 situations can result when a descriptor is present at the initial visit: 
1.The descriptor has achieved complete remission, in which case the score would be “0”; 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 74of 1442.The descriptor has not achieved a minim um of 50% improvement, in which case the score 
would be identical to its corresponding SLEDAI -2K value; or 
3.The descriptor has improved by  ≥50% (according to the SRI -50 definition) but has not 
achieved complete remission, in which cas e the score is evaluat ed as one -half the score th at 
would be assigned for SLEDAI -2K. 
If a descriptor was not present at the initial visit, the value for the SRI -50 will be the same as that 
for SL EDAI -2K. This process is repeated for each of the 24 descriptors.
Finally , the SRI -50 score is evaluated as the sum of the scores of the 24 individual descriptors.
9.2 Patient-reported outcomes
The administration of the questionnaires for PRO assessments should be performed b y stud y 
personnel other than the treating ph ysician. The questionnaires should be filled in at the start of 
the study  visit in a quiet place and b y the subject sthemselves. 
The LupusQoL will be collected for all subjects at all sites participating in the study . In addition, 
the following exploratory PRO variables being developed b y UCB will be assessed at sites in 
English- and Spanish- speaking countries (approximately  45% to50% of the projected study  
population): SL E-S, SL E-F, SLE -M, SLE -P, and SL E-E. These newly  developed instruments are 
being piloted in the c urrent study  and the data generated from this study  will aid in refining the 
instruments for use in future studies. The Subject Experience Interview will also be assessed at 
sites in English -and Spanish- speaking countries.
The PRO questionnaires should be completed in the following order :LupusQoL , SLE - S, SLE -F, 
SLE-M, SLE -P,SLE-E, and Subject Experience Interview . The questionnaires should only  be 
checked for completeness.
The visits at which PRO assessments are to be performed are described in Table 5‒2.
9.2.1 LupusQoL
The LupusQoL (version 2007) is a disease
-specific HRQoL instrument developed with SL E 
patient qualitative input (McElhone etal,2007). It consists of 8 domains: phy sical health 
(8items), pain (3 items), planning (3 items), intimate relationships (2
items), burden to others 
(3items), emotional health (6 items), body  image (5 items), and fatigue (4 items). Scores are 
calculated independentl y for each domain and transformed to a 0 to 100 point scale with higher 
scores denoting better HRQoL . A recent study  has suggested minimal clinically  important 
difference (MCID) scores for minimally  improved (ranging from 1.1 to 9.2 points) and 
minimally  worse (ranging from - 0.5 to -6.4 points) for each of the 8 domains of L upusQo L 
(Devilliers etal,2015).
9.2.2 SLE-S
The SL E-S consists of 26 sy mptom items. The subject is asked to score each sy mptom item 
based on the severity  experienced during the past 7 days using the following scale: 1=none; 
2=mild; 3=moderate; 4=severe. 
9.2.3 SLE-F
The SL E-F consists of 55 fatigue items across 3 scales: 16 phy sical domain items, 18 mental 
domain items, and 21 fatigabilit y domain items. The subject is asked to score each fatigue it em 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 75of 144based on how frequentl y they experienced the item during the past 7 days using the following 
scale: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of 
the time.
9.2.4 SLE-M
The SL E-M consists of 12 mobility  items. The subject is asked to score each mobility  item based 
on how frequently  they experienced the item during the past 7 days using the following scale: 
1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the 
time.
9.2.5 SLE-
P
The SL E-P consists of 3 Numeric Rating Scales and 29 items across a Pain and Phy sical 
Sensations Scale and a Pain Checklist. The subject is asked to indicate on Numeric Rating Scales
the level of pain experienced in the past 7 day s at its LEAST , at its WORST, ON AVERAGE, 
and also RIGHT NOW . The subject is then asked to score each of 12 pain and phy sical 
sensation sitemsbased on the severit y experienced during the past 7 days using the following 
scale: 1=none; 2=very mild; 3=mild; 4=moderate; 5= severe; 6=very  severe. Finally , the subject 
is asked to indicate the locations of the pain experienced in the past 7 days using a checklist 
consisting of 17body  locations.
9.2.6 SLE-E
The SL E-E consists of seven feelings and mood items . The subject is asked to score each item 
based on how frequentl y they experienced the item during the past 7 day s using the following 
scale: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of 
the time. 
9.2.7 Subject Experience Interview
Qualitative subject interviews will be conducted by anexternal third part y vendor. 
The third 
party  vendor will call the subject at home to collect the subject's experience with lupus in terms 
of sy mptoms and impact on daily  activities, and the perceived c hanges during the course of the 
study . The extent to which the exploratory  PRO items and scales used fully captured their 
experience will also be assessed .
10 ASSESSMENT OF PK ANDPD VA RIABLE S
Subjects are to rest in a supine position for at least 10min befor e blood samples are taken. Blood 
samples are to be taken in the arm opposite the one used for infusion and be drawn at the time 
points and sampling windows designated in Table 5‒2Blood samples must not be drawn 
through the infusion cannula.
10.1 Assessment of PK variables
The following PK variables will be evaluated:
For plasma samples:
Plasma concentrations of DZP and PEG
For urine samples:
Urine c oncentration of PEG
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 76of 144The DZP concentrations in the plasma will be determined b y a validated 
electrochemiluminescence -based immunoassay . Concentrations of total PEG (both Fab' PEG and 
PEG) in plasma and of PEG in urine (following u ltrafiltration) will be determined by  a validated 
assay  using 1H nuclear magnetic resonance spectroscopy .Concentrations of DZP in urine may  be 
measured depending on the availability  of a bioanaly tical method. 
There are no time window requirements for blo od samples for PK measurements when measured 
pre-dose or at unspe cified times during the visit. Blood samples for PK measurements should be 
drawn within ±10min of the scheduled time point for each post -infusion time point or within 
10min after the infusion s ends for end of infusion time points . 
For urine PK assessments, urine collection containers will be dispensed to the subjects at the 
designated visits for urine collection at home prior to the next visit . As outlined in Table 5‒2, 
prior to Visits 9 and 10 only , the subject will collect overnight urine samples , which includes the 
first void after the subject goes to sle
ep the night before the visit through the first morning void 
the morning of the visit. The subject should note the times for the first and last urine collection . 
For all other visits requiring urine PK sample collection (Visits 2, 11, 12, 13, 14, and 16), the 
subject will collect only  their first morning void.
10.2 Assessment of PD variables
The following PD assessments will be performed. Additional assessments may  also be 
performed ,as deemed appropriate.
Whole blood mRNA signature profiling to characterize potential changes in gene expression 
relevant to the inflammatory  and immune response in SL E
Immunological variables:
Lupus Autoantibod y Profile: anti -dsDNA, ANAs, anti -ENA (anti -SM, anti -SSA, 
anti-SSB, and anti -RNP), RF, and aPL antibodies
Ig (total Ig, IgG, IgM, IgA, and IgE)
hsCRP
C3 and C4 levels
10.3 Handling and shipment ofblood and urine samples for PK and 
PD assessments
Sample work- up as well as the handling and shipment of samples should be performed as 
detailed in the Laboratory  Manual.
11 ASSESSMENT OF IMMUNOGENICITY VA RIABLES
The determination of the following immunogenicity  variables will be performed from plasma 
samples (as noted in the Laboratory  Manual) :
Anti- DZP and anti -PEG antibodies
Table 5‒2provides the timings for immunogenicity  assessments.
Blood samples must not be drawn through the infusion cannula. Sample work -up as well as 
the handling and shipment of samples should be performed as de tailed in the Laboratory  Manual.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 77of 144The detection of anti -DZP antibodies and anti -PEG antibodies will be done using validated 
methods. The details of analy tical methods (including validation status) and results will be 
presented in the bioanal ytical report.
12 ASSESSMENT OF BIOMA RKERS
In addition to the PD variables ( Section 1 0.2), the following samples will also be taken:
Serum will be taken and stored fo r protein and lipid anal ysis to characterize potential changes 
relevant to inflammatory  and immune responses and cardiovascular risk in SL E.
Whole blood will be taken and stored to isolate DNA which may  be used to examine genetic 
and epigenetic changes. Ifsamples are not used immediately , they  will be stored at -80°C for 
later anal ysis until the completion of the DZP development program. They will be stored at 
BioStorage Technologies GmbH (German y) and they will only be used in the context of 
understanding the molecular taxonomy  of SLE and/or response to treatment with DZP.
Table 5‒2provides the timings for biomarker assessments.
Blood samples must not be drawn through the infusion cannula. Sample work -up as well as 
the handling and shipment of samples should be performed as detailed in the Laboratory  Manual.
13 ASSESSMENT OF SA FETY
13.1 Adverse events
13.1.1 Definition of adverse event
An AE is an y untoward medical oc currence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessaril y have a causal relationship with 
this treatment. An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal labora tory finding), s ymptom, or disease temporall y associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product. All AEs that occur during the study  should be considered related unless clear ly 
unrelated.
In order to ensure complete safety  data collection, all AEs occurring during the study  (ie,after 
the signing of the Informed Consent form), including an y pretreatment and posttreatment periods 
required b y the protocol, must be reported in the eCRF even if no IMP was taken but specific 
study  procedures were conducted. This includes all AEs not pr esent prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
New or worsening manifestations of SLEshould be recorded as AEs onl y if they  are assessed as 
serious .
13.1.2 Procedures for reporting and recording adverse events
Thesubject will be given the opportunity  to report AEs spontaneously . A general prompt will 
also be given at each study  visit to detect AEs. For example:
“Did y ou notice any thing unusual about y our health (since y our last visit)?”
In addition, the Investigator should review an y self-assessment procedures ( eg,diary  cards) 
employ ed in the study for potential AEs .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 78of 14413.1.3 Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis of the underl ying 
disease, condition ,or syndrome using standard medical terminology , rather than recording 
individual sy mptoms or signs. The eCRF and source documents should be consistent. Any  
discrepancies between the subject’s own words on his/her own records ( eg,diary  card) and the 
corre sponding medical terminology  should be clarified in the source documentation.
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) 
are described in the eCRF Completion Guidelines.
13.1.4 Follow up of adverse events
An AE sh ould be followed until it has resolved, has a stable sequelae, the Investigator
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow -up requirement applies to AEs, SAEs, and AEs of special interest; furth er details 
regarding follow -up of PDILI events are provided in Section 13.7.
If an AE is ongoing at the end of the stud y for a subject, follow up sho
uld be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically  significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. For subjects withdraw nfrom the study  prior to Visit 12 
(Week 32), t he follow up will be continued throughout the SFU Period ( which ends 12 weeks 
after the final dose of study drug) .
Information on SAEs obtained after clinica l database lock will be captured through the PS
database without limitation of time.
13.1.5 Rule for repetition of an adverse event
An increase in the intensity  of an AE should lead to the repetition of the AE being reported with:
The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”
The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily  identifie d as the worsening of the first one
13.1.6 Hypersensitivity  and adverse drug reactions
In the event of a serious hypersensitivity  reaction, the subject must permanently  discontinue IMP 
and be progressed as described in Section 6.3.
In case of occurrence of a hy persensitivity  reaction (not determined by  the Investigator to be a 
minor local reaction at the infusion site, such as minimal itching) and depending u pon its 
severit y, appropriate countermeasures will immediate ly be taken by  the Investigator.
In the event of an anaph ylactic reaction, the infusion must be discontinued immediately  and 
emergency  resuscitation measures implemented. If the Investigator does not initially  choose to 
discontinue the infusion of IMP and sy mptoms persist or escalate during continued infusion, the 
infusion should be stopped. In case of an y severe infusion reaction(s), the infusion of IMP must 
be stopped imm ediately  and appropriate treatment initiated, as necessary , at the discretion of the 
Investigator and in accordance with the standard
-of-care. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 79of 144Suggested guidelines for the management of infusion reactions are provided in Appendix 19.3. 
Refer to 
Section 7.2.1.2 for details regarding premedication for proph ylaxis of infusion -related 
reactions.
Suspected anaph ylactic reactions should be classified using Sampson’s Criteria 
(Sampson etal,2006) as described in Appendix 19.4.
13.1.7 Thromboembolic events
If the Investigator suspects a subject has a thromboembolic event, the Investigator should 
manage the subject in accordance with the standard-of- care and should discuss the event with the 
Medical Monitor . The IMP should be withheld while the suspected thromboembolic event is 
being investigated. After investigation, IMP administration will be addressed as follows:
Suspected thromboembolic event is not c onfirmed: I MP may  be continued
Thromboembolic event is confirmed: IMP should be discontinued permanently
In the unexpected situation in which the study  needs to be terminated due to the incidence of 
thromboembolic events, the following will occur:
All Investigators will be informed of the detai ls of the thromboembolic events
All Investigators will be asked to evaluate each subject who received stud y
drug within the 
past 12 weeks , to assess the potential increased risk of thromboembolic event, and to 
consider appropriate management that may  include prophy lactic anticoagulant therapy in 
case an increased risk cannot be excluded. Before a proph ylactic anticoagulant treatment is 
started
, the I nvestigator should break the blind in order to assure that the subjectatrisk was 
treated with DZP . Based on the half -life of DZP , the Sponsor recommends that the duration 
of anticoagulant therap y be for 18 w eeks after the final dose of IMP .
All subjects who are in the Double- Blind Treatment Period ( Part1) will enter and complete 
the SFU Period
All subjects who are in in the SFU Period will complete the period as planned
13.1.8 Infections
Subjects who have the signs or s ymptoms of an y infection should be managed according to local 
guidelines. This may  include tests for possible infection with Epstein Barr virus and 
cytomegalovirus, if clinically  indicated. The tests for Epstein Barr virus and cy tomegalovirus 
will be performed at the central laboratory  using blood provided by  the site in accordance with 
the direction s provided in the Laboratory  Manual.
If a s ubject hasan infection that requires parenteral ( iv or im )antimicrobial treatment or that 
requires hospitalization, the subject’s continuation in the study  should be discussed with the 
Medical Monitor .
13.1.8.1 Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, an
y suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE ( Section 13.2); such cases must be reported 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 80of 144immediately , recorded in the AE module of the eCRF, and followed as any  other SAE. Any  
organism, virus, or infectious particle (eg, prion protein transmitting tran smissible spongiform 
encephalopath y), pathogenic or nonpathogenic, is considered an infectious agent.
13.1.9 Neurological events
Subjects who develop new neurological signs or sy mptoms or significantl y worsen ing
preexisting neurological signs or s ymptoms should be managed appropriately  to evaluate the 
underly ing disease or condition. This may  include involvement of a neurologist, imaging ,and 
other diagnostic activities as indicated. In case of severe and/or serious headache, positional 
headache, cranial nerve dysfunction , or signs and symptoms of meningitis, the Medical Monitor
should be contacted immediatel y and th eneurological event must be reported as an AE of 
interest to UCB within 24 hours.
13.1.10 Pregnancy
If an Investigator is notified that a subject has become pregnant after the first intake of any  IMP, 
the Investigator must immediately  notify UCB’s PSdepartment by providing the completed 
Pregnancy  Report and Outcome f orm (for contact details see S erious Adverse Event Reporting
information at the beginn ing of this protocol) . The subject should be discontinued from the study  
drug as soon as pregnancy is known (by positive pregnancy test) , and the following should be 
completed:
The IMP should be immediately  discontinued. 
The subject should complete the study per protocol .
If the Investigator becomes aware of a pregnancy  only  after an abortion, the withdrawal should 
be discussed with a Medical Monitor upfront. The Investigator must inform the subject of 
information currently  known about potential risks and about available treatment alternatives.
The pregnancy  will be documented on the Pregnancy  Report and Outcome form provided to the 
Investigator . The progression of the pregnancy  and the eventual birth (if applicable) must be 
followed up using the Pregnanc y Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every  reasonable attempt should be made to 
follow the health of the child for 30daysafter birth for any  significant medical issues. In certain
circumstances, UCB may request that follow up is continued for a period longer than 30days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by  the Investigator andfiled at the site. 
UCB’s PS department is the primary  contact for any  questions related to the data collection for 
the pregnancy , eventual birth , and follow up.
In cases where the partner of a male subject enrolled in a clinical study  becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner Pregnancy  Consent form thathas been approved b y the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/CRO contract monitor forthe study . The Investigator will 
complete the Pregnancy  Report and Outcome form and send it to UCB’s 
PS department (for 
contact details see S erious Adverse Event Reporting information at the beginning of this 
protocol) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy  Consent form .UCB’s PS department is also the primary  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 81of 144contact for an y questions related to the data collection for the partner pregnancy, eventual birth , 
and follow up.
A pregnancy  becomes a nSAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous ), unintended pregnancy  after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly  used), ectopic pregnancy , fetal demise, or any congenital 
anomaly /birth defect of the 
baby. Those SAEs must be additionally  reported using the 
Investigator SAE Report Form.
13.1.11 Overdose of IMP
Any SAE or nonserious AE associated with excessive dosing must be followed as any  other SAE 
or nonserious AE. These events are only  considered AEs or SAEs if there are associated clinical 
signs and s ymptoms or if the act of taking the excess medicine itself is an AE or SAE 
(eg,suicide attempt).
13.1.12 Safety  signal detection
Selected data from this study  will be reviewed periodically  to detect as earl y as possible an y 
safet y concern(s) related to the I MP so that Investigator s, clinical study  subje cts, regulatory  
authorities, and IRBs/IECs will be informed appropriately  and as earl y as possible.
The Study  Physician or medically  qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the I MP, 
medically  qualified personnel at UCB may  identify  additional safet y measures ( eg,AEs, vital 
signs, laboratory values, or ECG 
results) for w hich data will be periodically  reviewed during the 
course of the stud y.
In addition, a DMC will also monitor the ongoing safet y of the stud y (see Section 5.1.4).
13.2 Serious adverse events
13.2.1 Definition of serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:
Death
Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)
Significant or persistent disability /incapacit y
Congenital anomal y/birth defect (including that occurring in a fetus)
Important medical event that , based upon appropriate medical judgment, may  jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
(Important medical events may  include , but are not limi
ted to, potential Hy ’s Law [see
Section 13.3], allergic bronchospasm requiring intensive treatment in an emergency  room or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 82of 144at home, blood dy scrasias that do not result in inpatient hospitalization, or the development 
of drug dependency  or drug abuse.)
Initial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day , meets the 
criteria for the initial inpatient hospitalization. An emergency  room visit that r esults in 
admission to the hospital would also qualify  for the initial inpatient hospitalization criteria. 
However, emergency  room visits that do not result in admission to the hospital would not 
qualify  for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [ eg,life-threatening adverse experience, important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [ eg,preplanned 
surgery  or elective surgery  for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify
 for reporting. For example, if a 
subject has a condition recorded on his/her medical history  and later has a preplanned surgery  
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify  as an AE and, if necessary, the seriousness of the event would need to 
be determined.)
13.2.2 Procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by  
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly  completed “Investigator SAE Report Form for Development Drug” ( SAE Report Form ) 
provided b y UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any  conclusions. Information recorded on this form will be entered into 
the global safet y database.
An Investigator SAE report form will be provided to the Investigator . The Investigator SAE 
Report Form must be completed in English. 
It is important for the Investigator , when completing the SAE Report Form , to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very  important for UCB to consider in assessing the safet y of the IMP 
and in determining whether the SAE requires reporting to the regulatory  authorities in an 
expedited manner.
Additional information ( eg,autops y or laboratory reports) received b y the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by  a 
translation in English, or the relevant information included in the same doc ument must be 
summarized in the I nvestigator SAE Report Form.
The Investigator is specifically  requested to collect and report to UCB (or its representative) any  
SAEs (even if the Investigator is certain that they  are in no way  associated with the I MP), up to 
30daysfrom the end of the study  for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any  SAE within this period. Serious AEs that the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 83of 144Investigator thinks may  be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the stud y.
Upon receipt of the SAE Report Form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the list of Anticipated 
SAEs provided in Section 13.5.
13.2.3 Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the Investigator
determines that it is no longer clinicall y significant, or the su bject is lost to follow up. 
Information on SAEs obtained after clinical database lock will be captured through the PS 
database without limitation of time.
13.3 Adverse events of 
special interest
An AE of special interest is any  AE that a regulatory  authority  has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. There are currently  no AEs of special interest 
identified for DZP ; however, in accordance with the Sponsor’s internal guidelines for all drugs in 
development, Potential Hy's Law is to be reported as an AE of special interest as follows:
Potential Hy ’s law, defined as ≥3xULNALT or AST with coexisting 
≥2xULN bilirubin in the 
absence of ≥2 xULN ALP , with no alternative explanation for the biochemical abnormality , must 
ALWAYS be reported to UCB as an AEof special interest (ie,without waiting for any  
additional etiologic investigations to have been concluded). Foll ow-up information should then 
bereported if an alternative etiology  is identified during investigation and monitoring of the 
subject. Refer to Section 13.7 for details on investig ation and monitoring of PDILI.
13.4 Immediate reporting of adverse events
The following AEs must be reported immediately to UCB (or its representative) :
SAE s: AEs that the Investigator classifies as serious by  the above definitions regardless of 
causality
Suspe cted transmission of an infectious agent via a medicinal product (see Section 13.1.8.1)
AEsof special 
interest (see Section 13.3 )
AEs of interest (regardless of seriousness):
Moderate to s evere infections, including opportunistic infections and TB
Infusion reactions (including hy persensitivity  and anaph ylaxis)
Thromboemboli c events (including but not limited to cardiovascular events, stroke,
myocardial infarction, pulmonary  embolism, and deep vein thrombosis)
Prespecified neurological events: Severe and/or serious headache, positional headache, 
cranial nerve dy sfunction , or signs and s ymptoms of meningitis (photophobia, neck 
stiffness)
Malignancies
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 84of 14413.5 Anticipated serious adverse events
Table 13‒1 lists a nticipated SAEs that have been identified as these events are anticipated to 
occur in the population studied in this protocol at some frequency  that is independent of drug 
exposure. This original list will re
main in effect for the duration of the protocol.
This list does not change the Investigator ’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 13.2.2.
Table 13‒
1:Anticipated serious adverse events for subjects with SLE
Thromboembolism
Serious infecti on
Renal dysfunction
Neuropsychiatric episode
Leucopenia
Anemia
Thrombocytopenia
SLE
SLE=systemic lupus erythematosus
13.6 Assessment and management of TB and TB risk factors
Appropriate rigorous precau tions are being taken within this protocol to monitor the risk of TB 
infection in this study  (see Section 6.2 [Exclusion Criterion #16]) and Section 6.3 [Withdrawal 
Criteria ]).Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. 
Confirmed active TB must be reported as an SAE ( Section 13.2.2). The Investigator is to 
complete and submit the TB follow -
up form provided.
Signs and s ymptoms
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s history . Sites commonly  
infected b y TB include: the lungs, lary nx, ly mph glands, pleura, gastrointestinal sy stem, 
genito urinary  tract (including renal), bones and joints, meninges, peritoneum, pericardium, and 
skin. This is not an exhaustive list and unusual presentations and areas of involvement should 
alway s be considered.
Common sy mptom s with which the subject may  present with include cough, blood in sputum, 
night sweats, ly mphadenitis, joint pain/swelling, spinal deformity , headache/confusion, 
abdominal pain mimicking inflammatory  bowel disease , frequent or painful urination, scrotal 
mass in men and pelvic inflammatory  disease in women as well as other sy mptoms, or 
nonspecific s ymptoms. This is not an exhaustive list and unusual presentations should alway s be 
considered.
If active TB is identified, the subject must undergo appropriate st udy specified withdrawal 
procedures.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 85of 144Latent TB infection is defined as the absence of signs, symptoms (eg, evidence of organ -specific 
involvement), or ph ysical findings suggestive of TB infection with a pos itive interferon- γ release 
assay  (IGRA )test (or 2 indeterminate I GRA test results) and a chest x -ray (or other imaging) 
without evidence of TB infection. If the result of the IGRA test is indeterminate, the particular 
IGRA test previously performed may be repeated once; if positive or indeterminate on re test, the 
subject may  not be randomized to study  drug and, if alread y randomized, must undergo 
appropriate stud y specified withdrawal procedures. The retest m ust be done during the 
protocol -defined Screening window.
Note: If available, respiratory  or other specimens must also be smear and culture negative for TB 
(Centers for Disease Control, 2015).
Test c onversion
Tuberculosis test conversion is defined as a positive result (IGRA) for the current test but 
previous test results were negative (IGRA). All subjects with TB test conversion must 
immediately  stop study  drug administration. I n case of a TB test conversion, the subject must be 
considered as having either a suspected new latent or an active TB infection and be promptly  
referred to an appropriate specialist (eg, pulmonologist, infectious disease specialist) for further 
evaluation. If test conversion indicates L TB infection, active TB, or non- mycobacterial TB 
infection then, per UCB TB working instructions, TB test conversion (confirmed) should be 
classi fied as due to L TB, active TB infection, or non- TB m ycobacterial infection. Additional 
assessments (eg, bl ood tests or I GRA test, chest x -rays, or other imaging) should be performed as 
medically  indicated.
Latent TB : In case the evaluation by  the appropria te specialist indicates a new LTB, the subject 
must be withdrawn from the study .
Active TB /non -tuberculosis mycobacterium : Subjec ts who develop active TB or 
non-tuberculosis my cobacterium (NTMB) infection during the study  (conversion demonstrated 
by
 IGRA) must be withdrawn from the study . The subject must be immediately  discontinued 
from study  drug and a n EWV must be scheduled as soon as possible, but no later tha n the next 
scheduled visit. The subject should be encouraged to keep the SFU Visits as specified b y the 
protocol. The TB must be documented as an SAE. Treatment should be immediately  started.
Note that subjects with history  of or active NTMB infection are excluded from the study  
regardless of prior or current therap y. 
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided to 
the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow -up report s should be completed as per protocol requirement until such time as the TB 
infection resolves.
Once withdrawn from study  treatment, subjects should return for the End of Treatment/ EWV , 
complete all early  withdrawal assessments, and complete the SFU Visit s.
13.6.1 TBassessments
During conduct of the study , the TB assessment by IGRA ( QFT -GITor Elispot, if QFT -GITis 
not available locall y), should be repeated at Week 48 or earl y withdrawal for all subjects. The 
test results will be reported as positive, negative, or indeterminate and must be reviewed b y an 
experienced TB specialist, radiologist, or a pulmonologist. If the assessment by  IGRA is positive 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 86of 144or indeterminate on retest for subjects who were previously negative at Screening, the subject 
must undergo approp riate study -specified withdrawal procedures. The retest during Screening 
must be done during the protocol- defined Screening window.
13.6.2 Chest x -ray
A plain posteroanterior chest x- ray (or, if done, computed axial tomography  of the chest) should 
be performed during S creening unless one has been done within 3 months prior to the Screening 
Visit. The chest x -ray must be clear of signs of TB infection (previous or current) before first 
study  drug administration. The chest x -ray should be repeated onl y if the TB t est was confirmed 
positive or any  further evidence is suggestive of potential TB infection (eg, exposure). 
Radiographic findings suggestive of inactive TB or active TB may  include but are not limited to: 
apical fibrosis, pleural thickening, pulmonary  nodul
es, fibrotic scars, calcified granulomas, upper 
lobe infiltrates, cavitations and pleural effusions, calcified lung nodules, calcified hilar ly mph 
nodes, and pericardial calcification.
The chest x -ray (or, if done, computed axial tomography  of the chest) m ust be negative for TB 
infection as determined by  a qualified radiologist and/or pulmonary  physician. Any  new 
clinically  significant findings post-Baseline during phy sical examination or on chest x -ray must 
be documented in the source documents and eCRF as an AE.
13.6.3 TBsigns and sy mptoms questionnaire
The questionnaire “Evaluation of signs and s ymptoms of tuberculosis” should be used as a 
source document. The questionnaire will assist with the identification of subjects who may  
require therap y for TB. A subjec t who answers “Yes” to the question  
 
 at Screening is excluded. A “Yes” response to an y of the other questions within the 
questi onnaire at Screening should trigger further careful assessment to determine if subject has 
latent or active TB (see Section 6.2, Exclusion Criterion #16). A “Yes” response to any  of the
questions during the study
 should trigger further assessments to determine if the subject has 
either LTB or active TB infection.
Subjects with a L TB oractive TB infection must be withdrawn from the study and will have 
further assessments.
13.6.4 TBmanagement
For inclusion in the study, see Section 6.2, Exclusion Criterion #16.
LTB infection and active TB identified during study
During the study , subjects who develop evidence of L TB infection or active TB must 
immediately  stop further administration of study  drug and will be referred to an appropriate TB 
specialist (pulmonologist or infectiou s disease specialist) for further evaluation. Evidence of 
LTB infection is defined as the subject’s IGRA test converting to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire history  or phy sical 
examination in dicating that TB infection or exposure may  have occurred. Evidence of active TB 
includes, in addition to the aforementioned tests, signs and s ymptoms of organ involvement. In 
either situation, the subject should be carefull y assessed b y a TB specialist for active TB. 
Subjects diagnosed with active TB or LTB infection should receive appropriate TB or 
prophy laxis therapy and must be withdrawn from the study .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 87of 144Confirmed acti ve TB must be reported as a SAE . The Investigator is to complete and submit the 
TB follow -up form provided.
The subject should be transferred to the care of their physician and managed according to the 
standard -of-care. Subjects identified as having converted to active TB during the study  must be 
withdrawn and scheduled to return for the EWV as soon as possible but no later than the next 
scheduled stud y visit and complete all EWV assessments. The subject should be encouraged to 
complete the SFU Visits after the final dose of study  drug .
If infection with NTMB is identified during the stud y, the same procedure as for active TB 
acquired during the study must be followed. 
Follow -Up information of suspected and confirmed TB cases should be provided to UCB at least 
after 3, 9, and 12 months of the start date of anti-TB treatment, including hematological and 
biochemical safet y parameters, x -ray evolution data, and TB diagnostic procedures used to 
follow -up and confirm recovery  of TB.
13.7 Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study  are provided in Section
6.3.1, with the 
accompan ying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study  site and S
ponsor within 24 hours of learning 
of their occurrence. An y PDILI event that meets the criterion for potential Hy ’s Law must be 
reported as an AE of special interest (see Section 13.3), and, if applicable, also reported as an 
SAE (see Section
13.2.2).
Evaluation of PDILI consists of the diagnostic testing and cont
inued monitoring included in
Table 13‒2 ( specific tests dependent on lab results and corresponding s ymptoms) and consult 
with a local hepatologist (if applicable; discussed in Section
13.7.1). The local hepatologist is the 
expert usually  consulted by
 the treating phy sician for assessment and management of potential 
hepatic disease. This would usually be a hepatologist, but may  be a gastroenterologist. 
Additional investigation and monitoring m ay be required and adapted based on the diagnosis 
after the cause of the liver injury /abnormality  is confirmed (details in Section 13.7.3). 
The resu lts of all monitoring, including labs and other testing, should be made available to the 
study  site and Sponsor.
All initial abnormal hepatic lab values need to be repeated, but appropriate medical action must 
not be delay ed waiting for the repeat result.
If tests are done locall y for more rapid results, a concurrent sample should also be sent to the 
central laboratory  whenever possible. Medical care decisions are to be made initially  using the 
most rapidly  available results and a conservative approach must
be taken if the results from the 
2laboratory  tests are significantly  different. Data from the local and central laboratory  are to be 
recorded on the applicable e CRF pages.
When I MP is discontinued, all concomitant medications and herbal supplements that are not 
medically  necessary  should also be dis continued. In these cases, the I nvestigator should also 
consider dose reduction for medicall y necessary concomitant medication and consider changing 
any medicall y required concomitant medication known to be hep atotoxic to a suitable 
alternative.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 88of 144When I MP is stopped due to PDILI (as described in Section 6.3.1), I MP must be permanentl y 
discontinued unless a s
ubsequent alternative diagnosis fully  explains the hepatic findings. If a 
subsequent alternative diagnosis full y explains the hepatic findings, and the requirements 
provided in Section 13.7.2.1 are met, rechallenge with I MP may  be appropriate. 
Rechallenge with a substance potentiall y causing drug -induced liver injury is dangerous, may  be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 89of 144Table 13‒2: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg,by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.Immediate, 
permanent IMP 
discontinuation.Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see
Section 13.7.3 ); 
recommended to 
occur at the site 
with HCP.Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.d≥8xULN NA NA
≥3xULN NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN<2xULN No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.Further investigation 
–immediate IMP 
discontinuation not 
required (see
Section 13.7.2 ).Not required 
unless otherwise 
medically
indicated (at 
discretion of 
Investigator).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 90of 144Table 13‒2: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥5xULN 
(and ≥2x 
baseline) 
and 
<8xULN<2xULN No Hepatology consult if 
there is no evidence 
of resolution (see 
Follow up 
requirements).c
Discussion with 
Medical Monitor 
required.IMP discontinuation 
required if any of 
the following occur:
Subject cannot 
comply with 
monitoring 
schedule. 
Liver chemistry 
values continue to 
increase during 
2week monitoring 
period.
Liver chemistry 
values remain 
≥5xULN (and 
≥2xbaseline) after 
2week monitoring 
period.Essential: Eve ry 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see
Section 13.7.3 ).Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.d
Immediate IMP discontinuation required if liver 
chemistry values continue to increase.
After 2 weeks of monitoring liver che mistry 
values:
Discontinue IMP if levels 
remain ≥5xU LN (and ≥2x 
baseline); monitor until values 
normalize, stabilize, or return to 
within baseline values.d
Continue IMP if levels are no 
longer ≥5xULN (and ≥2x 
baseline); continue to monitor at 
least twice per week until 
values normalize, stabilize, or 
return to within baseline 
values.d
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosino philia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi calMonitor.
.cDetails provided in Section 13.7.1 . The local hepatologist is the expert u sually consulted by the treating physician for assessment and management of potential 
hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternati ve monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 91of 14413.7.1 Consultation with Medical Monitor and local hepatologist
Potential drug -induced liver injury events require notification of the Medical Monitor , within 
24hours (eg b y laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with t he local hepatologist
. The 
local h epatologist is the expert usually  consulted by  the treating phy sician for assessment and 
management of potential hepatic disease. This would usually  be a hepatologist, but may  be a 
gastroenterologist. If determined necessary , this discussion should be foll owed b y a full 
hepatology  assessment (see Section 13.7.3) and SAE report (if applicable) .
13.7.2 Immediate action: determination of IMP discontinuation
AllPDILI events require immediate action, testing, and monitoring.
The immediate action is dependent on the laboratory  values and s ymptoms of hepatitis or 
hypersensitivity  and ranges from continuation of IMP (followed by  immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 andTable 13‒2 for details).
When I MP is discontinued, all concomitant medications and herbal supplements that are not 
medically  necessary  should also be discontinued. The I nvestigator should also consider dose 
reduction for medicall y necessary  concomitant medication and consider changing an y medicall y 
required concomitant medication known 
to be hepatotoxic to a suitable alternative.
13.7.2.1 IMP restart/rechallenge (if applicable)
Rechallenge with a substance potentiall y causing drug -induced liver injury is dangerous, may  be 
fatal, and must not occur.
Subjects who are immediately  discontinued from I MP due to having met certain criteria for 
PDILI (as described in Section 6.3.1 andTable 13‒2), but for whom an alternative diagnosis is 
confirmed, can rarel y restart I MP. Rechallenge with I MP can occur only  if ALL of the following 
requirements are met:
The results of additional testing and monitor ing described in Section 13.7.3 and 
Section
13.7.4 confirm a nondrug -related cause for the abnormal hepatic laborato ry 
parameters and an y associated sy mptoms (ie, a subsequent alternative diagnosis fully  
explains the hepatic findings). 
No alternative treatment options are available to the subject.
The subject has shown clear therapeutic benefit from the I MP.
Subject’s ALT or AST elevations do not exceed ≥3xULN.
Subject’s total bilirubin is <1.5xUL N.
Subject has no signs or symptoms of h ypersensitivity . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 92of 144The rechallenge is approved by  the UCB responsible phy sician, DMC, and a hepatologist. 
The hepatologist must be extern al to UCB but may be a member of the DMC. I t is 
recommended that the hepatologist be a local hepatology  expert or the hepatologist treating 
the subject.
Subject agrees to the Investigator-recommended monitoring plan.
13.7.3 Testing: identification/exclusion of al ternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that it may  have been caused b y the IMP are detailed in 
Table 13‒3(laboratory  measurements) and Table 13‒4 (additional information). Results of the 
laboratory  measurements and information collected 
are to be submitted to the Sponsor on the 
corresponding eCRF. If medical history  of the subject indicates a requirement for other 
assessments not included below, th ese additional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locall y for more rapid results, a 
concurrent sample must also be sent to the central laboratory .
Table 13‒3: PDILI laboratory measurements
Virology
-related Hematology
Hepatitis A immunoglobulin M (IgM) antibody Prothombin timea
International Normalized Ratio (INR)
Hepatitis B surface antigen (HBsAg) Eosinophil count
Hepatitis E IgM antibody Urinalysis
Hepatitis B core antibody -IgM (HBcAb -IgM) Urine toxicology screen
Hepatitis C ribonucleic acid (RNA) Chemistry
Cytomegalovirus IgM antibody If bilirubin ≥1.5xULN, obtain fracti onated bilirubin 
to obtain % direct bilirubin
Epstein Barr viral capsid antigen IgM antibody (if 
unavailable, obtain heterophile antibody or 
monospot testing)Serum creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH) to evaluate possible muscle 
injury causing transaminase elevation
Immunology Amylase
Anti-nuclear antibody (qualitative and quantitative) Additional
Anti-smooth muscle antibody (qualitative and 
quantitative)Serum pregnancy test
Type 1 anti -liver kidney microsomal antibodies 
(qualitative and quantitative)PK sample
ALT=alanine aminotransferase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; ULN=upper limit 
of normal
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (w ithout clear alternative 
cause).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 93of 144The following additional information is to be collected:
Table 13‒4: PDILI information to be collected
New  or updated information
Concomitant prescription and over the counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
history of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty liver 
disease”)
adverse reactions to drugs
allergies
relevant family history or inheritable disorders (eg, Gilbert’s disease, alpha 1 antitrypsin deficiency)
recent travel and/or progression of malignancy involving the liver (note that metastatic disease to the 
liver, by itself, should not be used as an explanation for significant AST and/or ALT elevations)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased ap petite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use; include dates where available
Results of liver imaging or liver biopsy, if d one
Results of any specialist or hepatology consult, if done
Any postmortem/ pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase
13.7.4 Follow -up evaluation
All PDILI events require follow- up monitoring as described in Table 13‒2. Monitoring should 
continue until liver chemistry  values normalize, stabilize, or return to baseline. Determination of 
stabilization is at th e discretion of the Investigator in consultation with the hepatologist (as 
applicable) and UCB responsible phy sician, as needed .
13.8 Physical examination and 
interim medical history
The phy sical examination and the interim medical history  is an important base for recognition 
and appropriate documentation of AEs and is a critical part of disease activity  assessment 
instruments, such as the BILAG 2004 or the SLEDAI -2K. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 94of 144Physical examination findings will be recorded in the eCRF at Screening. Clinically  relevant 
changes in subsequent physical examinations will be recorded as AEs if not related to SLE . If 
physical examination findings are considered to be related to SLE ,they will be documented 
within the BILAG 2004 and/or SL EDAI -2K assessm ent. The outcome of p hysi cal examinations 
and the interim medical history must be documented in source documentation. The following 
body  systems will be examined:
General Appearance
Ear, Nose and Throat
Eyes
Hair and Skin
Respiratory
Cardiovascular
Gastrointestinal
Musculoskeletal
Hepatic
Neurological (including focused assessment of reflexes, sensitivity , muscle strength )
Mental Status
13.9 Laboratory  measurements
A central laboratory  will perform all blood -and urine -based laboratory  assessments except urine 
pregnancy  tests, which will be performed at the site.
Subjects are to rest in a supine position for at least 10min before blood samples are taken. Blood 
samples are to be taken in the arm opposite the one used for infusion. Blood samples must not 
be drawn through the infusion ca nnula.
Certain coagulation tests (in particular, activated partial thromboplastin time [aPTT]) should only  
be performed using the central laboratory  while subjects are receiving study  drug as PEG may  
interfere with some aPTT assay s leading to false results indicating prolongation of aPTT.
At visits for which serum creatinine values are available, eGFR will be calculated using the 
Modification of Diet in Renal Disease formula modified for race.
Laboratory  parameters that will be measured are listed in Table 13-5.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 95of 144Table 13-5:Laboratory  measurements
Category Parameters to be assessed
Clinical chemistry Liver function tests: bilirubin, AST, ALT, ALP, GGT, and LDH
Creatinine
Urea nitrogen
Electrolytes (sodium, potassium, calcium, and phosphate)
Total cholesterol and triglycerides
Total protein and albumin
Glucose
Lipase
Creatine phosphokinase
Hematology Hemoglobin
Hematocrit 
Mean corpuscular volume 
RBC count
Erythrocyte sedimentation rate
Mean corpuscular hemoglobin concentration 
Mean corpuscular hemoglobin 
WBC count with differential (basophils, eosinophils, lymphocytes, monocytes, 
and neutrophils)
Platelet count
T cells ( CD3 +)
B cells ( CD19 +)
Additional 
assessmentsHIVtest
Hepatitis screening
Tuberculosis test (QFT -GIT)
Anti- dsDNA antibodies
ANAs, anti-ENAs (anti-SM, anti-SSA, anti-SSB, and anti -RNP) and RF
aPL antibodies including anticardiolipin antibodies, lupus anticoagulanta, and 
anti-β2 glycoprotein antibodies
Total Ig, IgG, IgM, IgA, and IgE
High sensitivity C -reactive protein
Serum complement (C3, C4)
Whole blood mRNA signature profiling
Proteomic signature profile
Cardiovascular proteins, lipids, lipid particles
Coagulation and hemostasisa
Coombs’ test (reflex testing to be performed by the central laboratory as 
indicated if signs of anemia are observed)a
Pregnancy testing Serum test (β -hCG) (subjects of childbearing potential) at Screening ( Visit 1)
Urine test (β -hCG) (subjects of childbearing potential) at all other visits
Urinalysis pH
Protein
Glucose
Ketone
UrobilinogenBilirubin
Blood
Nitrite
Leukocytes
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 96of 144Table 13-5:Laboratory  measurements
Category Parameters to be assessed
Urine chemistry and 
microscopyProtein, albumi n, and creatinine (for protein: creatinine ratio [mg/m mol] and 
albumin: creatinine [mg/mmol ]ratios)
Microscopy of sediment for RBCs, RBC casts, WBCs, and WBC casts
Proteins and metabolites relevant to SLE
ANA=antinuclear antibody; anti-ENA=extractable nuclear antigen antibody; anti-RNP=anti -ribonucleoprotein 
antibody; anti-SSA=Sjögren’s syndrome antibody A; anti-SSB=Sjög ren’s syndrome antibody B; anti -SM=Smith 
antibody; aPL=antiphospholipid; ALP=alkaline phosphatase; ALT=alanine aminotra nsferase; AST=aspartate 
aminotransferase; β-hCG=beta human chorionic gonadotropin; dsDNA=double -stranded deoxyribonucleic acid; 
GGT=gamma- glutamyltransferase; HIV=human immunodeficiency virus; Ig=immunoglobulin; LDH=lactate 
dehydrogenase; mRNA=messenger ri bonucleic acid; RBC=red blood cell; RF=rheumatoid factor; SLE=systemic 
lupus erythematosus; WBC=white blood cell
aAs defined in the Laboratory Manual.
13.10 Vital signs
Vital sign measurements for all subjects will include height, weight, blood pressure ( systolic and 
diastolic), pulse rate , and body  temperature. 
Subjects will rest in the position used for dosing for at least 10min before and continue to rest in 
that position while 
pulse rate andblood pressure are measured. 
Table 5‒2indicates the timings for vital sign assessments. Vitals signs should be measured 
within ±5min of the scheduled time point for the every  15min assessments and within ±10mi n of 
the scheduled time point for the every  30min assessments.
13.11 12
-lead ECGs
Twelve -lead ECG assessments should be performed prior to dosing (if applicable) and prior to 
obtaining PK or other laboratory  samples. Electrocardiograms will be recorded digitally and read 
by the Investigator for recording in the eCRF. 
Care should be taken to assure proper lead placement and quality  ECG recording. Subjects 
should rest in a supine position in a controlled, calm environment for at least 15min prior to the 
recording and should be motionless during the recording.
The Investigator or designee will determine whether the results of the ECG are normal or 
abnormal. All important findings and abnormalities (including their specification) should be 
reported.
Table 5‒2indicates the visits at which 12-lead ECG assessments will be performed .
13.12 Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed b y trained study  personnel using the C-SSRS . 
This scale will be used for screening as well as to assess suicidal ideation and behavior that may  
occur during the stud y.Table 5‒2indicates the visits at which the C- SSRS assessments will be 
performed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 97of 14414 STUDY M ANAG EMENT A NDADM INISTRA TION
14.1 Adherence to protocol
The Investigator should not deviate from the prot ocol. However ,the Investigator should take any  
measure necessary  in deviation from or not defined by  the protocol in order to protect clinical 
study subjects from any  immediate hazard to their health and safet y.Inthis case ,
this action 
should be taken immediately ,without prior notification of the regulatory  authority ,IRB/IEC,or 
Sponsor .
After implementation of such measure ,the Investigator must notify  the CPM of the S ponsor 
within 24 hours and follow an y local regulatory  requirements.
14.2 Monitoring
UCB (or designee) will monitor the study  to meet the Sponsor ’s monitoring Standard Operating 
Procedures (SOPs), I CH-GCP guideline, and applicable regulatory  requirements, and to ensure 
that study  initiation, conduct, and closure are adequate. Monitoring of th e study  may  be 
delegated b y UC B to a CRO or a contract monitor.
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently  and to provide any  
missing information. The Investigator (s)/institution(s) will permit direct access to source 
data/documents for stud y
-related monitoring, audits, I RB/IEC review, and regulatory  
inspection(s).
The Investigator will allow UCB (or designee) to periodicall y review all eCRFs and 
corresponding source documents ( eg,hospital and laboratory  records for each study  participant). 
Monitoring visits will provide UCB (or designee) with the opportunity  to evaluate the progress 
of the study , verify  the accuracy  and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator ’s obligations are being 
fulfilled, and resolve an y inconsistencies in the study records.
14.2.1 Definition of source data
All source documents must be accurate, clear, unambiguous, permanent, and capable of bei ng 
audited. They  should be made using some permanent form of recording (ink, ty ping, printing, 
optical disc). They  should not be obscured by  correction fluid or have temporary  attachments 
(such as removable self -stick notes). Photocopies and/or printouts of e CRFs are not considered 
acceptable source documents. 
Source documents are original records in which raw data are first recorded. These may  include 
hospital/clinic/general practitioner records, charts, diar ies, x -rays, laboratory  results, printouts, 
pharmacy  records, care records, ECGs or other printouts, completed scales, or electronic 
questionnaires, for example. Source documents should be kept in a secure, limited access area.
Source documents that are computer generated and stored electronicall y must be printed for 
review b y the monitor ( eg,ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 98of 144Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed b y UCB (or designee).
UCB expects to select approximately  4 to 6 US sites to participate in an Electronic Healthcare 
Record (EHR) pilot , which will test data extraction from the subjects ’ EHR into the eCRF to 
populate fields in the Demograph y, Medical History , Conco
mitant Medications, and Vital Signs 
eCRFs. UCB stated the intention to pilot the use of EHR data in their response to FDA’s Federal 
Register Notice, Source Data Captur e from Electronic Health Records: Using Standardized 
Clinical Research Data. For the purp oses of the pilot, the EHR is considered the source for these 
fields. The sites participating in the EHR pilot are not expected to print the subjects’ EHRs.
14.2.2 Source data verification
Source data verification ensures accuracy  and credibility  of the data obta ined. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents ( eg,subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory  notes). All data rep orted on the eCRF should be supported by  source 
documents, unless otherwise specified in Section 14.2.1.
14.3 Data handling
14.3.1 Case R
eport F orm completion
The study  is performed using electronic data capture ( EDC). The Investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be acco mpanied b y a reason for the 
change.
Corrections made after the Investigator ’s review and approval (by  means of a 
password/electronic signature) will be reapproved by  the Investigator.
The Investigator should maintain a list of personnel authorized to enter data into the eCRF.
Detailed instructions will be provided in the eCRF Completion Guidelines.
14.3.2 Database entry  and reconciliation
Case Report F orms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data ma nagement sy stem (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure completeness, 
consistency ,and plausibility  of the data. 
An electronic audit trail system will be maintained withi n the CDMS to track all data changes in 
the database once the data have been saved initially  into the sy stem or electronically  loaded. 
Regular backups of the electronic data will be performed.
14.3.3 Subject Screening and Enrollment L og/Subject Identification Cod e 
list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 99of 144The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify  the study  and document the dates of the subject’s 
participation.
14.4 Termination of the study
UCB reserves the right t o temporaril y suspend or prematurel y discontinue this study  either at a 
single site, multiple sites, or at all sites at an y time for reasons including, but not limited to, 
safet y or ethical issues, inaccurate or incomplete data recording, noncompliance, or
unsatisfactory  enrollment with respect to qualit y or quantity.
If the stud y is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigator s/institutions and the regulatory  authority (ies) of the termination or suspension a nd 
the reason(s) for the termination or suspension, in accordance with applicable regulatory  
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by  the Sponsor or by the Investigator /institution , as specified b y the 
applicable regulatory  requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study .
14.5 Archiving and data retention
The Investigator will maintain adequate records for the study, including e CRFs, medical records, 
laboratory  results, I nformed Consent documents, drug dispensing and disposition records, safety  
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained b y the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an I CH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required b y the applicable regulatory requirement(s) or b y an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The Investigator will contact 
UCB for authorization prior to the destruction of any  study  records or in the event of accidental 
loss or destruction of an y study  records. The Investigator will also notify  UCB should he/she 
relocate or move the study -related files to a location other than that specified in the Sponsor’s 
study  master file.
14.6 Audit and inspection
The Investigator will permit study -related audits mandated b y UCB, after reasonable notice, and 
inspections by  domestic or foreign regulatory  authorities.
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, that enrolled subjects ( ie,signing consent and undergoing 
study  procedures) are appropriate for the study , and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and I RB/IEC SOPs, ICH GCP, and applicable regulatory  
requirements.
TheInvestigator will provide direct access to all study  documents, source records, and source 
data. If an inspection b y a regulatory  authority  is announced, the Investigator will immediately  
inform UCB (or designee).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 100of 14414.7 Good Clinical Practice
Noncompliance with the protocol, I CH-GCP, or local regulatory  requirements by  the 
Investigator , institution, institution staff, or designees of the Sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may  result in the termination of the 
site’s involvement in the study .
15 STATISTICS
A brief description of the planned statistical methods is provided in the sections that follow. Full 
details will be provided in the SAP .An additional interim SAP will describe the complete 
analysis of the 
Double- Blind Treatment Period ( Part1) of the stud y .
15.1 Definition of analy sis sets
Seven analysis sets will be defined for this study : the Enrolled Set (ES), the Randomized Set 
(RS), the Safet y Set (SS), the Full Anal ysis Set (FAS), the Per Protocol Set (PPS), the 
Pharmacokinetic Per Protocol Set (PK- PPS) , and the Completer Set (CS). 
15.1.1 Enrolle d Set
The ESwill consist of all subjects who have given informed consent.
15.1.2 Randomized Set
The RS will consist of all subjects randomized into the study .
15.1.3 Safety Set
The SS will consist of all subjects who are randomized and have received at least 1 dose (any 
amount) of study  drug. Safet y variables will be analyzed using the SS.
It is expected that subjects will receive treatment as randomized; hence, safety  anal yses will be 
based on the randomized treatment group. However, if it is determined that a subject has 
consistently  received treatment other than what they  were randomized to, then for safet y 
analyses, the subject will be allocated to the actual treatment they  received.
15.1.4 Full A nalysis Set
The FAS will consist of all subjects who have received at least 1 full dose of study  drug and have 
at least 1post-
Baseline efficacy  measurement during the Double -Blind Treatment Period . The 
FAS is the primary  analysis set for efficacy  anal yses.
In case of mistreatment, subjects will be anal yzed as randomized for the FAS .The FAS will only  
be used for subjects in Part1of the study  (until the end of Double -Blind Treatment Period of the 
study ).
15.1.5 Per Protocol Set
The PPS will consist of subjects in the FAS who have received at least 1 full dose of study  drug 
and have no imp ortant protocol deviations during the Double -Blind Treatment Period that may  
influence the validity  of the data for the primary  efficacy  variable , the BICLA .
Analy ses of the primary  efficacy  variable will be repeated using the PPS.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 101of 14415.1.6 Pharmacokinetic Set
The PK-PPS will consist of all subjects in the SS who have provided at least 1 PK sample and 
for whom no important protocol deviations affecting the PK variables have been documented. 
This analy sis set will be used for all PK analy ses.
15.1.7 Completer Set
The CS wil l consist of all subjects who did not permanently  discontinue study  drug during the 
Double- Blind Treatm ent Period (Part 1), completed Week 24 of Part 1, and continued into the 
Observational Period (Part 2) of the stud y.
15.2 General statistical consideration s
For continuous data in general, summary  statistics (n [number of available measurements], 
arithmetic mean, standard deviation, median, minimum, and maximum) will be presented b y 
treatment group. 
For descriptive statistics of continuous variables, change from Baseline and the value at the time 
point itself will be displayed.
Frequency  tables (frequency  counts and percentages) will be presented for categorical data. If 
there are missing values, either a missing category will be included in the display  orthenumber 
of nonmissing results will be used for calculations.
In general, percentages will be calculated bas ed on the utilized analy sis set; however , in case any  
analysis subsets are affected then the N of the subset will be used as denominator. Subsets of 
analysis sets will be described more in detail in SAPs.
Unless otherwise specified in the SAPs, the last measurement before study  drug infusion will be 
used as the Baseline value. For almost all variables, this will be the Baseline assessment. 
However, for some variables, assessments may be scheduled for Screening only  and not for 
Baseline. In this case the Screening value will be utilized as Baseline value. If a Baseline 
measurement is missing, and a Screening value available, the Screening value will be u tilized as 
Baseline instead.
In general (if not otherwise specified in the SAPs), tables and figures will be presented b y 
randomized treatment during the Double
-Blind Treatment Period for the entire study .
The end of the Double- Blind Treatment Period ( Part1) of the stud y is defined as the date of the 
last Week 24 visit of the last subject in the study  or the date of the last SFU Visit of the last earl y 
terminating subject (before Week 24) in the study , whichever is later. The end of the study  is 
defined as the date of the last visit of the last subject in the study .
For the calculation of the SL EDAI -2K, the central laboratory  information will be used for 
anti-dsDNA and complement, not the eCRF -
derived information.
Assessments of SRI -4, -5, and -6 will inclu de an assessment of nonresponders based on 
concomitant medication rules.
Data from EWVs will be recoded to the closest scheduled treatment period visit (after the last 
nonmissing visit value).
Handling of an y mistreatments will be described in more detail in the SAPs.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 102of 144Analyses of the primary  and secondary  efficacy  variables will be repeated for the PPS.
15.3 Planned efficacy  analy ses
For Baseline assessments, if the BILAG 2004 is completed, but the grade for 1 or more 
individual sy stem(s) is missing, the grade f or the sy stem will be set to a grade of BILAG 2004 D 
level disease if no value can be imputed from the S creening V isit. For post -Baseline assessments, 
if the BILAG 2004 is scored, but the grade for 1or more individual sy stem(s) is missing or 
scored as “No t applicable ,” then the grade for that sy stem will be set to the grade at the previous 
visit. 
The underl ying assumption supporting imputation of missing post-B aseline BILAG 2004 grades 
with results from the prior visit is that the value at the preceding v isit is the most accurate 
estimate of the value at the current visit. The underlying assumption supporting imputation of 
missing 
BILAG 2004 grades at Baseline with a grade of BILAG 2004 D level disease is that this 
is a conservative reasonable approach, since no improvement can occur following a B aseline 
grade of BILAG 2004 D level disease.
Missing values for P hysician’s G lobal Assessment of D isease will be imputed via last 
observation carried forward ( LOCF).
15.3.1 Analysis of the primary  efficacy  variable
The pr imary  efficacy  variable is the BICLA responder at Week 24 across 3 doses of DZP and 
PBO . The BICLA is a binary  efficacy  response variable, which is a composite endpoint derived 
from the efficacy  components: BILAG 2004, SLEDAI -2K, and the Phy sician’s Global 
Assessment of Disease Activity . The BILAG 2004 and SL EDAI -2K are themselves composite 
endpoints comprising of multiple assessments of several organ s ystems affected by  SLE. In 
addition, usage of specified concomi
tant medication as escape treatment is also a factor in 
determining BICLA responder status. See Section 9.1.9.1 for a complete description of the 
BICLA composite variable. Modified nonresponder imputation will be used to impute missing 
data, after appl ying additional rules within each component, which are further detailed as 
follows:
If 1 of the 3 efficacy  components (BILAG 2004, SLEDAI -2K, or Phy sician’s Global Assessment 
of Disease) is missing, but the visit was performed and all other assessments were completed, the 
missing component will be imputed from the subject’s previous post -baseline assessment , prior 
to computing the treatment response variab
le, following the last observation carried forward 
principle. 
Furthermore, for BILAG 2004 and SL EDAI -2K, if the assessment was done, but individual 
system or item scores are missing, the respective individual score will be imputed from the 
respective prev ious post -baseline score, in order to obtain a score for the current visit, prior to 
computing the s ystem or score. If the value at the previous visit is also missing, or if the subject 
has 2 or more missing components at Week 
24, then the treatment respon se value is considered 
to be unknown (ie, left as missing and therefore considered a nonresponder).
In addition, subjects who discontinue treatment prematurel y (while still remaining in the study) 
are primarily  categorized as nonresponder from that visit and all subsequent visits.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 103of 144The Week 24 BI CLA dose -response relationship across 3 doses of DZP and PBO will be 
evaluated using the Multiple Comparison Procedure–Modelling (MCP -Mod) methodology  
(Bretz etal,2005). Monotonic dose
-response trends will be test ed using the appropriate contrasts 
as determined b y the MCP -Mod methodology  such that the overall Ty pe1 error rate is controlled 
at 0.05 (one -sided testing).
The SAP will describe additional features and detail around the MCP -Mod methodology  as well 
as ha ndling of missing data.
15.3.2 Other efficacy  analy ses
The anal ysis of the secondary  and other efficacy  responder rates will use a similar approach for 
handling of dropouts as previously  described for the primary  efficacy  variable of treatment 
response at 
Week 24(ie,dropouts are included as nonresponders). 
The number and percent of responders in each treatment group will be presented. The crude 
difference in proportions of responders between each DZP treatment group and PBO will also be 
presented along with 95% CIs for the difference in proportions (Fleiss
,1981). Treatment group 
differences between each DZP group and PBO will be computed along with odds ratio and 95% 
CI.
Additionally , an estimate of the treatment differences at Week 24 will be obtained from a 
longitudinal generalized estimating equ ation model for binary  outcome , and with a treatment b y 
week interaction term. An unstructured covariance matrix will be used for this analy sis. Missing 
values are not explicitly  imputed, and remain missing in the mode l. All available scheduled 
post-Baseline assessments are utilized for deriving Week 24 treatment differences.
Analy ses ofcontinuous 
efficacy variables will be performed using mixed effect smodel sfor 
repeat measurement . These models will use all available post- Baseline data at all visits up to and 
including Week 24, and will be incorporated as repeated measures within each subject. Data 
from EWVs (prio r to 
Week 24) will be re coded to the closest scheduled treatment p eriod visit 
(after the last non missing visit value). Multiple visits for each subject will be incorporated as 
repeated measures within each subject. An unstructured covariance matrix will be utilized and 
least squares means for changes from Baseline and 95% CIs for each treatment group will be 
presented. Estimated treatment differences for each DZP dose group versus PBO and 
corresponding 95% CIs and p -values will be presented for each scheduled time point. This will 
apply  to the following variables: Phy sician’ s Global Assessment of Disease Activity  scores and 
SLEDAI -2K scores.
Supportive models of the continuous efficacy  variables will involve anal ysis of covariance 
models with treatment group as a factor and Baseline score as a covariate. L east squares means 
f
or changes from Baseline at each visit and 95% CIs for treatment groups and treatment 
difference will be presented. These supportive analyses will be performed using as observed case 
models using all available data at each visit.
Analyses ofthe secondary  efficacy  variable will be repeated for the PPS for the Double -Blind 
Treatment Period ( Part1).
Patient
-reported outcomes variables will be analy zed as continuous efficacy variables. For PRO 
variables that cannot be considered continuous (if any ), anal ysis methods for longitudinal ordinal 
data may  be used. Anal yses of PRO variables will be performed for the D ouble -Blind Treatment 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 104of 144Period ( Part1) and for the Observational Period ( Part2) of the stud y. Analysis of the PRO data 
in the Observational Period ( Part2) will aim to explore the maintenance of patient -perceived 
treatment benefits after end of treatment. Analy
ses to support the interpretation of change in 
PRO variables will be performed (cumulative distribution functions, responder anal ysis). In 
addition, psy chometric analy ses of the newly  developed measur es (SLE -S, SL E-F, SLE -M, 
SLE-P, and SLE -E) will be performed blinded from treatment arms. The association between 
PROs and clinical variables will also be explored, as well as the association between the various 
PROs.
For all efficacy  variables, DZP treatment arms, when statistically  compared with PBO, will use a 
two-sided α=0.05 level of significance, without any  adjustment for multiple comparisons. As 
such, these results are considered exploratory  i
n nature and caution should be exercised in 
interpreting these results. Pairwise treatment comparisons for efficacy  variables w ill be 
performed for the Double -Blind Treatment Period ( Part1) onl y.
An observed case anal ysis will be also performed as another sensitivity  analy sis for responder 
efficacy  variables (BICLA, SRI ).
15.4 Planned safety  and other analy ses
All safet y summaries will be performed using the SS.
15.4.1 Safety  analy ses
The frequency  of all AEs during the study  period will be presented for each treatmen t group 
separately  by System Organ Class, high level term, and preferred term (Medical Dictionary  for 
Regulatory  Activities). The data will be display ed as number of subjects experiencing the AEs, 
percentage of subjects, and number of AEs. Data will also b
e corrected f or exposure and reported 
by 100 patient -years.
The incidence of subjects with AEs will be presented by  treatment group and total treatment. 
Additional tables will summarize AEs leading to permanent discontinuation of study  drug (for 
Part1 onl y), AEs by  maximum intensity ,AEs b y intensity , and AEs b y relationship to study  
drug b y treatment group and total treatment. Adverse events will be categorized by  severity . The 
countermeasures taken for each AE, the time of onset of AEs after dosing, and AE duration will 
be listed. Additional tables with respect to all categories of AEs will also include the numbers of 
subjects who experienced the respective AE.
Laboratory  evaluations, vital signs, and ECGs will be anal yzed in the SS for observed cases. 
Descriptive statistics will be presented b y treatment group at each time point: change from 
Baseline in vital signs, serum chemistry , hematology ,and urinal ysis.  For laboratory  data, 
changes between the Baseline (predose) or, if missing, Screening value a nd each posttreatment 
assessment may  be presented in shift tables or using other summaries as detailed in the SAP .
15.4.2 PK analy ses
Individual subject concentrations of DZP and PEG will be display ed graphically . They  will be 
summarized using the statistics desc ribed for continuous variables (number of available 
observations, mean, median, standard deviation, minimum, and maximum) and in addition by  the 
geometric mean and the geometric coefficient of variation (assuming log normally  distributed 
data). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 105of 144For DZP and PEG , the C maxand C trough per visit will be obtained directl y from the plasma 
concentration time profiles. The AUCτ will be derived via a population approach using nonlinear 
mixed effects modeling . Dapirolizumab pegol PK data from SL0023 may  be combined with 
other studies in the population PK approach and the anal ysis will be described in a separate Data 
Analy sis Plan. The AUC τfollowing the last treatment visit in SL 0023 will be derived, listed, and 
summarized together with the C maxand C trough values.
The concentration of PEG in urine will also be summarized.
If data merit, PK/PD analyses may  be conducted for the clinical efficacy  endpoints and PD 
variables of interest. All PK/PD analy ses will be described in more detail in a separate Data 
Analy sis Plan ,and results will be reported in an appendix to the CSRs.
Data Anal ysis Plans for PK/PD will be created separatel y for the Double -Blind Treatment Period 
(Part1) alone, and for the complete study  including the Observational Period (Part2).
15.4.3 Immunogenicity  
analyses
Anti- DZP and anti -PEG antibodies will be tabulated. More detailed specifications will be 
presented in the SAP.
15.5 Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially  could have a 
meaningful impact on study  conduct or on the primary  efficacy ,key safety , or PK outcomes for 
an individual subject. The criteria for identify ing important protocol deviations will be defined 
within the appropriate protocol- specific document. I mportant protocol deviations will be 
reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prior to unblinding to confirm exclusion from 
analysis sets.
Important protocol deviations for the primary  efficacy  variable will be identified through 
Week 24.
Further details on the handling of protocol deviations will be described in the SAPs.
15.6 Handling of dropouts or missing data
Handling of missing endpoint data for the primary  efficacy  anal ysis is describe d in Section
15.3
and the anal ysis of the secondary  and other efficacy  responder rates will use a similar approach 
for handling of dropouts or missing data. 
In the case where laboratory  results are missing at a non- Baseline visit, the laboratory  result from 
the central laboratory  at the prior visit will be used in determining the BILA G 2004 body /organ 
system score at the visit at which the laboratory  value is missing. In the case where the 
laboratory  result is missing at the Baseline Visit, the 
BILAG 2004 body /organ s ystem score for 
the body  system requiring the missing laboratory  result will be set to a score of BILAG 2004 D 
level disease.
In addition, for purposes of computing a SLEDAI -2K total score, in the case where the 
SLEDAI -2Kassessment has been done y et individual items have been left blank (ie, a “Yes” or 
“No” response for the item was not provided), these individual items will be imputed from the 
previous visit value prior to computing the total score. As an additional sensitivity  analy sis, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 106of 144rather than imputing missing component values from previous visit values, when a total score 
cannot be computed due to 1 or more missing indivi dual items, the total score will be imputed by  
extrapolating from the score based on the nonmissing items at the visit. I n this scenario, provided 
that at least 75% of the individual items have a nonmis sing response, the total of nonmissing 
items will be c omputed. This total will then be extrapolated to the equivalent value based on the 
total maximum value of the SLEDAI -2Kinstrument. Additional sensitivity  anal yses based on 
alternate approaches for handling of dropouts or missing data may  be performed to support the 
robustness of the study  results and willbe described in the SAP s.
15.7 Planned interim analy sis and data monitoring
An initial biomarker analysis may  be performed on all evaluable biomarker data from Part1of 
the study  when 25%-35 % of the randomize d subjects have completed Visit 7 (Week 12) of the 
Double-Blind Treatment Period. Data from subjects who have prematurel y withdrawn from the 
study  prior to Visit 7 will be included. The initial biomarker anal ysis will focus on transcriptomic 
biomarker vari ables (eg, mRNA), prespecified in a Biomarker Plan, in order to provide guidance 
for the DZP development program, and will not affect the conduct of the study . This initial 
biomarker anal ysis will not affect the conduct of the study  and no adjustment to th e final anal ysis 
is planned.
The tabulations for the initial biomarker anal ysis will be provided by  individuals not otherwise 
involved in the conduct of the study . Blinding aspects of the initial biomarker anal ysisare 
described in Section 7.9.1 .
After the last subject completes Part1of the study (including the SFU Period for earl y 
withdrawals from Part1or subjects not continuing in to Part2, if applicable), the data for those 
subjects will be secured and an interim CSR will be written for the Double
-Blind Treatment 
Period ( Part1) of the study ; this interim CSR will not include any  data from the Observational
Period (Part2). A biomarker anal ysis on the full Doub le-Blind Treatment Period ( Part1) dataset 
will be included in the interim CSR. A complete final CSR will be written for the entire stud y 
following completion of the Observational Period (Part2) of the stud y.
15.8 Determinati on of sample size
The size of this study  is governed by  determining whether there is a dose- response relationship 
across the 3 doses of DZP and PBO using the MCP -Mod methodology , as described in 
Section
15.3.1. The primary  endpoint of the stud y is a binary  indicator of whether the subject
responds to treatment. Four different dose-response models (“candidate models”) were 
identified :a linear model, a logistic model ,and 2Emax models
,and the MCP -Mod methodology  
controls for multiplicity .
The sample size assessment was estimated using the “DoseFinding” librar y in the R statistical 
package ( Bretzetal,2005) . This library  implements design and anal ysisaspects of the 
MCP -Mod method. The sample size requirement was obtained for each candidate model in turn 
and the maximum value was taken, thus maintaining the power requirement.
Since the Dose Finding library  assumes Normal data with constant variance, and the primary  
endpoint (responder rate) is binary , the Normal approximation was used. This entailed 
calculating the predicted response probabilities at each dose, for each of the candidate models, 
computing the binomial variances and then using these varia nces in the sample -size calculations. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 107of 144Based upon prior experience in SL E, a placebo responder rate for this study of 25% is postulated. 
The desired clinical effect is 29% above PBO , resulting in a responder rate of 54%. With power 
of 80%, a (multiple -comp arison corrected) one-sided type-1 error of 5% and all dose groups of 
thesame size, 112 subjects are required to complete Part1 of the study .
Adjusting for an expected dropout rate of 30% results in the need to randomize 160 subjects 
(40 subjects per tre atment group). Assuming a screening failure rate of approximately  40%, it is 
anticipated to enroll around 267subjects in this study .
16 ETHICS A ND REGULA TOR Y REQUIREMENTS
16.1 Informed consent
Subject’s informed consent must be obtained and documented in accordan ce with local 
regulations, I CH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by  the Investigator (or 
designee). Each subject will have the opportunity to discuss the study  and its alternatives with 
the Investigator .
Prior to participation in the study , the written Informe d Consent form should be signed and 
personall y dated b y the subject, and b y the person who conducted the informed consent 
discussion ( Investigator or designee). The subject must receive a cop y of the signed and dated 
Informed Consent form. As part of the consent process, each subject must consent to direct 
access to his/her medical records for stud y-related monitoring, auditing, IRB/IEC review, and 
regulatory  inspection.
If the Informed Consent form is amended during the study , the Investigator (or the Sponsor , if 
applicable) must follow all applicable regulatory  requirements pertaining to the approval of the 
amended Informed Consent form b y the IRB/ IEC and use of the amended form.
All studies conducted at centers in the USmust include the use of a Health Insurance Portability  
and Accountability  Act Authorization form.
The subject may  withdraw his/her consent to participate in the study  at any  time. A subject is 
considered as enrolled in the study  when he/she has signed the Informed Consent form. A n eCRF 
must not be started, nor may  any study -specific procedure be performed for a given subject, 
without having obtained his/her written consent to pa rticipate in the stud y.
16.2 Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject will be provided 
with a subject identification card in the language of the subject. The Investigator will fill in the 
subjec t identify ing information and medical emergency  contact information. The Investigator
will instruct the subject to keep the card with him/her at all times.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 108of 14416.3 Institutional Review Boards and Independent Ethics 
Committees
The study  will be conducted under the auspices of an I RB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The Investigator /UCB will ensure that an appropriately  constituted I RB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study . Prior to 
initiation of the study , the Investigator /UCB will forwar d copies of the protocol, I nformed 
Consent form, Investigator’s Brochure, Investigator ’s curriculum vitae (if applicable), 
advertisement (if applicable), and all other subject -related documents to be used for the stud y to 
the IRB/IEC for its review and approval.
Before initiating a study , the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly  report to the IRB/IEC all changes in the study , all 
unanticipated problems involving risks to human subjects or others, and any  protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any  changes in the study  or study  conduct without I RB/IEC 
approval, except where necessary  to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously  approved protocol during the period covered by  the original 
approval, it may  be possible for the Investigator to obtain an expedited review by  the IRB/IEC as 
allowed.
As part of the IRB/ IEC requirements for continuing review of approved studies, the Investigator
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but n o less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study  
completion.
UCB (or its representative) will communicate safety  information to the appropriate regulatory  
authorities and all active Investigator s in a ccordance with applicable regulatory  requirements. 
The appropriate IRB/IEC will also be informed b y the Investigator or the Sponsor , as specified 
by the applicable regulatory  requirements in each concerned country . Where applicable, 
Investigator s are to pr ovide the Sponsor (or its representative) with evidence of such IRB/IEC 
notification.
16.4 Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study , all data forwarded to UCB (or designee) will be ident ified only  by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory  authorities will be allowed to review that portion of the 
subject’s primary  medical records that directl y concerns this study (including, but not limited to, 
laboratory  test result reports, ECG reports, admission/discharge summaries for hospital 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 109of 144admissions occurring during a subject’s study  participation, and auto psy reports for deaths 
occurring during the study).
16.5 Protocol amendments
Protocol changes may affect the legal and ethical status of the study  and may  also affect the 
statistical evaluations of sample size and the likelihood of the study  fulfilling its prim ary 
objective.
Significant changes to the protocol will only  be made as an amendment to the protocol and must 
be approved b y UCB, the I RB/IEC, and the regulatory  authorities (if required), prior to being 
implemented.
17 FINA NCE, INSURANCE, AND PUBLICA TION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
18 REFERENCES
Albrecht J, Tay lor L, Berlin JA, Dulay  S, Ang G, Fakharzadeh S, e t al. The CL ASI (Cutaneous 
LE Disease Area and Severity  Index): an outcome instrument for cutaneous lupus ery thematosus. 
J Invest Dermatol. 2005;125(5):889–94.
AlSawah S, Zhang X, Zhu B, Magder L S, Foster SA, I ikuni N, et al. Effect of corticosteroid use 
by dose on the risk of developing organ damage over time in sy stemic lupus ery thematosus—the 
Hopkins L upus Cohort. Lupus Sci Med. 2015;2:e000066.
Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology  of systemic lupus 
erythematosus. Autoimm un Rev. 2010;9:A277-87.
Boumpas DT, Furie R, Manzi S, I llei GG, Wallace DJ, Balow JE, et al. A short course of 
BG9588 (anti -CD40 ligand antibody ) improves serologic activity  and decreases hematuria in 
patients with proliferative lupus glomerulonephritis. A rthritis Rheum. 2003;48:719 -27.
Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005;61:738 -48.
Burkl y LC. CD40L pathway  blockade as an approach to immunotherapy . Adv Exp Med Biol. 
2001;489:135-52.
Centers for Disease Control. Tuberculosis: Testing and Diagnosis. 
http://www.cdc.gov/TB/topic/testing/default.htm.  Accessed 23 Jul 2015.
Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity  and 
mortalit y in systemic lupus ery thematosus during a 10- year period: a comparison of earl y and 
late manifestations in a cohort of 1,000 patients. Me dicine (Baltimore). 2003;82:299 -308.
CPMP/I CH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.
Davi s JC, Tortoritis MC, Rosenberg J, Sklenar TA, Wofsy  D. Phase I clinical trial of a 
monoclonal antibody  against CD40 ligand (IDEC- 131) in patients with sy stemic lupus 
erythematosus. J Rheumatol. 2001;28:95-101.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 110of 144Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali J L, Wahl D, et al. Responsiveness 
of the 36- item Short Form Health Survey and the Lupus Quality of Life questionnaire in SL E. 
Rheumatol (Oxford). 2015;54(5):940 -9.
Fleiss J. Statistical methods for rates and proportions. 2nded. New York: John Wiley  & Sons, 
Inc; 1981 p.101.
Food and Drug Administration. Guidance for Industry , Drug Induced Liver Injury : Premarketing 
Clinical Evaluation. July  2009.
Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam L S. Accrual of organ damage over time 
in patients with sy stemic lupus ery thematosus. J Rheumatol. 2003;30:1955 -9.
Gladman DD, Ibañez D, Urowitz MB. Sy stemic lupus ery thematosus disease activity  index 
2000. J Rheumatol. 2002;29:288 -91.
Jakes RW, Bae SC, L outhrenoo W, Mok CC, Navarra SV, Kwon N. S ystematic review of the 
epidemiology  of systemic lupus ery thematosus in the Asia Pacific region: prevalence, incidence, 
clinical features, and mortality . Arthrit Care Res. 2012;64:159 -68.
Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy  D, IDEC -131 Study  Grou p. Treatment 
of sy stemic lupus ery thematosus by  inhibition of T cell costimulation with anti -CD154: a 
randomized, double -blind, placebo -controlled trial. Arthritis Rheum. 2002;46:3251-8.
Kuwana M, Nomura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, et al. Effect of a single 
injection of humanized anti
-CD154 monoclonal antibody  on the platelet -specific autoimmune 
response in patients with immune thrombocy topenic purpura. Blood. 2004;103:1229 -36.
Lim SS, Bay akly AR, Helmick CG, Gordon C, Easley KA, Drenkard C . The inicidence and 
prevalence of s ystemic lupus ery thematosus, 2002 -2004: The Georgia Lupus Registry . Arthritis 
Rheum. 2014;66:357-68.
McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and 
validation of a disease -specif ic health -related quality  of life measure, the LupusQol, for adults 
with sy stemic lupus ery thematosus. Arthritis Rheum. 2007;57:972 -9.
Muangchan C, van Vollenhoven RF, Bernatsky  SR, Smith CD, Hudson M, I nanç M, et al. 
Treatment algorithms in sy stemic lupus erythematosus. Arthritis Care Res (Hoboken). 
2015;67(9):1237 –45.
Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically  diagnosed sy stemic lupus 
erythematosus 1992
-1998 using the UK General Practice Research Database. 
Pharmacoepidemiol Drug Saf. 2006;15:656 -61.
Patel VL , Schwatz J, Bussel JB. The effect of anti CD40 ligand in immune thrombocy topenic 
purpura. Brit J Haematol. 2008;141:545-8.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and 
Validation of the Sy stemic L upus International Collaborating Clinics Classification Criteria for 
Systemic Lupus Ery thematosus. Arthritis Rheum. 2012;64(8):2677 –86.
Robles
-Carrillo L , Mey er T, Hatfield M, Desai H, Dávila M, Langer F, et al. Anti -CD40L  
immune complexes potently  activate platelets in vitro and cause thrombosis in FCGR2A 
transgenic mice. J I mmunol. 2010;185:1577 -83. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 111of 144Ruperto N, Hanrahan LM, Alarcón GS, Belmont HM, Brey  RL, Brunetta P, et al, International 
consensus for a definition of disease flare in lupus. L upus. 2011;20(5):453 -462.
Sampson HA, Muñoz- Furlong A, Campbell RL , Adkinson NF Jr, Bock SA, Branum A, et al. 
Second sy mposium on the definition and management of anaphy laxis: summary  report --Second 
National Institute of Allergy  and Infectious Disease/Food Aller gy and Anaphy laxis Network 
symposium. J Allergy  Clin I mmunol. 2006;117(2):391 -7.
Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, et al. Population based 
incidence and prevalence of sy stemic lupus ery thematosus: The Michigan Lupus Epidemiolog y 
and Surveillance Program. Arthritis Rheum. 2014;66:369-78.
Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity , and permanent 
organ damage. J Rheumatol. 2009;36:560 -4.
Touma Z, Gladman DD, Ibañez D, Taghavi -Zadeh S, Urowitz MB. Sy stemic L upus 
Erthematosus Disease Activity  Index 200 Responder Index -50 enhances the ability  of SLE 
Responder Index to identify responders in clinical trials. J Rheumatol. 2011:38:2395 -9.
Tsokos GC, Gordon C, Smolen JS, editors. Sy stemic L upus Ery thematosu s: A companion to 
Rheumatology . Penns ylvania: Mosby  Elsevier; 2007.
Van Kooten C, Banchereau J. CD40 -CD40 ligand. J L eukocy te Biol. 2000;67:2-17.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 112of 14419 APPENDICES
19.1 SLICC classification criteria for SLE
A subject is classified as having SLE if he or she satisfies 4 of the clinical and immunologic 
criteria used in the SLICC classification criteria, including at least 1 clinical criterion and 
1 immunologic criterion, OR if he or she has biopsy- proven nephri tis compatible with SL E in the 
presence of ANAs or anti -dsDNA antibodies. 
The criteria do not need to be present concurrentl y. A criterion should only be judged as fulfilled 
if better explained b y other causal relatio nships (eg, other disease, drug -site e ffects).
2012 SLICC SLE Criteria
Clinical Criteria
Has the subject ever experienced any of the following clinical criteria?
1. Acute Cutaneous Lupus
Lupus malar rash (do not count if malar discoid) Yes No
Bullous lupus Yes No
Toxic epi dermal necrolysis variant of SL Yes No
Maculopapular lupus rash Yes No
Photosensitive lupus rash i n the absence of dermatomyosit Yes No
Subacute cutaneous lupus (nonindurated p soriaform and/or annular polycyclic lesions that resolve without 
scarring, although occasionally with postinflammatory dyspigmentation or telangiectasia s) Yes No
2. Chronic Cutaneous Lupus
Localized classical discoid rash (a bove the neck) Yes No
Generalized classical discoid rash (above and below the neck) Yes No
Hypertrophic (verrucous) lupus Yes No
Lupu s panniculitis (profundus) Yes No
Mucosal lupus Yes No
Lupus erythematosus tumidus Yes No
Chillblains lupus Yes No
Discoid lupus/lichen planus overlap Yes No
3. Oral or nasal ulcers in the absence of other causes, such as vasculitis, Behcets disease, infection 
(herpes), inflammatory bowel disease, reactive arthritis, and acidic foods
Palate Yes No
Buccal Yes No
Tongue Yes No
Nasal Yes No
4. Non -scarring alopecia in the absence of other causes such as alopecia areata, drugs that cause alopecia, 
iron deficiency and androgenic alopecia (diffuse thinning or hair fragility with visible broken hairs) Yes No
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 113of 1445. Synovitis involving 2or more joints, characterized by swelling or effusion OR tenderness in 2 or more 
joints and thirty minut es or more of morning stiffness Yes No
6. Serositis
Typic al pleurisy for more than 1 day Yes No
Pleural effusions Yes No
Pleural rub Yes No
Typical pericardial pain (pain with recumbency improved by sitting forward) for more than 1 da y Yes No
Pericardial effusion Yes No
Pericard ial rub Yes No
Pericarditis by ECG in the absence of other causes, such as infection, uremia, and Dressler's pericarditis ........................... Yes No
7. Renal
Urine protein/creatinine ratio (or 24 hr urine protein) rep resenting 500mg of protein/24hr Yes No
Red blood cell casts Yes No
8. Neurologic
Seizures Yes No
Psychosis Yes No
Mononeuritis multiplex in the absence of other known ca uses such as primary vasculitis Yes No
Myelitis Yes No
Peripheral or crania l neuropathy in the absence of other known causes such as primary vasculitis, i nfection, 
and diabetes mellitus Yes No
Acute confusional state in the absence of other causes, including toxic -metabolic, uremia, drugs Yes No
9. Hemolytic anemia Yes No
10. Leukopenia
Leucocytes < 4000/mm3at least once in the absence of other known causes such as Felty's syndrome, drugs, 
and portal hypertension Yes No
Lymphocytes < 1000/mm3at least once in the absence of other known causes such as corti costeroids, drugs 
and infection Yes No
11. Thrombocytopenia (<100000/mm3)in the absence of other known causes such as drugs, portal 
hypertension, and thrombotic thrombocytopenic purpura (TTP) Yes No
Immunological criteria
1. ANA above laboratory reference range in the absence of drugs known to cause ANA increase ................................ Yes No
2. Anti -dsDNA antibody above laboratory reference range, except enzyme -linked immunosorbent assay 
(ELISA ): twice a bove laboratory reference range Yes No
3.Anti -Sm antibod Yes No
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 114of 1444. Antiphospholipid antibody
Positive lupus anticoagulant test Yes No
False-positive rapid plasma reagin Yes No
Medium or high titer anticardiolipin antibody level (IgA, IgG, or IgM) Yes No
Positive test result for anti -β2glycoprotein I (IgA, IgG ,or IgM) Yes No
5. Low complement (C3, C4, CH50)
Low C3 Yes No
Low C4 Yes No
Low CH50 Yes No
6. Direct Coombs’ test (in the absence of hemolytic anemia) Yes No
Pathohistological Findings
Biopsy proven Nephritis compatible with SLE:
Class I Yes No
Class II Yes No
Class III Yes No
Class IV Yes No
Class V Yes No
Class VI Yes No
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 115of 14419.2 Equivalent doses of oral steroids
Oral Steroids Equivalent Dose (mg/day)
Cortisone, oral 25
Hydrocortisone, oral 20
Deflacort, oral 6
Prednisolone, oral 5
Prednisone, oral 5
Methylprednisolone 4
Triamcinolone, oral 4
Dexamethasone, oral 0.75
Betamethasone, oral 0.6
Note: For topically applied corticosteroids and intra -articular, subcutaneous, or ocular steroids, equivalent dose=0.
Cortisol (hy drocortisone) is the standard of comparison for glucocorticoid potency .
Hydrocortisone is the name used for pharmaceutical preparations of cortisol.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 116of 14419.3 Suggested management guidelines for infus ion reactions
Type of reaction Sponsor recommendations for management
Acute – Mild
Eg, flushing; dizziness; 
headache; sweating; 
palpitations; nauseaSlow infusion rate to 5mL/h
Infuse 0.9% NaCl 500 -1000mL/h iv
Antihistamine iv/im 
Paracetamol 1g po
Monitor vital signs every 10min until back to baseline
Wait 20min, then increase infusion rate to 8mL/h for 15min, then 
16mL/h, 20mL/h, 25mL/h every 15min, as tolerated until intended dose 
has been given
Acute – Moderate 
eg, flushing; chest tightness; 
dyspnea; hypo/hypertension 
(change >20mmHg in SBP); 
raised temperature; 
palpitations; urticariaStop infusion
Infuse 0.9% NaCl 500 -1000mL/h iv
Antihistamine iv/im
Paracetamol 1g po 
Monitor vital signs every 5min until back t o baseline
Wait 20min
If there is no indication of anaphylaxis (eg, generalized urticaria and/or 
bronchospasm), and if clinically appropriate, consider restarting the 
infusion at a lower rate following this suggested regimen:
Restart infusion at 5mL/h for 15min
Increase infusion rate to 8mL/h for 15min, then 16mL/h, 20mL/h, 
25mL/h every 15min, as tolerated until intended dose has been given
Acute – Severe 
Eg, hypo/hypertension 
(change >40mmHg in SBP); 
raised temperature with 
rigors; chest tightness; 
dyspnoea with wheezing; 
stridorStop infusion definitively
Alert crash team
Maintain airway, ensure oxygen is available
If wheezing, give epinephrine 0.5mg im (0.5mL 1:1000 epinephrine)
Antihistamine iv/im 
Corticosteroids iv 
Monitor vital signs every 2mi n until back to baseline
im=intramuscular; NaCl=sodium chloride; iv=intravenous ; po=oral; SBP=systolic blood pressure
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 117of 14419.4 Criteria for diagnosis of anaphy laxis
Anaph ylaxis is highly  likely  when any  of the following 3 criteria is fulfilled 
(Sampson etal,2006):
1.
Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips- tongue -uvula)
AND at least 1of the following:
Respiratory  compromise (eg, dy spnea, wheeze -bronchospasm, stridor, reduced peak 
expiratory  flow [PEF], hy poxemia)
Reduced blood pressure or associated s ymptom s of end -organ dy sfunction (eg, hypotonia 
[collapse], sy ncope, incontinence)
2. Two or more of the following that occur rapidly  after exp osure to a likel y allergen for that 
subject (minutes to several hours):
Involvement of the skin -mucosal tissue (eg, generalized hives, itch -flush, swollen 
lips-tongue -uvula)
Respiratory  compromise (eg, dy spnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia)
Reduced blood pressure or associated s ymptoms (eg, h ypotonia [collapse], syncope, 
incontinence)
Persistent gastrointestinal sy mptoms (eg, crampy  abdominal pain, vomiting)
3. Reduced blood pressure after exposure to known allergen for that subje ct (minutes to several 
hours): s ystolic blood pressure of < 90mmHg or >30% decrease from the subject ’s Baseline.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 118of 14419.5 Protocol- specific clarification and extension of BILAG2004
definitions
A quick Reference Guide will be provided to all study  personnel, which contains detailed 
protocol -specific clarifi cations and extensions of BILAG 2004 clinical parameter definitions and 
guidance for correlating SL EDAI -2K and BILAG 2004 clinical parameters. Please refer to this 
guide when completing disease activity  assessment s. Importa nt extensions of selected 
BILAG 2004 glossary  definitions are included as follows:
Protocol specific ex tensions of BILAG 2004 and SL EDAI -2K clinical parameter definitions:
a.BILAG 2004 A or B score in the musculoskeletal organ s ystem due to active poly arthritis, 
defined as follows:
“BILAG 2004 A”: severe arthritis ( BILAG 2004 #41) manifested b y observed active 
synovitis in ≥2 joints with marked loss of functional range of movements and significant 
impairment of basic activities of daily  living (ADL) , that has been present on several 
days cumulatively  over the past 4 weeks, including at the time of the Screening Visit. 
Basic ADL are defined as the following activities which require assistance or assistive 
devices (at least 1 must be present and docume nted in source): ambulation, toileting, 
grooming including bathing, dressing, feeding oneself (not responsive to steroids up to 
10mg/day , antimalarials, NSAIDs).
“BILAG 2004 B”: moderate arthritis or ten donitis or tenosy
novitis ( BILAG 2004 #42) 
defined as tendonitis/tenosy novitis or active s ynovitis in ≥1joint (observed or through 
history ) with some loss of functional range of movements which leads to some loss of 
functional range of motion as manifested b y effects on instrumental ADL s (such as 
cooking, dr iving, using the telephone or computer, shopping, cleaning, etc), which has 
been present on several day s over the last 4
weeks and is present at the time of the 
Screening Visit.
b.BILAG 2004 and SLEDAI -2K “lupus headache”: lupus headache is rare; migraine, t ension 
or cluster headaches should not be recorded. Lupus headache should only  be recorded if it is 
disabling, lasts at least 3 day s, and does not respond to narcotics. It is expected that its 
severit y would prompt formal testing (lumbar puncture, magnetic resonance imaging, 
computed tomograph y, etc) and require corticosteroids and/or immunosuppressants and 
potentially  hospitalization for treatment. Lupus headache is considered a manifestation of 
lupus cerebritis.
19.6 Protocol A mendment 1
Rationale for the amen
dment
The primary  objective for this amendment is to allow for qualitative subject interviews to be 
conducted b y an experienced, external third part y vendor and to allow for assessments of hsCRP 
at 4
-week intervals and serum complement (C3 and C4) at Visit 14. Anti- DZP and anti -PEG 
antibody  assessments have been removed from Visits 13 and 14 and additional text has been 
added. The inclusion of subjects who lack capacity  to consent mentally  or phy sicall y has been 
removed 
since some protocol assessments require mental and ph ysical abilities. Theeligibility  of 
subjects with an overlap sy ndrome has been clarified . The protocol hasalso been updated 
according to the new UCB protocol template ( forexample, with the update of text regardi ng 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 119of 144PDILI ); these changes were strictl y template -driven .They do not reflect a change in the liver 
safet y signal for DZP and are included onl y for alignment with updated standard Sponsor text 
across programs.
Modifications and changes
Global changes
“Drug Safety ” was changed to “Patient Safet y” to reflect the renaming of that functional group 
at UCB.
“International Conference on Harmonisation” was changed to “International Council for 
Harmonisation.”
Minor sty listic and ty pographical changes were made for consistency  within the document (eg, 
“the investigator” was changed to “the Investigator” at all occurrences ).
Specific changes
The following table presents specific changes made with Amendment 1. Th is table does not 
include global changes unless they  occur in other changed text.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 120of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Study contact 
informationSponsor
UCB Biosciences Inc.
8010 Arco Corporate Drive, Ste 100
Raleigh, NC 27617
USASponsor
UCB Biopharma SPRL
Allée de la Recherche 60, 1070 
Brussels, BelgiumUpdate to match title page.
Update to reflect current 
contact information.
Clinical Project Manager Clinical Project Manager
Clinical Trial Biostatistician
UCB BIOSCIENCES GmbH
Alfred- Nobel -Str. 10
40789 Monheim
GERMANYClinical Trail Biostatistician
UCB Biosciences Inc.
8010 Arco Corporate Drive, Ste 100
Raleigh, NC 27617
USA
SAE
reporting Email
Global: safetyreportingCDP7657@ucb.com
(for interventional clinical studies)Email
Global: safetyreportingCDP7657@ucb.comRemoval o f unnecessary 
information about 
interventional studies.
List of 
Abbre -
viationsDS: Drug Safety
ICH: International Conference on 
HarmonisationPS: Patient Safety
ICH: International Council for HarmonisationAdministrative update.
Table 5- 2 and 
Sections 8.8 
and 8.9Assessment of anti -DZP and anti -PEG 
antibodies included at Visits 13 and 14.Assessment of anti -DZP and anti -PEG 
antibodies removed/excluded from Visits 13 
and 14.Removal since e xtensive 
testing during the observation 
period no longer considered 
necessary.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 121of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Table 5-2 and
Section 8.9No assessment of serum complement (C3, C4) 
included at V14.Assessment of serum complement (C3, C4) 
added to V14.Correction of omitte d serum 
complement measurement
needed for SLEDAI -2K
calculation .
Table 5-2and
Sections 8.1, 
8.3, 8.4, 8.6, 
8.8, 8.9, and 
8.11No assessment of hsCRP included at V1, V3, 
V4, V6, V8, V9, V11, V14, or the 
Unscheduled Visit.Assessment of hsCRP added toV1, V3, V4, 
V6, V8, V9, V11 , V14 , and the Unscheduled 
Visit (Section 8.11) .Alignment with other 
laboratory assessments of 
safety.
Section 6.1 1.  An Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC) 
approved written Informed Consent form is 
signed and dated by the subject or legal 
representative prior to the in itiation of any 
study -specific assessment at Screening 
(Visit 1). 1a. An Institutional Review Board 
(IRB)/Independent Ethics Committee 
(IEC) approved written Informed Consent 
form is signed and dated by the subject 
prior to the initiation of any study -specific 
assessment at Screening (Visit 1). Revision to not include
subje cts who lack capacity to 
consent mentally or 
physically since some 
protocol assessments require 
mental and physical abilities .
13. Female subjects of childbearing 
potential must agree to use a highl y 
effective method of birth control during 
the study and for a period of 12 weeks after 
their final dose of study drug (ie, through 
completion of the SFU Period). Highly 
effective forms of birth control are methods 
which achieve a failure rate of less than 1% 
per year when used cons istently and 
correctly. Highly effective methods of birth 
control include :13a.Female subjects of childbearing 
potential must agree to use a highl y 
effective method of birth control during 
the study and for a period of 12 weeks 
after their final dose of st udy drug 
(ie,through completion of the SFU 
Period). Highly effective forms of birth 
control are methods which achieve a 
failure rate of less than 1% per year when 
used consistently and correctly. Highly 
effective methods of birth control include, 
but are not limited to:Revision to provide clarity 
that the birth control methods
are examples only .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 122of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 6.25. Subject has a mixed connective tissue 
disease, scleroderma, and/or overlap 
syndromes of SLE.
Subjects with SLE and secondary 
Sjögren’s syndrome are permitted 
provided they meet the eligibility 
criteria.5a. Subject has a mixed connective tissue 
disease, scleroderma, and/or overlap 
syndromes of SLE.
Subjects with SLE and secondary 
Sjögren’s syndrome are permitted 
provided they meet the eligibility
criteria.
Clarification: Subjects with 
rheumatoid arthritis in their medical 
history are not considered as having an 
overlap syndrome and are thereby 
eligible, except when erosive arthritis 
is the only symptom at Screening.Clarification provided for the 
eligibility of subjects with a 
medical history of rheumatoid 
arthritis.
Section 6.3 Subject has potential drug -induced 
liver injury (PDILI), as described in 
Section 6.3.1.Removed. Update to UCB protocol 
template text.
Section 6.3 Investigators should at tempt to obtain 
information on subjects in the case of 
withdrawal or discontinuation.Investigators should attempt to obtain 
information on subjects in the case of 
withdrawal.Update to UCB protocol 
template text.
Section 6.3.1 Header: PDILI -related withdrawal criteria
To enable the effective management and 
assessment of any PDILI as outlined in the 
Food and Drug Administration (FDA) 
Guidance for Industry, Drug Induced Liver 
Injury: Premarketing Clinical Evaluation Header: Po tential drug -induced liver injury 
IMP discontinuation criteria
Subjects with potential drug- induced liver 
injury (PDILI) must be assessed to determine if 
IMP must be discontinued. In addition, all 
concomitant medications and herbal Update to UCB protocol 
template text.
Sponsor language for 
monitoring of PDILI events 
added to increase clarity for 
the sites and to align across 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 123of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
(2009), UCB has developed prespecifi ed 
criteria for managing any PDILI events and 
discontinuing IMP.
Subjects with PDILI must have IMP 
discontinued. In addition, all concomitant 
medications and herbal supplements that are 
not medically necessary should also be 
discontinued. 
The following PD ILI criteria require 
immediate and permanent discontinuation of 
IMP:
Subjects with any of the following:
ALT and/or aspartate aminotransferase 
(AST) ≥8xULN
ALT and/or AST ≥3xULN and co- existing 
total bilirubin ≥2xULN
The following PDILI criterion requires 
immediate discontinuation of IMP: 
Subjects with ALT and/or AST ≥3xULN 
who exhibit a temporally associated 
fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness , fever (without 
clear alternative cause), r ash, or 
eosinophilia (ie, >5%) must be 
immediately discontinued from IMP.
If a non -drug related cause for the symptoms supplements that are not medically necessary 
should also be discontinued. 
The following PDILI criteria require 
immediate and permanent discontinuation of 
IMP:
Subjects with any of the following:
ALT or aspartate aminotransferase 
(AST) ≥8xULN
ALT or AST ≥3xULN and co -existing 
total bilirubin ≥2xULN
The following PDILI criterion requires 
immediate discontinuation of IMP: 
Subjects with ALT and/or AST ≥3xULN 
who exhibit temporally associated 
symptoms of hepatitis (excluding 
SLE-related hepatitis) or hypersensitivity. 
Hepatitis sympt oms include fatigue, 
nausea, vomiting, right upper quadrant 
pain or tenderness. Hypersensitivity 
symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, 
>5%).
If a non -drug related cause for the symptoms 
can be confirmed, these subjects may resume 
IMP administration after discussion with the programs. (Exception: 
program -specific exclusion of 
lupus hepatitis from hepatitis 
symptoms requiring 
immediate discontinuation of 
IMP). The additio
n of PDILI 
language is to align with FDA 
guidance regarding 
monitoring of PDILI events 
and does not reflect a change 
in the liver safety signal for 
DZP.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 124of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
can be confirmed, these subjects may resume 
IMP administration after discussion with the 
Medical Monitor. 
The following PDILI criteria a llows for 
subjects to continue on IMP at the discretion of 
the investigator:
ALT and/or AST ≥3xULN (and ≥2x 
baseline) and <8xULN, total bilirubin 
<2XULN, and no eosinophilia (ie, ≤5%), 
with no fever, rash or symptoms of 
hepatitis (eg, fatigue, nausea, vomi ting, 
right upper quadrant pain or tenderness)
Monitoring and investigation of PDILI must be 
initiated as described in Section 13.7. If 
subjects are unable to comply with the 
applicable monitoring schedule, IMP must be 
discontinued immediately. responsible UCB physician, but only when the 
requirements for rechallenge with IMP as 
provided in Section 13.7.2.1 are followed. 
The following PDILI criteria allows for 
subjects to continue on IMP at the discretion of 
the Investigator:
ALT or AST ≥3xULN (and ≥2x baseline) 
and <8xULN, total bilirubin <2xULN, and 
no eosinophilia (ie, ≤5%), with no fever, 
rash or symptoms of hepatitis (eg, fatigue, 
nausea, vomiting, right upper quadrant 
pain or tenderness)
Evaluation of PDILI must be initiated as 
described in Section 13.7. If subjects are 
unable to comply with the applicable 
monitoring schedule, IMP must be 
discontinued immediately (see Section 8.10). 
Section 7.5 The Investigator (or designee) is responsible 
for the safe and proper storage of IMP at th e 
site. Investigational medicinal product stored 
by the Investigator is to be kept in a secured 
area with limited access.
Appropriate storage conditions will be 
specified on the label and in the Pharmacy 
Manual. A temperature log will be completed 
in accor dance with local requirements on a 
regular basis (eg, once a week), showing The Investigator (or designee) is responsible 
for the safe and proper storage of IMP at th e 
site. Investigational medicinal product stored 
by the Investigator is to be kept in a secured 
area with limited access according to the 
storage conditions mentioned in the IMP 
Handling Manual.
Appropriate storage condition must be ensured 
by controlled r efrigerator temperature either Update to UCB protocol 
template text and IMP 
Handling Manual.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 125of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
minimum and maximum temperatures reached 
over the period of IMP storage in order to 
document that appropriate storage was 
maintained.
In case an out -of-range temperature is noted, it 
must be immediately communicated to the 
unblinded Clinical Project Manager (CPM) (or 
designee) before further use of the IMP.
The unblinded CPM (or designee) will transmit 
the out -of-range temperature (copy of the 
temperature log and duration of the 
out-of- range temperature, if available) to the 
Clinical Supply Manager. Based on discussion 
with a UCB Quality Assurance representative, 
the Clinical Supply Manager will then provide 
the unblinded CPM (or designee) with 
instructions for the site regarding use of the 
IMP.
The PBO and other materials used during 
drug administration will be stored and 
handled per specific requirements of each 
material and site requirements.using an automated temperature monitoring 
and recording system or by using a 
minimum /maximumthermometer and 
completing daily a temperature log in 
accordance with local requirements. 
Temperature data for IMP should be recorded 
on each working day with the actual and 
minimum/maximum temperatures reached 
during this period. 
In case an out -of-range temperature is noted, it 
must be immediately reported as per 
instructions contained in the IMP Handling 
Manual.
The physiological saline [0/9% sodium 
chloride] used for administration should be 
handled per specific site requirements and 
stored according to label requirements.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 126of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 7.6 A Drug Accountability form will be used to 
record IMP dispensing and return information 
on a by -subject basis and will serve as source 
documentation during the course of the study. 
Details of any IMP lost (due to breakage or 
wastage), not used, disposed of at the study 
site, or returned to the Sponsor or designee 
must also be recorded on the appropriate 
forms. 
Periodically, and/or after completion of the 
clinical phase of the study, all used (including 
empty containers) and unused IMP vials must 
be reconciled and returned to UCB (or 
designee), preferably in their original package 
or destroyed at the site following local 
procedures.A Drug Accountability form will be used to 
record IMP dispensing and return information 
on a by -subject basis and will serve as source
documentation during the course of the study. 
Details of any IMP lost, damaged (due to 
breakage or wastage), not used, partially used, 
disposed of at the study site, or returned to the 
Sponsor or designee must also be recorded on 
the appropriate forms. 
Periodically, and/or after completion of the 
clinical phase of the study, all used (including 
empty containers)/partially used, unused, 
damaged, and/or expired IMP must be 
reconciled and either destroyed at the site 
according to local laws, regulations, and UCB 
SOPs or returned to UCB (or designee).Update to UCB protocol 
template text.
Section 9.2.7 Qualitative subject interviews will be 
conducted by a study nurse/study personnel to 
collect the subject's experience with lupus in 
terms of symptoms and impact on daily 
activities, and the perceived changes during the 
course of the study. The extent to which the 
exploratory PRO items and scales used fully 
captured their experience will also be assessed.Qualitative subject interviews will be 
conducted by a n external third party vendor. 
The third party vendor will call the subject at 
home to collect the subject's experience with 
lupus in terms of symptoms and impact on 
daily activities, and the perceived changes 
during the course of the study. The extent to 
which the exploratory PRO items and scales 
used fully captured their experience will also 
be assessed.Provision for collection of 
subject interviews by an 
external third party vendor 
with experience in such 
interviews.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 127of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 11 Not applicable. The dete ction of anti -DZP antibodies and anti -
PEG antibodies will be done using validated 
methods. The details of analytical methods 
(including validation status) and results will be 
presented in the bioanalytical report.Provide information about 
methodology and reporting.
Section 
13.1.4An AE should be followed until it has 
resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically 
significant, or the subject is lost to follow up. An AE should be followed until it has 
resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically 
significant, or the subject is lost to follow up. 
This follow -up requirement applies to AEs, 
SAEs, and AEs of special interest; further 
details regarding follow -upof PDILI events are 
provided in Section 13.7.
Information on SAEs obtained after clinical 
database lock will be captured through the PS 
database without limitation of time.Update to UCB protocol 
template text.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 128of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 
13.1.8.1Not applicable. Header: Suspected transmission of an 
infectious agent via a medicinal product
For the purposes of reporting, any suspected 
transmission of an infectious agent via a 
medicinal product should be considered as an 
SAE (Section 13.2); such cases must be 
reported immediat ely, recorded in the AE 
module of the e CRF, and followed as any other 
SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting 
transmissible spongiform encephalopathy), 
pathogenic or nonpathogenic, is considered an 
infectious agent.Update to UCB protocol 
template requirements .
Section 
13.1.10The subject should be withdrawn from the 
study as soon as pregnancy is known (by 
positive pregnancy test), and the following 
should be completed:
The IMP should be immediately 
discontinued. 
The subject should return for an EWV.
The subject should complete the SFU 
Period per protocol.The subject should be discontinued from the 
study drug as soon as pregnancy is known (by 
positive pregnancy test), and the following 
should be completed:
The IMP should be immediately 
discontinued. 
The subject should complete the study per 
protocol.Update to UCB protocol 
template text.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 129of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 
13.2.1(Important medical events may include allergic 
bronchospasm requiring intensive treatment in 
an emergency room or at home, blood 
dyscrasias that do not result in inpatient 
hospitalization, or the development of drug 
dependency or drug abuse.)(Important medical events may include, but are 
not limited to, potential Hy’s Law [see Section 
13.3], allergic bronchospasm requiring 
intensive treatment in an emergency room or at 
home, blood dyscrasias that do not result in 
inpatient hospitalization, or the development of 
drug dependency or drug abuse.)Update to UCB protocol 
template text.
Section 13.3There are currently no AEs of special interest 
identified for DZP.
Potential Hy’s law, defined as ≥3xULN ALT 
and/or AST with coexisting ≥2xULN bilirubin 
in the absence of ≥2xULN ALP, with no 
alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to 
UCB as an AE of special interest and a serious 
unexpected AE (ie, without waiting for any 
additional etiologic investigations to have been 
concluded). There are currently no AEs of special interest 
identified for DZP; however, in accordance 
with the Sponso r’s internal guidelines for all 
drugs in development, Potential Hy's Law is to 
be reported as an AE of special interest as 
follows:
Potential Hy’s law, defined as ≥3xULN 
ALT or AST with coexisting ≥2xULN 
bilirubin in the absence of ≥2xULN ALP, 
with no alternative explanation for the 
biochemical abnormality, must ALWAYS 
be reported to UCB as an AE of special 
interest (ie, without waitin g for any 
additional etiologic investigations to have 
been concluded). Update to UCB protocol 
template text with 
clarification regarding 
reporting of Hy’s law . 
Section 13.4Suspected transmission of an infectious 
agent via a medicinal productSuspected transmission of an infectious 
agent via a medicinal product (see Section 
13.1.8.1)Provision of assistance in 
document navigation.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 130of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 13.6 Not applicable. Any presumptive diagnosis or diagnosis of a 
TB infection is a reportable event. Confirmed 
activ e TB must be reported as an SAE (Section 
13.2.2). The Investigator is to complete and 
submit the TB follow -up form provided.Restatement of requirements 
for reporting for additional 
emphasis.
Section 13.7 Section header: Investigation and monitoring 
of PDILI 
UCB has developed prespecified procedures 
for managing PDILI events that are consistent 
with the FDA Guidance for Industry, Drug 
Induced Liver Injury: Premarketing Clinical 
Evaluation (2009). All PDIL I events must be 
reported as SAEs and reported to the Sponsor 
within 24 hours of learning of its occurrence. If 
a PDILI event meets the criteria for Hy’s law 
(ie,≥3xULN ALT and/or AST with coexisting 
≥2xULN bilirubin in the absence of ≥2xULN 
ALP, with no alternative explanation for the 
biochemical abnormality), it must also be 
reported as an AE of special interest and a 
serious unexpected AE (ie, without waiting for 
any additional etiologic investigations to have 
been concluded) (see Section 13.3 on AEs of
Special Interest, Hy’s law).
Table 13- 2 summarizes the approach to 
investigate PDILI.
Table 13- 2: Required testing and follow up for Section header: Evaluat ion of PDILI
The PDILI IMP discon tinuation criteria for this 
study are provided in Section 6.3.1, with the 
accompanying required follow -up investigation 
and monitoring detailed below. All PDILI 
events must be reported as an AE and reported 
to the study site and Sponsor within 24 hours 
of learning of their occurrence. Any PDILI 
event that meets the criterion for potential Hy’s 
Law must be reported as an AE of special 
interest (see Section 13.3), and, if applicable, 
also reported as an SAE (see Section 13.2.2). 
If tests are done locally fo r more rapid results, 
a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical 
care decisions are to be made initially using the 
most rapidly available results and a 
conservative approach must be taken if the 
results from the 2 laboratory tests are 
significantly different. Data from the local and 
central laboratory are to be recorded on the Update to UCB protocol 
template text and table.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 131of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
PDLI. Replaced. The table that was replaced is 
provided below.applicable e CRF pages.
When IMP is discontinued, all concomitant 
medications and herbal supplements that are 
not medically necessary should also be 
discontinued. In these cases, the Investigator 
should also consider dose reduction for 
medically necessary concomitant medication 
and consider changing any medically required 
concomitant medication known to be 
hepatotoxic to a suitable alter native.
When IMP is stopped due to PDILI (as 
described in Section 6.3.1), IMP must be 
permanently discontinued unless a subsequent 
alternative diagnosis fully explains the hepatic 
findings. If a subsequent alternative diagnosis 
fully explains the hepatic findings, and the 
requirements provided in Section 13.7.2.1 are 
met, rechallenge with IMP may be appropriate. 
Rechallenge with a substance potentially 
causing drug- induced liver injury is dangerous, 
may be fatal, and must not occur.
The table below summarizes the approach to 
investigate PDILI.
Table 13- 2: Required investigations and follow 
up for PDILI. Replacement added.
Section 
13.7.1Section header: Consultation with local 
hepatologist and/or Sponsor Study PhysicianSection header: Consultation with Medical 
Monitor and local hepatologistUpdate to UCB protocol 
template.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 132of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
All PDILI events, as detailed in Table 13 -2, 
require the Investigator to consult with a local 
hepatologist and/or Sponsor Study Physician, 
as applicable, within 24 hours. The local 
hepatologist is the expert usually consulted by 
the treating phy sician for assessment and 
management of potential hepatic disease. This 
would usually be a hepatologist, but may be a 
gastroenterologist. If deemed necessary, this 
discussion should be followed by a full 
hepatology assessment (see Section 13.7. 2) and 
updat ed SAE report.Potential drug -induced liver injury events 
require notification of the Medical Monitor, 
within 24 hours (eg by laboratory alert), and 
the subject must be discussed wit h the Medical 
Monitor as soon as possible. If required, the 
subject must also be discussed with the local 
hepatologist. The local hepatologist is the 
expert usually consulted by the treating 
physician for assessment and management of 
potential hepatic dise ase. This would usually 
be a hepatologist, but may be a 
gastroenterologist. If determined necessary, 
this discussion should be followed by a full 
hepatology assessment (see Section 13.7.3) and 
SAE report (if applicable).
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 133of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 
13.7.2Not applicable. Header : Immediate action: determination of 
IMP discontinuation
All PDILI events require immediate action, 
testing, and monitoring.
The immediate action is dependent on the 
laboratory values and symptoms of hepatitis or 
hypers ensitivity and ranges from continuation 
of IMP (followed by immediate investigation) 
to immediate and permanent discontinuation 
(see Section 6.3.1 and Table 13 -2 for details).
When IMP is discontinued, all concomitant 
medications and herbal supplements tha t are 
not medically necessary should also be 
discontinued. The Investigator should also 
consider dose reduction for medically 
necessary concomitant medication and 
consider changing any medically required 
concomitant medication known to be 
hepatotoxic to a suitable alternative.Update to UCB protocol 
template.
Section 
13.7.2.1Not applicable. Header: IMP restart/rechallenge (if applicable)
Rechallenge with a substance potentially 
causing drug- induced liver injury is dangerous, 
may be fatal, and must not occur.
Subjects who are immediately discontinued 
from IMP due to having met certain criteria for 
PDILI (as described in Section 6.3.1 and Table 
13-2), but for whom an alternative diagnosis is 
confirmed, can rarely restart IMP. Rechallenge Update to UCB protocol 
template.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 134of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
with IMP can occur only if ALL of the 
following requirements are met:
The results of additional testing and 
monitoring described in Section 13.7.3 and 
Section 13.7.4 confirm a nondrug -related 
cause for the abnormal hepatic laboratory 
parameters and any associated symptoms 
(ie, a subsequent alternative diagnosis fully 
explains the hepatic findings). 
No alternative treatment options are 
available to the subject.
The subject has shown clear therapeutic 
benefit from the IMP.
Subject’s ALT or AST elevations do not 
exceed ≥3xULN .
Subject’s total bilirubin is <1.5xULN.
Subject has no signs or symptoms of 
hypersensitivity. 
The rechallenge is approved by the UCB 
responsible physician, DMC, and a 
hepatologist. The hepatologist must be 
external to UCB but may be a member of 
the DMC. It  is recommended that the 
hepatologist be a local hepatology expert 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 135of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
or the hepatologist treating the subject.
Subject agrees to the Investigator -
recommended monitoring plan.
Section 
13.7.3
(original 
protocol 
Section
13.7.2)Header: Immediate testing: 
identification/exclusion of alternative etiologyHeader: Testing: identification/exclusion of 
alternative etiologyUpdate to UCB protocol 
template.
The measurements and additional information 
required for the assessment of PDILI events 
when there is a reasonable possibility that it 
may have been caused by the study drug are 
detailed in Table 13 -3(laboratory 
measurements) and Table 13 -4(additional 
information). Results of the laboratory 
measurements and collection of information is 
to be collected and submitted to the Sponsor on 
the corresponding eCRF. If medical history of 
the subject indicates a requirement for other 
assessments not included below, these should 
be completed and submitted, as applicable.
Table 13- 3: Pancreatic amylase specified.The measurements and additional information 
required for the assessment of PDILI events 
when there is a reasonable possibility that it 
may have been caused by the IMP are detailed 
in Table 13-3 (laboratory measurements) and 
Table 13-4 (additional information). Results of 
the laboratory measurements and information 
collected are to be submitted to the Sponsor on 
the corresponding eCRF. If medical history of 
the subject indicates a requirement for other 
assessments not included below, these 
additional assessments should be completed 
and submitted, as applicable.
All blood samples should be stored, if possible. 
If tests are done loca lly for more rapid results, 
a concurrent sample must also be sent to the 
central laboratory.
Table 13- 3: Prothombin time added to 
hematology assessments.
Table 13- 3: Pancreatic amylase changed to 
amylase.
Table 13- 3: The following added to the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 136of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
abbreviation list: ALT=alanine 
aminotransferase
Table 13- 3: The following footnote (“a”) added 
to prothrombin time: Measured only for 
subjects with ALT >8xULN, elevations in total 
bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include 
fatigue, nausea, vomiting, and right upper 
quadrant pain or tenderness; hypersensitivity 
symptoms include eosinophilia (>5%), rash, 
and fever (without clear alternative cause).
Table 13- 4: The following lead -in text added: 
“The following additional informati on is to be 
collected:”
Section 
13.7.4
(original 
protocol 
Section
13.7.3)Header: Follow -up monitoring
All PDILI events require follow -up monitoring 
as described in Table 13-3 Monitoring should 
continue until liver chemistry values 
normalize, stabilize, or return to baseline. 
Determination of stabilization is at the 
discretion of the Investigator in consultation 
with the hepatologist and study team.Header: Follow -up evaluation
All PDILI events require follow -up monitoring 
as described in Table 13-2. Monitoring should 
continue until liver chemistry values 
normalize, stabilize, or return to baseline. 
Determination of stabilization is at the 
discretion of the Investigator in cons ultation 
with the hepatologist (as applicable) and UCB 
responsible physician, as needed.Update to UCB protocol 
template.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 137of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 
14.2.1All source documents must be accurate, clear, 
unambiguous, permanent, and capable of being 
audited. They should be made using some 
permanent form of recording (ink, typing, 
printing, optical disc). They should not be 
obscured by correction fluid or have temporary 
attachments (such as removable self -stick 
notes). Photocopies of eCRFs are not 
considered acceptable source documents. All source documents must be accurate, clear, 
unambiguous, permanent, and capable of being 
audited. They should be made using some 
permanent form of recording (ink, typing, 
printing, optical disc). They should not be 
obscured by correction flu id or have temporary 
attachments (such as removable self -stick 
notes). Photocopies and/or printouts of eCRFs 
are not considered acceptable source 
documents. Update to UCB protocol 
template.
Section 
15.1.6The PK -PPS will consist of all subjects in the 
SSwho are randomized to 1 of the DZP 
treatment arms, have provided at least 1 PK 
sample, and for whom no important protocol 
deviations affecting the PK variables have been 
documented.The PK -PPS will consist of all subjects in the 
SS who have provided at le ast 1 PK sample 
and for whom no important protocol deviations 
affecting the PK variables have been 
documented.Clarification regarding 
composition of the PK -PPS.
Section 15.3 For purposes of computing a SLEDAI -2K total 
score, in the case where the SLEDAI -2K 
assessment has been done yet individual items 
have been left blank, these individual items 
will be imputed from the previous visit value 
prior to computing the total score. Deleted. Remove repetition of 
information provided in 
Section 15.3.1.
Section 
15.3.1The primary efficacy variable is the responder 
rate at Week 24 across 3 doses of DZP and 
PBO according to a combined response index 
(BICLA); the analysis will use a modified 
nonresponder imputation (mNRI) for missing 
data.The primary efficacy variable is the BICLA 
responder at Week 24 across 3 doses of DZP 
and PBO . The BICL A is a binary efficacy 
response variable, which is a composite 
endpoint derived from the efficacy 
components: BILAG 2004, SLEDAI -2K, and Update to provide additional 
informati on about 
methodology.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 138of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
If Visit 24 was done but t he value for a single 
component (BILAG 2004, SLEDAI -2K, or 
Physician’s Global Assessment of Disease) is 
not available, then the missing component 
value will be imputed from the previous visit 
value prior to computing the treatment 
response variable. In the case where a subject 
has a missing component, but already is known 
to have failed to achieve responder status on 
the basis of the nonmissing components (eg, 
SLEDAI -2K is missing but the nonmissing 
BILAG 2004 may not have demonstrated 
sufficient improvement), the missing value 
does not need to be imputed to know the 
subject’s treatment response classification. 
Thus, imputation only has a role for those 
subjects who have data at Visit 24 with all 
observed components meeting their respective 
criterion for tre atment response, and hence the 
imputed missing component will ultimately 
dictate whether or not the subject is classified 
as a responder. If the value at the previous visit 
is also missing, or if the subject has 2 or more 
missing components at the visit, t hen the 
treatment response value is considered to be 
unknown (ie, left as missing and subject to the 
missing data approach specific to the given 
analysis).
In addition, subjects who discontinue treatment 
prematurely are primarily categorized as the Physician’s Global Assessment of Disease 
Activity. The BILAG 2004 and SLEDAI -2K 
are themselves composite endpoints 
comprising of multiple assessments of several 
organ systems affected by SLE. In addition, 
usage of specified concomitant medication as 
escape treatment is also a factor in determining 
BICLA responder status. See Section 9.1.9.1
for a complete description o f the BICLA 
composite variable. Modified nonresponder 
imputation will be used to impute missing data, 
after applying additional rules within each 
component, which are further detailed as 
follows:
If 1 of the 3 efficacy components (BILAG 
2004, SLEDAI -2K, or Physician’s Global 
Assessment of Disease) is missing, but the visit 
was performed and all other assessments were 
completed, the missing component will be 
imputed from the subject’s previous post -
baseline assessment , prior to computing the 
treatment response variable, following the last 
observation carried forward principle. 
Furthermore, for BILAG 2004 and SLEDAI -
2K, if the assessment was done, but individual 
system or item scores are missing, the 
respective individual score will be imputed 
from the respective previous post -baseline 
score, in order to obtain a score for the cu rrent 
visit, prior to computing the system or score. If 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 139of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
nonresponde rs. In any situation where a subject 
is known to be a nonresponder based on 
available data, imputation will not be 
performed for missing data required to 
determine treatment response status, since the 
subject is known to be a nonresponder 
regardless of the result of the missing 
assessment(s).
The primary efficacy analysis will be tested 
across 3 doses of DZP and PBO using the 
Multiple Comparison Procedure –Modelling 
(MCP -Mod) methodology (Bretz etal,2005). 
Monotonic dose -response trends will be tested 
using the appropriate contrasts as determined 
by the MCP -Mod methodology such that the 
overall Type 1 error rate is controlled at 0.05 
(one-sided testing).the value at the previous visit is also missing, 
or if the subject has 2 or more missing 
components at Week 24, then the treatment 
response value is considered to be unknown 
(ie, left as missing and t herefore considered a 
nonresponder).
In addition, subjects who discontinue treatment 
prematurely (while still remaining in the study) 
are primarily categorized as a nonresponder 
from that visit and all subsequent visits.
The Week 24 BICLA dose -response 
relationship across 3 doses of DZP and PBO 
will be evaluated using the Multiple 
Comparison Procedure –Modelling (MCP -
Mod) methodology (Bretz etal,2005). 
Monotonic dose -response trends will be tested 
using the appropriate contrasts as determined 
by the MCP -Mod methodology such that the 
overall Type 1 error rate is controlled at 0.05 
(one-sided testing).
The SAP will describe additional features and 
detail around the MCP -Mod methodology as 
well as handling of missing data.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 140of 144Specific changes with SL0023 Amendment 1
Protocol
section(s)
impactedKey components of previous text Key components of amended text Rationale
Section 16.1 Prior to participation in the study, the written 
Informed Consent form should be signed and 
personally dated by the subject, or his/her legal 
representative, and by the person who 
conducted the informed consent discussio n 
(Investigator or designee). The subject or 
his/her legal representative must receive a copy 
of the signed and dated Informed Consent 
form. As part of the consent process, each 
subject must consent to direct access to his/her 
medical records for study -related monitoring, 
auditing, IRB/IEC review, and regulatory 
inspection.Prior to participation in the study, the written 
Informed Consent form should be signed and 
personally dated by the subject, and by the 
person who conducted the informed consent 
discussi on (Investigator or designee). The 
subject must receive a copy of the signed and 
dated Informed Consent form. As part of the 
consent process, each subject must consent to 
direct access to his/her medical records for 
study -related monitoring, auditing, IRB/ IEC 
review, and regulatory inspection.Update to UCB protocol 
template.
Section 16.2 Upon signing the Informed Consent and Assent 
form (as applicable), the subject or legal 
representative will be provided with a subject 
identification card in the language of the 
subject.Upon signing the Informed Consent and Assent 
form (as applicable), the subject will be 
provided with a subject identification card in 
the language of the subject.Update t o UCB protocol 
template.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 141of 144The following table from the original protocol has been replaced b y Table 13 -2 of Amendment 1 
as noted in the specific changes for Section 13.7 above:
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 142of 144Original protocol Table 13- 2:  Required testing and follow up for PDILI
Lab value Symptoms aof 
hepatitis or 
hypersensitivityConsultation requirements Additional immediate testing Continued 
monitoringALT and/or 
ASTBilirubin
≥3xULN NA No Subject must be discussed with 
the Sponsor Study Physician 
within 24hMust have repeat liver chemistries 
and additional testing completed as 
soon as possible (see Section 
13.7.2); recommended to occur 
within 24hrs at site or with HCPMonitoring of 
liver chemistries 
required at least 
2times weekly 
until liver 
chemistries 
normalize, 
stabilize, or return 
to within baseline 
values. d≥3xULN NA Yes Hepatology bconsult
Subject must be discussed with 
the Sponsor Study Physician 
within 24h
≥3xULN ≥2xULN cN/A Hepatology bconsult
Subject must be discussed with 
the Sponsor Study Physician 
within 24h
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST= aspartate aminotransferase ; HCP=health care practitioner; NA=no t applicable; 
PDILI=potential drug -induced liver injury; ULN=upper limit of normal
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, fever (without clear alter native cause).
bDetails provided in Section 13.7.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of potential
hepatic disease. This would usually be a hepatologist, but may be a gastroenter ologist.
cIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Spon sor Study Physician.
dUnless an alternative monitoring schedule is agreed by the Investigator and Sponsor Study Physici an. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist and study team.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 143of 14420 DECLA RATION AND SIGN ATURE OF INVESTIGA TOR
I confirm that I have carefully  read and understood this protocol and agree to conduct this 
clinical study  as outlined in this protocol, according to current Good Clinical Practice and local 
laws an d requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study -related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially , and will not be made available to third parties without prior authorization by  
UCB.
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contr act.
Investigator:
Printed name Date/Signature
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 14Dec 2016
Clinical Study Protocol Dapirolizumab pegol SL0023
Confidential Page 144of 14421 SPONSOR DECLARA TION
I confirm that I have carefully  read and understand this protocol and agree to conduct this 
clinical study  as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 
 
 
  
 
 
 
 
ELECTRONIC SIGNATURES  
 
Signed by Meaning of Signature Server Approval Date 
(dd-mon-yyyy 
(HH:mm)) 
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
 SL0023 Protocol Amendment 1
Clinical Approval 15-Dec-2016 13:40 GMT+01
Clinical Approval 16-Dec-2016 23:17 GMT+01
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 